

07/27/99
U.S. PTO**PATENT APPLICATION TRANSMITTAL LETTER**
(Large Entity)Docket No.
1038-921 MIS:jbTO THE ASSISTANT COMMISSIONER FOR PATENTS

Transmitted herewith for filing under 35 U.S.C. 111 and 37 C.F.R. 1.53 is the patent application of:

Sheena M. Loosmore; Ken Sasaki; Yan Ping Yang; and Michel H. Klein

For: RECOMBINANT HIGH MOLECULAR WEIGHT MAJOR OUTER MEMBRANE PROTEIN OF MORAXELLA

Enclosed are:

Certificate of Mailing with Express Mail Mailing Label No.

Sixty-Eight (68) sheets of drawings.

A certified copy of a application.

Declaration Signed. Unsigned.

Power of Attorney

Information Disclosure Statement

Preliminary Amendment

Other:

1038-921 MIS:jb
07/27/99
U.S. PTO**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	23	- 20 =	3	x \$18.00	\$54.00
Indep. Claims	8	- 3 =	5	x \$78.00	\$390.00
Multiple Dependent Claims (check if applicable)	<input type="checkbox"/>				\$0.00
				BASIC FEE	\$760.00
				TOTAL FILING FEE	\$1,204.00

A check in the amount of \$1,204.00 to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed.


Charge the amount of as filing fee.

Credit any overpayment.

Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.

Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: July 26, 1999


Michael I. Stewart Signature
(24,973)

cc:

TITLE OF INVENTION

RECOMBINANT HIGH MOLECULAR WEIGHT MAJOR OUTER MEMBRANE
PROTEIN OF MORAXELLA

FIELD OF INVENTION

5 The present invention relates to the field of immunology and is particularly concerned with outer membrane proteins from *Moraxella*, methods of recombinant production thereof, genes encoding such proteins and uses thereof.

10 BACKGROUND OF THE INVENTION

Otitis media is the most common illness of early childhood with approximately 70% of all children suffering at least one bout of otitis media before the age of seven. Chronic otitis media can lead to hearing, speech and cognitive impairment in children. It is caused by bacterial infection with *Streptococcus pneumoniae* (approximately 50%), non-typable *Haemophilus influenzae* (approximately 30%) and *Moraxella (Branhamella) catarrhalis* (approximately 20%). In the United States alone, treatment of otitis media costs between one and two billion dollars per year for antibiotics and surgical procedures, such as tonsillectomies, adenoidectomies and insertion of tympanostomy tubes. Because otitis media occurs at a time in life when language skills are developing at a rapid pace, developmental disabilities specifically related to learning and auditory perception have been documented in youngsters with frequent otitis media.

M. catarrhalis mainly colonizes the respiratory tract and is predominantly a mucosal pathogen. Studies using cultures of middle ear fluid obtained by tympanocentesis have shown that *M. catarrhalis* causes approximately 20% of cases of otitis media (ref. 1 - Throughout this application, various references are referred to in parenthesis to more fully describe the

state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby
5 incorporated by reference into the present disclosure).

The incidence of otitis media caused by *M. catarrhalis* is increasing. As ways of preventing otitis media caused by pneumococcus and non-typable *H. influenzae* are developed, the relative importance of *M. catarrhalis* as a cause of otitis media can be expected
10 to further increase.

M. catarrhalis is also an important cause of lower respiratory tract infections in adults, particularly in the setting of chronic bronchitis and emphysema (refs.
15 2, 3, 4, 5, 6, 7, and 8). *M. catarrhalis* also causes sinusitis in children and adults (refs. 9, 10, 11, 12, and 13) and occasionally causes invasive disease (refs.
14, 15, 16, 17, 18, and 19).

Like other Gram-negative bacteria, the outer
20 membrane of *M. catarrhalis* consists of phospholipids, lipopolysaccharide (LPS), and outer membrane proteins (OMPs). Eight of the *M. catarrhalis* OMPs have been identified as major components. These are designated by letters A to H, beginning with OMP A which has a
25 molecular mass of 98 kDa to OMP H which has a molecular mass of 21 kDa (ref. 20).

Recently, Klingman and Murphy purified and characterized a high molecular-weight outer membrane protein of *M. catarrhalis* (ref. 21). The apparent
30 molecular mass of this protein varies from 350 kDa to 720 kDa as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). This protein appears to be an oligomer of much smaller proteins or subunits thereof of molecular mass about 120
35 to 140 kDa and is antigenically conserved among strains of *Moraxella*.

Helminen et al also identified a protein of molecular mass of about 300 to 400 kDa, named UspA, that was reported to be present on the surface of *Moraxella* (ref. 22).

5 In WO 96/34960 and US Patent No. 5,808,024, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference, there is described a new protein of *M. catarrhalis* which had an apparent molecular mass of about 200 kDa. Western blot 10 analysis using antiserum raised against the 200 kDa protein suggested that this protein was different from the large UspA protein (> 300 kDa), reported by the two groups in refs. 21 and 22. Recently, the gene sequences encoding two related proteins, UspA1 and UspA2, have 15 been published (ref. 23). A sequence comparison between the two genes encoding the UspA proteins and the gene encoding the 200 kDa protein confirmed that the 200 kDa protein is different from either of the UspA1 and UspA2 proteins.

20 Fitzgerald et al (ref. 29) have identified a 200 kDa protein associated with haemagglutination. Transmission electron microscopy studies (ref. 30) showed that the 200 kDa protein associated with haemagglutination is present on the outer fibrillar 25 layer of *M. catarrhalis*. Recently, a non-clumping variant of strain 4223 was prepared by serial passaging and it was observed that the non-clumping variant had reduced expression of both UspA and a 200 kDa protein that is not UspA (ref. 31). It is possible that this 200 30 kDa protein is the same as that described in WO 96/34960 and herein.

The 200 kDa protein described herein has been detected in most, but not all, strains of *Moraxella catarrhalis*, which have been isolated from various 35 sources, including otitis media (OM), sputum, nasopharynx, expectorate and bronchial secretions. Table 1A below contains a listing of *M. catarrhalis* strains

tested, their source and whether or not the 200 kDa protein is expressed.

5 *M. catarrhalis* infection may lead to serious disease. It would be advantageous to provide recombinant means for providing large quantities of 200 kDa outer membrane protein of *M. catarrhalis* strains and genes encoding such proteins from various *M. catarrhalis* strains for use as antigens in immunogenic preparations including vaccines, carriers for other antigens and 10 immunogens and the generation of diagnostic reagents.

SUMMARY OF THE INVENTION

The present invention is directed towards the provision of a recombinantly-produced purified and isolated outer membrane protein of *Moraxella catarrhalis* 15 and other *Moraxella* strains, having an apparent molecular mass of about 200 kDa, as well as genes encoding the same from various strains of *Moraxella catarrhalis*.

In one aspect of the present invention, there is 20 provided an isolated and purified nucleic acid molecule having (a) a nucleotide sequence set forth in Figure 3, 4 or 5 (SEQ ID Nos: 5, 6, 8, 9, 11, 12) for *Moraxella catarrhalis* strains 4223, Q8 and LES-1 respectively or the complementary sequence thereto; (b) a nucleotide 25 sequence encoding an about 200 kDa outer membrane protein of a strain of *Moraxella catarrhalis* and having the derived amino acid sequence shown in Figures 3, 4 or 5 (SEQ ID Nos: 7, 10, 13) for *Moraxella catarrhalis* strains 4223, Q8 and LES-1 respectively; and (c) a 30 nucleotide sequence encoding an about 200 kDa outer membrane protein of another strain of *Moraxella catarrhalis* which is characterized by a tract of consecutive G nucleotides which is 3 or a multiple thereof in length, an ATG start codon about 80 to 90 bp upstream of said tract and said tract being located 35 between about amino acids 25 and 35 encoded by the nucleotide sequence.

The another strain of *Moraxella catarrhalis* in (c) is a strain as identified in Table 1A other than strains 4223, Q8 and LES-1 and expressing an about 200 kDa protein.

5 In another aspect of the invention, there is provided (a) a nucleotide sequence set forth in Figure 8 (SEQ ID No: 12) for a 5'-truncation of the gene encoding an about 200 kDa outer membrane protein of *Moraxella catarrhalis* strain 4223; (b) a nucleotide
10 sequence encoding the derived amino acid sequence set forth in Figure 9 (SEQ ID No: 13) for a N-terminal truncation of an about 200 kDa outer membrane protein of *Moraxella catarrhalis* strain 4223; and (c) a nucleotide sequence encoding a 5'-truncation of a gene encoding an
15 about 200 kDa outer membrane protein of another strain of *Moraxella catarrhalis* and being capable of expressing the corresponding N-terminally truncated about 200 kDa outer membrane protein from *E. coli*.

A further aspect of the invention providing an
20 isolated and purified nucleic acid molecule which is a contiguous *Nde I - Pst I* fragment of SEQ ID No: 5.

The invention, in an additional aspect, provides a vector for transforming a host comprising a nucleic acid molecule as provided herein, which may be a plasmid
25 vector. The plasmid vector may be one which has the identifying characteristics of pKS348 (ATCC 203,529) or pKS294 (ATCC 203,528). The plasmid vector also may be one having the identifying characteristics of pQWE or pQWF.

30 A further aspect of the invention provides a host cell, such as *E. coli*, transformed by a vector provided herein and expressing an about 200 kDa protein of a strain of *Moraxella catarrhalis* or an approximately C-terminal half thereof. The invention further provides,
35 in an additional aspect, a recombinant about 200 kDa outer membrane protein of a strain of *Moraxella*

catarrhalis or an approximately C-terminal half thereof producible by the transformed host provided herein.

The recombinant about 200 kDa outer membrane protein or an approximately C-terminal half thereof may 5 be formulated into an immunogenic composition, which may be formulated as a vaccine for *in vivo* administration to protect against disease caused by *Moraxella catarrhalis*, which may be provided in combination with a targeting molecule for delivery to specific cells of the immune 10 system, formulated as a microparticle, capsule or liposome preparation, and may further comprise an adjuvant.

The invention, in a further aspect, includes a method of inducing protection against disease caused by 15 *Moraxella catarrhalis* by administering to a susceptible host, which may be a human, an effective amount of the immunogenic composition provided herein.

In an additional aspect, the invention provides a method for the production of an about 200 kDa outer 20 membrane protein of a strain of *Moraxella catarrhalis* or an approximately C-terminal half thereof, which comprises:

transforming a host cell, such as *E. coli*, with a vector as provided herein,

25 growing the host cell to express the encoded about 200 kDa protein or an approximately C-terminal half thereof, and

isolating and purifying the expressed about 200 kDa protein or an approximately C-terminal half thereof.

30 The encoded about 200 kDa protein may be expressed in inclusion bodies. The isolation and purification of the about 200 kDa protein may be effected by:

disrupting the grown transformed cells to produce supernatant and the inclusion bodies,

35 solubilizing the inclusion bodies to produce a solution of the recombinant about 200 kDa protein,

chromotographically purifying the solution of recombinant about 200 kDa protein free from contaminating proteins, and

isолating the purified recombinant about 200 kDa
5 protein.

BRIEF DESCRIPTION OF DRAWINGS

Figure 1 shows restriction maps of subclones of a gene encoding the 200 kDa outer membrane protein of *M. catarrhalis* from λ EMBL3 clone 8II and the location of
10 PCR primers used to amplify the 5'-region of the gene. The open reading frame of the about 200 kDa outer membrane protein is indicated by the shaded box. The numbers in parenthesis are approximate sizes of DNA inserts in plasmids. Restrictions sites are Sal: *Sal*I,
15 N: *Nco*I, B: *Bgl*II, K: *Kpn*I, Xb: *Xba*I, Xh: *Xho*I, RV:
*Eco*RV;

Figure 2 shows the nucleotide sequence (SEQ ID No: 1 - entire sequence, SEQ ID No: 2 - coding sequence) of the gene encoding the about 200 kDa outer membrane protein of *M. catarrhalis* strain 4223, as determined
20 from λ EMBL3 clone 8II, and deduced amino acid sequence (SEQ ID No: 3 - identified GTG start codon, SEQ ID No: 4 - putative ATG start codon shaded) of the about 200 kDa outer membrane protein. A ten-G nucleotide segment of
25 the 5'-UTR is identified by underlining. An ATG start codon for the same sequence but with a nine-G nucleotide segment is identified by a shaded box (see Figure 3);

Figure 3 shows the nucleotide sequence (SEQ ID No: 5 - entire sequence, SEQ ID No: 6 - coding sequence) of the gene encoding the about 200 kDa outer membrane protein of *M. catarrhalis* strain 4223, as determined
30 from PCR-amplified genomic DNA of strain 4223 and the deduced amino acid sequence (SEQ ID No: 7) of the corresponding about 200 kDa outer membrane protein. A nine-G nucleotide segment of the sequence corresponding
35 to the 10-G nucleotide segment of the sequence of Figure 2, is

identified by underlining. The GTG start codon identified in Figure 2 is identified by a light box;

Figure 4 shows the nucleotide sequence (SEQ ID No: 8) of the gene encoding the about 200 kDa outer membrane protein of *M. catarrhalis* strain Q8 and the deduced amino acid sequence (SEQ ID No: 9) of the corresponding about 200 kDa outer membrane protein. A nine-G nucleotide segment is identified by underlining;

Figure 5 shows the nucleotide sequence (SEQ ID No: 10) of the gene encoding the about 200 kDa outer membrane protein of *M. catarrhalis* strain LES-I and the deduced amino acid sequence (SEQ ID No: 11) of the corresponding about 200 kDa outer membrane protein. A three-G nucleotide segment is identified by underlining;

Figure 6 contains an alignment of the amino acid sequence (in single letter code) of the about 200 kDa proteins of *M. catarrhalis* strain 4223 (SEQ ID No: 7), Q8 (SEQ ID No: 9) and LES-I (SEQ ID No: 11). The alignments of the sequences were made using BLAST and manual methods and are compared to the 4223 sequence. Gaps in the sequence where no corresponding or related amino acid exists are designated by "-" while identical amino acids are designed by ".";

Figure 7 shows the restriction sites of the *M. catarrhalis* strain 4223 derived 200 kDa protein gene as well as the identity of various plasmids containing partial or full length 200 kDa genes;

Figure 8 shows the nucleotide sequence (SEQ ID No: 12) and deduced amino acid sequence (SEQ ID No: 13) of the 5'-truncated gene encoding the M56 200 kDa protein of *M. catarrhalis* strain 4223 contained in pKS348;

Figures 9A and 9B contain a schematic of the procedure for producing plasmid pKS294 expressing the full length 200 kDa protein of *M. catarrhalis* strain 4223;

Figure 10 is a schematic of the procedure for producing plasmid pKS348 expressing the N-truncated M56 r200 kDa protein of *M. catarrhalis* strain 4223;

5 Figure 11 shows a schematic procedure for the purification of recombinantly-produced 200 kDa protein from *E. coli*;

10 Figure 12 shows SDS-PAGE analysis of the expression of M56 r200 kDa protein gene from *E. coli*. *M. catarrhalis* strain 4223 lysate was run as a positive control (a) and uninduced KS358 cultured overnight was run as a negative control (b). In each lane, 20 µg of total protein was loaded;

15 Figure 13 shows the SDS-PAGE analysis of the purification of the M56 r200 kDa protein according to the scheme of Figure 11. Lane 1, *E. coli* whole cells; Lane 2, soluble proteins after 50 mM Tris/NaCl, pH8, extraction; Lane 3, soluble proteins after Tris/Triton X-100/EDTA extraction; Lane 4, soluble proteins after Tris/OG extraction; Lane 5, pellet after Tris/OG extraction; Lanes 6, 7, purified 200 kDa protein;

20 Figure 14 shows the anti-M56 r200 kDa protein antibody titers obtained in mice. Mice were immunized on day 1, day 29 and day 43 with 0.3 µg, 1 µg, 3 µg or 10 µg of the purified M56 r200 kDa protein in adjuvant. Antisera were obtained on days 14, 28, 42 and 56 and anti-M56 r200 kDa protein IgG titers were determined. The reactive titers of antisera were defined as the reciprocal of the dilution consistently showing a two-fold increasing in absorbance over that obtained with the pre-bleed serum sample collected on day 0;

25 Figure 15 shows the anti-M56 r200 kDa antibody titers in guinea pigs. Guinea pigs were immunized and antisera were analyzed according to the protocol of Figure 14;

30 Figure 16 shows the location of PCR primers used to amplify a DNA fragments carrying portions of the 200 kDa protein gene from chromosomal DNA of *M. catarrhalis*

strain RH408, a spontaneous mutant of strain 4223 which does not produce the 200 kDa protein;

Figure 17 is a partial nucleotide and derived amino acid sequence for the 200 kDa protein of *M. catarrhalis* 5 strain 4223, indicating by arrows the locations of the initial amino acid of the respective three truncations ALA¹², VAL¹⁹ and GLY³⁹;

Figure 18 shows schematic diagrams for two 3' half clones of the 4223 200 kDa gene. Clone pQWE contains a 10 fusion between the 5' end of the 200 kDa gene and the 3' half of the gene. Clone pQWF contains the 3' half of the gene alone. The location of the PCR primers used to generate pQWF is indicated.

Figure 19 is a construction diagram for producing 15 plasmid pQWE expressing a C-terminal portion of the 200 kDa protein of *M. catarrhalis* strain 4223 fused to the N-terminus; and

Figure 20 is a construction diagram for producing 20 plasmid pQWF expressing a C-terminal portion of the 200 kDa protein of *M. catarrhalis* strain 4223.

GENERAL DESCRIPTION OF THE INVENTION

In WO 96/34960 (Figure 6), the sequence of a cloned gene from *M. catarrhalis* 4223 encoding an about 200 kDa protein, was described. The open reading frame was 25 predicted to start at a GTG codon. Sequence analysis of 200 kDa genes from additional strains, suggested that a slightly longer open reading frame was more generally found. A re-examination of the sequence from the lambda phage-derived 200 kDa gene confirmed the GTG start codon 30 and an upstream stretch of 10 G nucleotides in a G tract. However, when sequence analysis was performed on 4223 genomic PCR-amplified subclones, the longer open reading frame was found starting from an ATG codon. The G-tract was found to contain 9 G nucleotides in the 35 chromosomal gene. An additional G nucleotide had been inserted during cloning from the phage library. Analysis of the 5' end of the 200 kDa gene from 24 strains

suggests that the number of G nucleotides in the G tract acts as regulator of expression.

Utilizing the techniques described herein, the genes encoding the about 200 kDa protein from *M. catarrhalis* strains Q8 and LES-1 have been cloned and sequenced. Figures 4 and 5 show respectively the nucleotide and derived amino acid sequences. An amino acid sequence comparison of the derived amino acid sequences of the 200 kDa protein from the three strains of *M. catarrhalis* is contained in Figure 6.

Based on the sequence information, a plasmid (pKS294) was constructed that contained the full-length 200 kDa protein gene of strain 4223 starting at the ATG codon, under control of the bacteriophage T7 promoter. However, even a basal level of expression of the full-length gene from the ATG was lethal to *E. coli*. Deletion of a 165 bp 5' fragment of the 200 kDa coding region greatly reduced the toxicity of the resultant protein to *E. coli*. Plasmid pKS348 contains the T7 promoter transcriptionally driving a 200 kDa protein gene which starts at amino acid residue 56. The V56 codon was changed to M56. The M56 r200 kDa protein was produced and the purified protein was used to generate guinea pig antiserum.

In WO 96/34960, a bactericidal antibody assay was described that was used to demonstrate that anti-200 kDa antibody was bactericidal for *M. catarrhalis*. The assay was used herein to demonstrate broad bactericidal antibody activity against heterologous clinical isolates from different geographical locations, by anti-M56 r200 kDa antibody. A single anti-M56 r200 kDa antibody was lytic for 62% of strains tested.

The 200 kDa protein was originally identified as a putative adhesin when its presence was detected in a clumping strain, but not a non-clumping derivative. In order to determine whether it were truly an adhesin, an *in vitro* adherence assay was developed in which the

inhibition of binding by antibody between *M. catarrhalis* and epithelial cells was measured. Using this assay, anti-M56 r200 kDa antibody was capable of inhibiting adherence of the homologous strain by 48%, demonstrating
5 that the 200 kDa protein was an adhesin. When an additional 25 strains of *M. catarrhalis* were assayed, 21 were found to have reduced adherence to epithelial cells in the presence of anti-M56 r200 kDa antibody. 19 of these strains had not been killed by the same antibody.
10 Thus, a single anti-M56 r200 kDa antibody was capable of killing or blocking adherence of 91% of the strains tested.

The sequence comparison for the 200 kDa gene from three strains of *M. catarrhalis* showed that the C-terminal half of the protein was quite conserved. Strain LES-1 contained an insert of about 300 amino acids. Thus, based upon the C-terminal region, the strains may be divided into two families depending upon whether they contained the insert 4223 and Q8 formed one family while
20 LES-1 formed the other. The carboxy terminal halves (3' halves) of the 4223 or LES-1 200 kDa genes were expressed in *E. coli* with good yields and the purified carboxy terminal half of the proteins were used to generate antibodies. When tested in the bactericidal
25 antibody assay, these antisera were bactericidal, as seen in Table 1B.

It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination,
30 diagnosis, treatment of *Moraxella* infections, and in the generation of immunological reagents. A further non-limiting discussion of such uses is further presented below.

1. Vaccine Preparation and Use

35 Immunogenic compositions, including those suitable to be used as vaccines, may be prepared from the about 200 kDa outer membrane protein as disclosed herein, as

well as immunological fragments and fusions thereof, which may be purified from the bacteria or which may be produced recombinantly. The vaccine elicits an immune response in a subject which produces antibodies,
5 including anti-200 kDa outer membrane protein antibodies and antibodies that are opsonizing or bactericidal. Should the vaccinated subject be challenged by *Moraxella* or other bacteria that produce proteins capable of producing antibodies that specifically recognize 200 kDa
10 outer membrane protein, the antibodies bind to and inactivate the bacterium. Furthermore, opsonizing or bactericidal anti-200 kDa outer membrane protein antibodies may also provide protection by alternative mechanisms.

15 Immunogenic compositions including vaccines may be prepared as injectables, as liquid solutions or emulsions. The about 200 kDa outer membrane protein may be mixed with pharmaceutically acceptable excipients which are compatible with the about 200 kDa outer
20 membrane protein. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to
25 enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously or intramuscularly. Alternatively, the immunogenic compositions formed according to the present invention,
30 may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of
35 administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example,

polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate. These compositions can take
5 the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain about 1 to 95% of the about 200 kDa outer membrane protein. The immunogenic preparations and vaccines are administered in a manner compatible with
10 the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize antibodies,
15 and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgement of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may
20 be of the order of micrograms of the about 200 kDa outer membrane protein. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend
25 on the route of administration and will vary according to the size of the host.

The immunogenic preparations including vaccines may comprise as the immunostimulating material a nucleotide vector comprising at least a portion of the gene encoding the about 200 kDa protein, or the at least a portion of the gene may be used directly for immunization.

The concentration of the about 200 kDa outer membrane antigen in an immunogenic composition according
35 to the invention is in general about 1 to 95%. A vaccine which contains antigenic material of only one pathogen is a monovalent vaccine. Vaccines which

contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains 5 of the same pathogen, or from combinations of various pathogens.

Immunogenicity can be significantly improved if the antigens are co-administered with adjuvants, commonly used as 0.05 to 0.1 percent solution in phosphate-buffered saline. Adjuvants enhance the immunogenicity 10 of an antigen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of 15 antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses.

Immunostimulatory agents or adjuvants have been 20 used for many years to improve the host immune responses to, for example, vaccines. Intrinsic adjuvants, such as lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulators which are 25 typically non-covalently linked to antigens and are formulated to enhance the host immune responses. Thus, adjuvants have been identified that enhance the immune response to antigens delivered parenterally. Some of these adjuvants are toxic, however, and can cause 30 undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in 35 increasing antibody responses to diphtheria and tetanus toxoids is well established and a HBsAg vaccine has been adjuvanted with alum. While the usefulness of alum is

well established for some applications, it has limitations. For example, alum is ineffective for influenza vaccination and inconsistently elicits a cell mediated immune response.

5 A wide range of extrinsic adjuvants can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's
10 complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.

To efficiently induce humoral immune responses (HIR) and cell-mediated immunity (CMI), immunogens are
15 typically emulsified in adjuvants. Many adjuvants are toxic, inducing granulomas, acute and chronic inflammations (Freund's complete adjuvant) FCA, cytolysis (saponins and Pluronic polymers) and pyrogenicity, arthritis and anterior uveitis (LPS and
20 MDP). Although FCA is an excellent adjuvant and widely used in research, it is not licensed for use in human or veterinary vaccines because of its toxicity.

Desirable characteristics of ideal adjuvants include:

25 (1) lack of toxicity;
(2) ability to stimulate a long-lasting immune response;
(3) simplicity of manufacture and stability in long-term storage;
30 (4) ability to elicit both CMI and HIR to antigens administered by various routes, if required;
(5) synergy with other adjuvants;
(6) capability of selectively interacting with populations of antigen presenting cells (APC);
35 (7) ability to specifically elicit appropriate T_H1 or T_H2 cell-specific immune responses; and

(8) ability to selectively increase appropriate antibody isotype levels (for example, IgA) against antigens.

U.S. Patent No. 4,855,283 granted to Lockhoff et al on August 8, 1989 which is incorporated herein by reference thereto, teaches glycolipid analogues including N-glycosylamides, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid, as immuno-modulators or adjuvants. Thus, Lockhoff et al. (US Patent No. 4,855,283 and ref. 27) reported that N-glycolipid analogs displaying structural similarities to the naturally-occurring glycolipids, such as glycosphospholipids and glycoglycerolipids, are capable of eliciting strong immune responses in both herpes simplex virus vaccine and pseudorabies virus vaccine. Some glycolipids have been synthesized from long chain-alkylamines and fatty acids that are linked directly with the sugars through the anomeric carbon atom, to mimic the functions of the naturally occurring lipid residues.

U.S. Patent No. 4,258,029 granted to Moloney, assigned to the assignee hereof and incorporated herein by reference thereto, teaches that octadecyl tyrosine hydrochloride (OTH) functioned as an adjuvant when complexed with tetanus toxoid and formalin inactivated type I, II and III poliomyelitis virus vaccine. Also, Nixon-George et al. (ref. 24), reported that octadecyl esters of aromatic amino acids complexed with a recombinant hepatitis B surface antigen, enhanced the host immune responses against hepatitis B virus.

Lipidation of synthetic peptides has also been used to increase their immunogenicity. Thus, Wiesmuller (ref. 25) describes a peptide with a sequence homologous to a foot-and-mouth disease viral protein coupled to an adjuvant tripalmitoyl-S-glyceryl-cysteinylserylserine, being a synthetic analogue of the N-terminal part of the

lipoprotein from Gram negative bacteria. Furthermore, Deres et al. (ref. 26) reported *in vivo* priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine which comprised of modified synthetic peptides derived from influenza virus nucleoprotein by linkage to a lipopeptide, N-palmityl-S-2,3-bis(palmitylxy)-(2RS)-propyl-[R]-cysteine (TPC).

2. Immunoassays

The about 200 kDa outer membrane protein of the present invention is useful as an immunogen for the generation of anti-200 kDa outer membrane protein antibodies, as an antigen in immunoassays including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art for the detection of anti-bacterial, anti-Moraxella, and anti-200 kDa outer membrane protein antibodies. In ELISA assays, the about 200 kDa outer membrane protein is immobilized onto a selected surface, for example, a surface capable of binding proteins such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed about 200 kDa outer membrane protein, a nonspecific protein such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample may be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from 2 to 4 hours, at temperatures such as

of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as
5 PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound about 200 kDa outer membrane protein, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined by subjecting
10 the immunocomplex to a second antibody having specificity for the first antibody. If the test sample is of human origin, the second antibody is an antibody having specificity for human immunoglobulins and in general IgG. To provide detecting means, the second antibody may have an associated activity such as an enzymatic activity that will generate, for example, a colour development upon incubating with an appropriate chromogenic substrate. Quantification may then be achieved by measuring the degree of colour generation
15 using, for example, a visible spectrophotometer.

3. Use of Sequences as Hybridization Probes

The nucleotide sequences of the present invention, comprising the sequence of the about 200 kDa protein gene, now allow for the identification and cloning of
25 the about 200 kDa protein gene from any species of *Moraxella*.

The nucleotide sequences comprising the sequence of the about 200 kDa protein gene of the present invention are useful for their ability to selectively form duplex
30 molecules with complementary stretches of other about 200 kDa protein genes. Depending on the application, a variety of hybridization conditions may be employed to achieve varying degrees of selectivity of the probe toward the other genes. For a high degree of
35 selectivity, relatively stringent conditions are used to form the duplexes, such as low salt and/or high temperature conditions, such as provided by 0.02 M to

0.15 M NaCl at temperatures of between about 50°C to 70°C. For some applications, less stringent hybridization conditions are required such as 0.15 M to 0.9 M salt, at temperatures ranging from between about 5 20°C to 55°C. Hybridization conditions can also be rendered more stringent by the addition of increasing amounts of formamide, to destabilize the hybrid duplex. Thus, particular hybridization conditions can be readily manipulated, and will generally be a method of choice depending on the desired results. In general, convenient hybridization temperatures in the presence of 10 50% formamide are: 42°C for a probe which is 95 to 100% homologous to the target fragment, 37°C for 90 to 95% homology and 32°C for 85 to 90% homology.

15 In a clinical diagnostic embodiment, the nucleic acid sequences of the about 200 kDa protein genes of the present invention may be used in combination with an appropriate means, such as a label, for determining hybridization. A wide variety of appropriate indicator 20 means are known in the art, including radioactive, enzymatic or other ligands, such as avidin/biotin and digoxigenin-labelling, which are capable of providing a detectable signal. In some diagnostic embodiments, an enzyme tag such as urease, alkaline phosphatase or 25 peroxidase, instead of a radioactive tag may be used. In the case of enzyme tags, colorimetric indicator substrates are known which can be employed to provide a means visible to the human eye or spectrophotometrically, to identify specific 30 hybridization with samples containing about 200 kDa protein gene sequences.

The nucleic acid sequences of the about 200 kDa protein genes of the present invention are useful as hybridization probes in solution hybridizations and in 35 embodiments employing solid-phase procedures. In embodiments involving solid-phase procedures, the test

DNA (or RNA) from samples, such as clinical samples, including exudates, body fluids (e. g., serum, amniotic fluid, middle ear effusion, sputum, bronchoalveolar lavage fluid) or even tissues, is adsorbed or otherwise affixed to a selected matrix or surface. The fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes comprising the nucleic acid sequences of the about 200 kDa protein encoding genes or fragments or analogs thereof of the present invention under desired conditions. The selected conditions will depend on the particular circumstances based on the particular criteria required depending on, for example, the G+C contents, type of target nucleic acid, source of nucleic acid, size of hybridization probe etc. Following washing of the hybridization surface so as to remove non-specifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label. It is preferred to select nucleic acid sequence portions which are conserved among species of *Moraxella*. The selected probe may be at least 18bp and may be in the range of about 30 to 90 bp.

4. Expression of the about 200 kDa Protein Gene

Plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell may be used for the expression of the genes encoding the about 200 kDa protein in expression systems. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. For example, *E. coli* may be transformed using pBR322 which contains genes for ampicillin and tetracycline resistance and thus provides an easy means for identifying transformed cells. The plasmids or phage, must also contain, or be modified to contain, promoters which can be used by the host cell for expression of its own proteins.

In addition, phage vectors containing replicon and control sequences that are compatible with the host can be used as a transforming vector in connection with these hosts. For example, the phage in lambda GEMTM-11 5 may be utilized in making recombinant phage vectors which can be used to transform host cells, such as *E. coli* LE392.

Promoters commonly used in recombinant DNA construction include the β -lactamase (penicillinase) and 10 lactose promoter systems and other microbial promoters, such as the T7 promoter system as described in U.S. Patent No. 4,952,496. Details concerning the nucleotide sequences of promoters are known, enabling a skilled worker to ligate them functionally with genes. The 15 particular promoter used will generally be a matter of choice depending upon the desired results. Hosts that are appropriate for expression of the about 200 kDa protein genes, fragments, analogs or variants thereof, may include *E. coli*, *Bacillus* species, *Haemophilus*, 20 fungi, yeast, *Bordetella*, or the baculovirus expression system may be used.

In accordance with this invention, it is preferred to make the protein by recombinant methods, particularly when the naturally occurring about 200 kDa protein as 25 purified from a culture of a species of *Moraxella* may include trace amounts of toxic materials or other contaminants. This problem can be avoided by using recombinantly produced protein in heterologous systems which can be isolated from the host in a manner to 30 minimize contaminants in the purified material. Particularly desirable hosts for expression in this regard include Gram positive bacteria which do not have LPS and are, therefore, endotoxin free. Such hosts include species of *Bacillus* and may be particularly 35 useful for the production of non-pyrogenic about 200 kDa protein, fragments or analogs thereof.

BIOLOGICAL DEPOSITS

Certain plasmids that contain portions and full-length of the gene having the open reading frame of the gene encoding the about 200 kDa outer membrane protein of *M. catarrhalis* strain 4223 that are described and referred to herein have been deposited with the America Type Culture Collection (ATCC) located at 10801 University Blvd., Manassas, VA 20110-2209, U.S.A., pursuant to the Budapest Treaty and pursuant to 37 CFR 1.808 and prior to the filing of this application.

Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application or relevant precursor applications. The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent or similar plasmids that encode similar or equivalent antigens as described in this application are within the scope of the invention.

	<u>Plasmid</u>	<u>ATCC Designation</u>	<u>Date Deposited</u>
	pKS47	97,111	April 7, 1995
	pKS5	97,110	April 7, 1995
	pKS9	97,114	April 18, 1995
25	pKS294	203,528	December 17, 1998
	pKS348	203,529	December 17, 1998

EXAMPLES

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are

intended in a descriptive sense and not for purposes of limitations.

Methods of molecular genetics, protein biochemistry, and immunology used but not explicitly 5 described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

Example 1

This Example describes the cloning of a gene 10 encoding the *M. catarrhalis* 200 kDa outer membrane protein.

A *M. catarrhalis* genomic library in phage lambda EMBL3 was prepared as described in Example 9 of USP 5,808,024 and WO 96/34960 and was screened using guinea 15 pig anti-200 kDa protein antiserum. A lambda phage clone 8III, which expressed an about 200 kDa protein, was confirmed by immunoblotting of the phage lysate using the about 200 kDa outer membrane-specific antiserum.

Plate lysate cultures of this recombinant phage 20 were prepared. The DNA was extracted from the plate lysates using a Wizard Lambda Preps DNA Purification System (Promega Corp, Madison, WI) according to the manufacturer's instructions. This phage clone carried a DNA insert of about 16 kb in size (the restriction map 25 for which is shown in Figure 1). The phage DNA was digested with a mixture of the restriction enzymes *Sall* and *XhoI*, and separated by agarose gel electrophoresis. Two DNA bands, approximately 5 kb and 11 kb in size, respectively, were cut out from the gel and extracted 30 using a Geneclean kit (BIO 101 Inc., LaJolla, CA) according to the manufacturer's direction.

The smaller 5 kb fragment was ligated into a plasmid vector, pBluescript II SK +/- (Stratagene Cloning Systems, LaJolla, CA), which had been previously 35 digested with *Sall* and *XhoI*, to produce plasmid pKS5. The larger 11 kb fragment was ligated into a plasmid vector, pSP72 (Promega Corp., Madison, WI), digested

with *Sal*I and *Xho*I,, to produce plasmid pKS9. Both ligated plasmids were used to transform *E. coli*, strain DH5 α .

The lambda phage DNA was also digested with a mixture of *Xho*I and *Kpn*I and the approximately 1.1 kb fragment was isolated after agarose gel separation as described above. This 1.1 kb fragment was ligated into a plasmid vector, pGEM-7Zf(+) (Promega Corp., Madison, WI), to produce plasmid pKS47.

10 Example 2

This Example describes the isolation of chromosomal DNA from *M. catarrhalis* for use in PCR amplification.

M. catarrhalis was cultured in 25 ml of BHI broth overnight and centrifuged at 5,000 rpm for 10 min. The 15 bacteria pellet was suspended in 10 ml of 10 mM Tris/HCl (pH 8.0) containing 100 mM EDTA and mixed with RNaseA (final concentration: 100 μ g/ml) and lysozyme (final concentration: 1 mg/ml). After incubation on ice for 10 min and at room temperature for 50 min, the suspension 20 was gently mixed with 1 ml of 10% SDS and then heated at 65°C for 20 min. The suspension was mixed with proteinase K (final concentration: 200 μ g/ml) and incubated at 50°C for 1 h. The suspension was gently mixed with 10 ml chloroform on a nutator for 15 min and 25 centrifuged at 5,000 rpm for 10 min. The upper phase was slowly removed with a wide-bore pipette and mixed with 10 ml of Tris-saturated phenol and 10 ml of chloroform on a nutator. After centrifugation at 5,000 rpm for 10 min, the upper phase was re-extracted with a mixture of 30 Tris-saturated phenol and chloroform, again, and then extracted with chloroform, and then twice dialyzed against 1M NaCl at 4°C and twice against TE buffer (pH 8.0) at 4°C.

Example 3

This Example describes subcloning and sequence analysis of fragments of the 200 kDa protein gene from *M. catarrhalis* strain 4223.

5 The procedures used to produce a phage λ EMBL3 clone 8II, and its subclones, pKS5, pKS9 and pKS47, are described in USP 5,808,024 and WO 96/34960. pKS10 was constructed from the λ EMBL3 clone 8II exactly as described for pKS9. pKS59 and pKS63 were constructed by
10 insertion of a 1.4 kb *Xba*I-*Nco*I fragment of pKS9 into pGEM5Z(+) that had been digested with *Nco*I and *Spe*I. pKS71 was made by insertion of the same 1.4 kb *Xba*I-*Nco*I fragment, isolated from the λ EMBL3 clone 8II into pGEM5Z(+). Sequence analysis confirmed that all three
15 plasmids, pKS59, pKS63 and pKS71, carried identical DNA fragments. Figure 1 shows partial restriction maps for the plasmids.

The full sequence of the 200 kDa gene locus from the λ DNA clone was described in USP 5,808,024 and WO 96/34960 and is shown in Figure 2. There is a tract of 10 consecutive G nucleotides between position 623 and 632 in clones derived from the λ library. The first possible start codon is, therefore, located at nucleotides 706 to 708 and is a GTG encoding a valine,
25 boxed lightly in Figure 2. A series of strains expressing a 200 kDa gene, were identified by immunoblot analysis and the 5' end of their 200 kDa genes was PCR amplified and sequenced. A summary of the findings is shown in Table 5 wherein the expression level of the
30 gene appeared to be related to the number of G nucleotides in the tract and for those strains within higher expression levels, the start codon was an ATG upstream of the GTG codon identified from the 4223 λ clones. Based upon these findings, the sequence of the
35 5' end of the 200 kDa gene from strain 4223 was re-examined.

Plasmids pKS9 and pKS10 were directly derived from the λ clone. The subclones pKS59 and pKS63 were derived from pKS9 whereas pKS71 contained the same fragment derived directly from the λ clone. All of these plasmids 5 contained 10 G nucleotides in the G tract, as described previously. To determine whether the λ clone contained an extra G nucleotide or the strain itself contained an aberrant gene, PCR amplification of the region was performed from chromosomal DNA preparations and from the 10 λ subclones. The data in Table 3 show that PCR fragments of the λ subclones all contained 10 G nucleotides. The data in Table 4, however, demonstrate that PCR fragments derived directly from chromosomal DNA, contain 9 G nucleotides in the tract. When the single extra G 15 nucleotide is removed from the 200 kDa sequence of strain 4223, the open reading frame is extended in the 5' direction to start from an ATG codon 156 nucleotides earlier, at positions 541 to 543 in Figure 2. This new start codon corresponds to that suggested for the 200 20 kDa genes sequenced from other strains and summarized in Table 5.

Example 4

This Example describes the construction of the full length 200 kDa protein gene from *M. catarrhalis* strain 25 4223. The construction scheme is shown in Figure 9.

The full-length 200 kDa protein gene was constructed from the new ATG start codon identified by analysis of the chromosomally derived DNA as described in Example 3 and shown in Figure 3. pKS47 was digested 30 with *Xba*I and *Kpn*I and separated by agarose gel electrophoresis. The 1.1 kb fragment was isolated from the gel and inserted into pKS5, which had previously been digested with the same two enzymes and purified to form pKS80. An about 5.8 kb *Pst*I fragment from pKS80 was 35 inserted into pT7-7 vector (ref. 28) that had been digested with *Pst*I and dephosphorylated. The orientation

of the insert was determined by restriction enzyme analysis and pKS122 was chosen for further construction (see Figure 7).

The 5' region of the 200 kDa protein gene was amplified from strain 4223 chromosomal DNA. PCR reactions were performed using Taq Plus or Tsg Plus enzyme (Sangon Ltd., Scarborough, Ont., Canada) and a Perkin Elmer DNA Thermocycler (Perkin Elmer Cetus, Foster City, CA, USA). The lower PCR reaction mixture (50 µl) contained 5 µl of 10X buffer, 0.4 mM each of four deoxynucleotide triphosphates (Perkin Elmer, Foster City, CA, USA) and 1 to 2 µM each of two primers. The upper PCR reaction mixture (50 µM) contained 5 µl of 10X buffer, 0.5 to 1 µl of Taq Plus or Tsg Plus enzyme, and template DNA. The lower and upper mixtures were separated by a layer of AmpliWax PCR Gem50 (Perkin Elmer, Foster City, CA, USA) before heating cycles started. The thermocycling condition employed for the provision of PCR products in the construction of various plasmids are set forth in Table 11 below. The PCR products were purified using a QIAquick PCR purification kit (Qiagen Inc., Mississauga, Ont., Canada). The purified PCR products were sequenced on both strands directly and/or after cloning in appropriate vectors using an Applied Biosystem sequencer.

The 5' primer (designated 5295.KS) was designed, so that it contained the first possible translation start codon, ATG, and its flanking sequences with a mutation to introduce an *Nde*I site at the ATG. The 3' primer (designated 4260.KS) was based upon the non-coding strand in the region about 1 kb downstream from the ATG start codon. (The nucleic acid sequences and SEQ ID's of the PCR primers utilized herein are identified in Table 10). The PCR-product was digested with *Nde*I and an approximately 650 bp DNA fragment was gel purified and

inserted into pKS122, which had previously been linearized with *Nde*I and dephosphorylated.

The new construct, designated pKS294 (Figure 8), was confirmed by restriction enzyme analyses and by sequencing of the PCR-amplified DNA and its joint regions. The number of G nucleotides in the G tract was nine, and the open reading frame continued from the newly found translation start codon, ATG, to the remaining portion of 200 kDa protein gene in pKS122. pKS294, therefore, carried the correct, full-length 200 kDa protein gene from *Moraxella catarrhalis* strain 4223. During construction of pKS294, *E. coli* strain DH5 α was used for transformation and plasmid analyses.

Example 5

This Example describes the cloning and sequence analysis of genes encoding the 200 kDa protein from additional *M. catarrhalis* clinical isolates.

A panel of *M. catarrhalis* clinical isolates was analysed by immunoblot with guinea pig anti-200 kDa antibody, as described in USP 5,808,024 and WO 96/34960. From these analyses, it was evident that there is size heterogeneity among the 200 kDa proteins from various strains. In order to assess the possible genetic heterogeneity, representative strains were chosen for gene cloning. Strain Q8 is a naturally occurring relatively non-clumping strain that produces a 200 kDa protein of about the same size as the 4223-derived protein. Strain LES-1 produces a larger 200 kDa protein. These strains were also selected based upon bactericidal antibody data as illustrated in Table 1. The 200 kDa genes were cloned from these two strains of *M. catarrhalis* and sequenced.

The nucleotide and derived amino acid sequences of the 200 kDa genes from strains Q8 and LES-1 are shown in Figures 4 and 5 respectively. An alignment of the amino acid sequences with the 4223-derived sequence is shown in Figure 6. As can be seen, the first 68 residues of

the N-terminus are quite conserved, especially between strains 4223 and Q8. In addition, the final 456 residues of the C-terminus are nearly identical among the three strains. The remainder of the sequence has regions of 5 high homology and significant diversity, including an insert of more than 300 residues for strain LES-1.

The N-terminal sequence of the 200 kDa proteins is homologous to the *H. influenzae* Hia and Hsf proteins, as well as other high molecular weight proteins or 10 adhesins, such as AIDA (ref. 33).

The C-terminal region also has some homology to *H. influenzae* Hia and Hsf proteins as do some stretches of internal sequence. There is also some homology in the C-terminal region to UspA (ref. 23). A further indication 15 of the relatedness of this family of proteins, is the finding that guinea pig anti-200 kDa antibody raised to gel-purified native protein was able to recognize recombinant Hia protein by immunoblot. This data has been described in copending United States Patent 20 Application No. 09/268,347 (Hia) filed March 16, 1999, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference.

Example 6

This Example shows the expression of the full-length about 200 kDa protein from pKS294.

E. coli strain, BL21(DE3)/pLySS was transformed by electroporation with pKS294, prepared as described in Example 4, for the expression study of the full-length 200 kDa protein gene.

30 The product of the pKS294 construct was found to be toxic to the host *E. coli*. At room temperature, the BL21(DE3)/pLySS transformants grew very slowly on LB-agar plates containing ampicillin (Amp) and chloramphenicol (Cm) and at 37°C, no transformants were 35 detected. When the transformants which grew at room temperature, were cultured overnight at 30°C on BHI agar containing the two antibiotics and glucose, they grew

well, producing colonies with a normal size. However, when these clones were cultured overnight in liquid medium at 30°C, subcultured into broth without glucose, and then induced by addition of IPTG, no recombinant 5 protein was found on Western blot using anti-200 kDa protein serum. When the cells cultured overnight were examined before subculturing, a small quantity of recombinant 200 kDa protein was detected by SDS-PAGE stained with Coomassie Blue and by Western blot, showing 10 that the gene was expressed during the overnight culture.

When *E. coli* strain, DH5α, which cannot express the gene under the control of a T7 promoter, was transformed with pKS294, the transformants grew well at 37°C both on 15 LB-agar and in LB-broth containing the antibiotics. These results suggest that the gene product is very toxic to host *E. coli*, and that even a basal level of expression of the full-length 200 kDa protein gene from the ATG is lethal to *E. coli*.

20 *M. catarrhalis* strain LES-1 also produced similar toxicity in *E. coli* when the full length 200 kDa protein was expressed.

Example 7

This Example describes the deletion of a short 5'-sequence from the strain 4223 or strain LES-1 200 kDa protein gene and expression of the truncated genes producing a M56 r200 kDa product.

The deletion of a short 5' region from the 4223 200 kDa protein gene is shown in Figure 10 and was performed 30 using a similar approach as described in Example 4. An about 500 bp 5' region of the 200 kDa gene was PCR amplified from strain 4223 using primers 5471.KS and 4257.KS (Table 8) from chromosomal DNA. The 5' primer (designated 5471.KS) was based upon the region 35 surrounding the previously identified GTG downstream start codon. In primer 5471.KS, the flanking regions around the GTG codon were incorporated and the GTG was

mutated to ATG with further mutations used to introduce an *NdeI* site incorporating the new ATG. Using numbering from the full-length 200 kDa protein, the new start codon would be M56 replacing the previous V56 codon. The 5' primer (designated 4257.KS) was based upon the non-coding strand located about 500 bp downstream from the GTG codon in the 200 kDa protein gene. The PCR-product was digested with *NdeI*, purified using a QIAquick PCR purification kit (Qiagen Inc., Mississauga, Ont.), and inserted into *NdeI* digested and dephosphorylated pKS122 to provide pKS348 (see Figure 7). Plasmid pKS348 was confirmed by restriction enzyme analyses and by sequencing of the PCR-amplified DNA piece and its joint regions. The nucleotide sequence (SEQ ID No: 12) and the deduced amino acid sequence (SEQ ID No: 13) for the 5'-truncation contained in pKS348 are shown in Figure 8. A similar N-terminal truncated 200 kDa gene from strain LES-1 was generated in the same manner and was designated pKS444.

A single colony of *E. coli*, BL21(DE3)/pLyss, (KS358) which carried pKS348, was suspended in 5 ml of BHI broth containing Amp (100 μ M), Cm (50 μ M) and 0.4% of glucose, and cultured overnight at 37°C. To study the kinetics of expression, 2.5 ml of the overnight culture was added to 250 ml of LB (Luria-Bertani) broth containing Amp (100 μ M) and Cm (50 μ M), and grown with shaking at 37°C to A_{600} = 0.33 to 0.36. Another 0.3 ml of the overnight culture was added to 30 mL of LB broth containing Amp (100 μ M) and Cm (50 μ M) and grown with shaking at 37°C to A_{600} = 0.26 to 0.44. Gene expression from the cultures was induced by addition of IPTG (final concentration: 4 mM). The bacteria were grown and harvested at different time points by centrifugation. The expression of the 200 kDa protein gene in the culture was confirmed by SDS-PAGE analysis using Coomassie Blue staining and by Western blot analysis

using guinea pig anti-200 kDa protein serum, as described in USP 5,808,024 and WO 96/34960.

When *E. coli* BL21(DE3)/pLySS was transformed with pKS348, transformants grew well even on LB agar plates 5 and in LB broth containing antibiotics at 37°C. After induction with IPTG, these clones produced a large amount of the N-terminally truncated r200 kDa protein which was clearly seen by SDS-PAGE Coomassie Blue stain, as shown in Figure 12.

10 The bacterial culture induced at $A_{600} = 0.26$ produced slightly more truncated r200 kDa protein than the culture induced when the OD reading was 0.44. The largest amount of truncated r200 kDa protein was seen at 3 hr after induction. Similar results were observed for 15 the M56 r200 kDa expression from strain LES-1.

Example 8

This Example describes the purification of the M56 r200 kDa proteins from strain 4223 or LES-1, according to the procedure shown in Figure 11.

20 *E. coli* cell pellets were obtained from 500 ml culture prepared as described in Example 7, by centrifugation and were resuspended in 50 ml of 50 mM Tris-HCl, pH 8.0, containing 0.1 M NaCl, and disrupted by sonication. The sonicate was centrifuged at 20,000 xg 25 for 30 min. and the resultant supernatant (sup1) was discarded. The pellet (ppt1) was extracted, in 50 ml of 50 mM Tris-HCl, pH 8.0 containing 0.5% Triton X-100 and 10 mM EDTA, then centrifuged at 20,000 xg for 30 min. and the supernatant (sup2) was discarded. The pellet 30 (ppt2) was further extracted in 50 ml of 50 mM Tris-HCl, pH 8.0, containing 1% octylglucoside, then centrifuged at 20,000 xg for 30 min. and the supernatant (sup3) was discarded.

The resultant pellet (ppt3) contained the inclusion 35 bodies. The pellet was solubilized in 6 ml of 50 mM Tris-HCl, pH 8.0, containing 6 M guanidine and 5 mM DTT. Twelve ml of 50 mM Tris-HCl, pH 8.0 was added, the

mixture centrifuged at 20,000 xg for 30 min, and the pellet (ppt4) discarded. The supernatant (sup4) was precipitated by adding polyethylene glycol (PEG) 4000 at a final concentration of 5% and incubated at 4°C for 30
5 min. The resultant pellet (ppt5) was removed by centrifugation at 20,000 xg for 30 min. The supernatant was then precipitated by $(\text{NH}_4)_2\text{SO}_4$ at 50% saturation at 4°C overnight. After the addition of $(\text{NH}_4)_2\text{SO}_4$, the solution underwent phase separation with protein going
10 to the upper phase (as judged by the cloudiness of the layer). The upper phase was collected, then subjected to centrifugation at 20,000 xg for 30 min. The resultant pellet was collected and dissolved in 2 ml of 50 mM Tris-HCl, pH 8.0, containing 6 M guanidine and 5 mM DTT.
15 The clear solution was purified on a Superdex 200 gel filtration column equilibrated in 50 mM Tris-HCl, pH 8.0, containing 2 M guanidine HC1. The fractions were analysed by SDS-PAGE and those containing the purified r200 kDa were pooled. The pooled fraction was
20 concentrated 5 to 10 fold using a centriprep 30 and then dialysed overnight at 4°C against PBS, and centrifuged at 20,000 xg for 30 min to clarify.

The protein remained soluble under these conditions and glycerol was added to the M56 r200 kDa preparation
25 at a final concentration of 20% for storage at -20°C (Figure 12). The average yield of the purified M56 r200 kDa protein is about 10 mg L⁻¹ culture. The purified protein was used for the immunization of animals, as described below.

30 The procedure of this Example 8 and was repeated for *M. catarrhalis* strain LES-1 and a corresponding r200 kDa protein was produced. The N-terminal truncated M56 r200 kDa protein from strain LES-1 gave approximately the same recovery of purified protein as described above
35 for strain 4223.

Example 9

This Example illustrates the immunogenicity of the M56 r200 kDa protein.

The immunogenicity of M56 r200 kDa, prepared as described in Example 8, was examined using mice and guinea pigs. Groups of five BALB/c mice (Charles River, Quebec) were immunized sub-cutaneously (s.c.) on days 1, 29 and 43 with 0.3, 1.3 and 10 µg of 4223 M56 r200 kDa antigen, prepared as described in Example 8, in the presence AlPO₄ (1.5 mg per dose). Blood samples were collected on days 0, 14, 28, 42 and 56.

Groups of five guinea pigs (Charles River, Quebec) were immunized i.m. on days 1, 29 and 43 with 25, 50 and 100 µg of 4223 M56 r200 kDa antigen prepared as described in Example 8, in the presence AlPO₄ (1.5 mg per dose). Blood samples were collected on days 0, 14, 28, 42 and 56.

Anti-M56 r200 kDa IgG titers were determined by antigen-specific enzyme-linked immunosorbent assays (EIAs). Microtiter wells (Nunc-MAXISORP, Nunc, Denmark) were coated with 50 µL of protein antigen 0.2 µg mL⁻¹. The reagents used in the assays were as follows: affinity-purified F(ab')₂ fragments of goat anti-mouse IgG (Fc-specific) conjugated to horseradish peroxidase (Jackson ImmunoResearch Labs, Mississauga, Ontario); affinity-purified guinea pig anti-IgG antibody (1 µg mL⁻¹) (prepared by the inventors); and affinity-purified F(ab')₂ fragment of goat anti-guinea pig IgG (H+L) antibodies conjugated to horseradish peroxidase (HRP) (Jackson ImmunoResearch Laboratories) used as a reporter. The reactions were developed using tetramethylbenzidine (TMB/H₂O₂, ADI, Mississauga, Ontario) and absorbancies were measured at 450 nm (using 540 nm as a reference wavelength) in a Flow Multiskan MCC microplate reader (ICN Biomedicals, Mississauga, Ontario). The reactive titer of an antiserum was defined

as the reciprocal of the dilution consistently showing a two-fold increase in absorbance over that obtained with the pre-bleed serum sample.

The mice generated dose-dependent anti-M56 r200 kDa antibody responses, as shown in Figure 14. These results clearly show that the protein remained immunogenic after inclusion bodies extraction, solubilization and purification. Only a slight difference in the antibody titers were found for the higher dose range tested in guinea pigs (Figure 15), indicating that the amount of antigen used was nearly at saturation.

Example 10

This Example describes the generation of hyper-immune sera against the M56 r200 kDa proteins in rabbits and guinea pigs.

To generate hyper-immune sera against M56 r200 kDa proteins, groups of two rabbits and two guinea pigs (Charles River, Quebec) were immunized intramuscularly (i.m.) on day 1 with a 5 µg dose of purified M56 r200 kDa protein, prepared as described in Example 8, emulsified in complete Freund's adjuvant (CFA). Animals were boosted on days 14 and 29 with the same dose of protein emulsified in incomplete Freund's adjuvant (IFA). Blood samples were taken on day 42 for analyzing the anti-M56 r200 kDa antibody titers and bactericidal activities. Anti-r200 kDa IgG titers were determined by antigen-specific enzyme-linked immunosorbent assays (EIAs), as described in Example 9. The results obtained in the two animals using r200 kDa protein from strains 4223 and LES-1 are illustrated in Table 6.

Example 11

This Example describes a bactericidal antibody assay.

The bactericidal antibody activity of guinea pig anti-M56 r200 kDa sera from 4223 or LES-1 protein prepared as described in Example 10 against various

strains of *M. catarrhalis* was estimated using a viability plating assay. Each test strain of *M. catarrhalis* was cultured overnight in brain heart infusion (BHI) broth (Difco Laboratories, Detroit, MI) at 37°C. The overnight culture was subcultured into 10 ml BHI broth, and grown to an absorbance at 578 nm of 0.5. The number of bacteria at $A_{578} = 0.5$ changes from strain to strain. Therefore, several ten-fold dilutions of each strain were used in order to achieve 100 to 300 colonies per plate for the preimmune serum group. Bacteria were diluted in Veronal buffered saline (VBS, pH 7.6) containing 140 mM NaCl, 93 mM NaHCO₃, 2 mM Na-barbiturate, 4 mM barbituric acid, 0.5 mM MgCl₂.6H₂O, 0.4 mM CaCl₂.2H₂O, and 0.1% bovine serum albumin. Guinea pig anti-M56 r200 kDa serum and pre-immune control serum were heated at 56°C for 30 min. to inactivate endogenous complement. Serum and antiserum were diluted in VBS, and placed on ice.

Twenty-five μ l of diluted pre-immune serum or test antiserum were added to the wells of a 96-well Nunclon microtitre plate (Nunc, Roskilde, Denmark). Twenty-five μ l of diluted bacterial cells were added to each of the wells. A guinea pig complement (BioWhittaker, Walkerville, MD) was diluted 1:10 in VBS, and 25 μ l portions were added to each well. The plates were incubated for 60 min, gently shaking at 70 rpm on a rotary platform. Fifty μ l of each reaction mixture were plated onto Mueller Hinton agar plates (Becton-Dickinson, Cockeysville, MD). The plates were incubated at 37°C for 24 hours, and then left at room temperature for a further 24 hours. The number of colonies per plate was counted, and average values of colonies per plate were estimated from duplicate pairs.

When pre-immune serum plates were compared with PBS control plates (no serum), pre-immune serum had no bactericidal effect on the homologous strain 4223.

Therefore, it was assumed that the number of colonies per plate on pre-immune serum plates represented 100% viability for each strain and percent bactericidal killing was calculated as follows:

$$100\% - \frac{\text{average number of colonies per plate in anti-r200 kDa antiserum group} \times 100}{\text{average number of colonies per plate in pre-immune serum group}} \%$$

5 When the bactericidal antibody activity of the 4223 anti-M56 r200 kDa antiserum was examined against the homologous strain (Table 7), 50% killing was observed at a serum dilution between 1/512 and 1/1024, showing that the antiserum raised against M56 r200 kDa protein
10 possesses bactericidal antibody activity. Next, the bactericidal antibody activity of the antiserum was tested at a dilution of 1/64 against a total of 55 different strains, which were isolated from otitis media patients in various geographical locations (Table 1B).
15 The antiserum raised against the M56 r200 kDa protein from strain 4223 showed more than 30% bactericidal antibody activity against 38 out of 56 (68%) strains examined. When LES-1 anti-M56 r200 kDa antibody was tested in the bactericidal antibody assay, 36/55 (65%)
20 strains were killed, including 11 strains that were not killed by the 4223 anti-M56 r200 kDa antibody. Only six strains out of 55 strains examined were not killed by either one of the two antisera. These results indicate that the 200 kDa protein is a very good candidate for
25 inclusion in an otitis media vaccine.

Example 12

This Example describes the inhibition of binding of *M. catarrhalis* strains to either Chang or Hep-2 epithelial cells by 4223 anti-M56 r200 kDa serum.

30 The 200 kDa protein had previously been proposed to be an adhesin on the basis of its apparent absence from a spontaneous non-clumping variant of strain 4223. This strain, obtained by serial passaging of culture supernatants, was designated RH408 and is described in
35 WO 96/34960. Electron microscopy also suggested that the

200 kDa protein was an adhesin. The sequence homology demonstrated between the *M. catarrhalis* 200 kDa proteins and other high molecular weight adhesins from different organisms, also suggested that it was an adhesin. Based
5 upon these observations, an assay was developed to try to demonstrate that anti-r200 kDa antibody could block adherence between *M. catarrhalis* and epithelial cells, thus identifying it definitively as an adhesin.

On day 1, 24 well tissue culture plates were seeded
10 with approximately 3×10^5 Chang cells per well, to achieve a confluent monolayer following overnight incubation at 37°C in the presence of 5% CO₂. *M. catarrhalis* 4223 or Q8 was cultured in 10 ml of BHI broth at 37°C for 18 hr, shaking at 200 rpm.

15 On day 2, bacterial cultures were pelleted by centrifugation at 3500 rpm for 10 min, and washed with 10 ml of PBS. After a centrifugation as above, each pellet was resuspended in 2 ml of DMEM supplemented with 10% FBS and 2 mM glutamine. The bacteria cultures were
20 diluted 1/10 in the supplemented DMEM to OD of approximately 1.8 at 578 nm. Confluent monolayers of Chang cells were washed once with 1 ml of PBS per well, and 0.5 ml of 10% BSA in PBS was added to each well as a blocking agent. Plates were incubated at 37°C for 30 min
25 and monolayers were washed twice with PBS as above.

A guinea pig anti-4223 M56 r200 kDa antiserum, prepared as described in Example 10 and pooled pre-immune guinea pig sera were heated at 56°C for 30 min to inactivate endogenous complement. Equal volumes of
30 appropriately diluted antisera and bacteria were mixed, and 200 µl of the mixture were added into each well. Examples of antiserum dilutions tested included 1/4, 1/16 and 1/64. The plate was incubated at 37°C for 1 hr, with gentle shaking. The plate was carefully washed four
35 times with 1 ml of PBS per well to remove the bacteria. To each well, 100 µl of trypsin were added, and the

plate was incubated at 37°C for 5 min. After inactivation of trypsin by addition of 900 µl Dulbecco's Minimal Essential Medium (DMEM) to each well, the cells were resuspended by pipetting up and down several times.

5 Ten-fold dilutions of resuspended cells were prepared in a new 96-well plate. Fifty µl each of the 1 x 10⁻², 1 x 10⁻³, 1 x 10⁻⁴ and 1 x 10⁻⁵ diluted samples were plated on a Mueller-Hinton agar plate. Plates were incubated at 37°C overnight, and then left at room
10 temperature for a further 24 hours. The number of colonies per plate was counted for the estimation of the total bound bacteria.

Dilution plating was also carried out for each bacterial strain, to estimate bacterial concentrations
15 and to calculate the total amount of bacteria added to each well. It was assumed that the number of bacteria bound to tissue culture cells in the presence of pre-immune sera represented 100% optimal binding for each assay, and 0% inhibition. Therefore, in order to
20 calculate the percent inhibition of the antiserum, we used the following formula:

$$\% \text{ inhibition} = 100 - \left[\frac{\text{total bacteria bound in 4223 anti-r200 kDa antiserum samples}}{\text{total bacteria bound in pre-immune sera samples}} \times 100 \right]$$

When the guinea pig 4223 anti-M56 r200 kDa protein serum was examined for the inhibition of binding of strain 4223 to Chang cells (Table 8), inhibition of 98%,
25 92% and 83% was observed at antiserum dilutions of 1/4, 1/16 and 1/64, respectively. With the heterologous strain Q8, the inhibition of binding to the tissue culture cells was estimated to be 77%, 82% and 55% at antiserum dilutions of 1/4, 1/16 and 1/64, respectively.
30 The results clearly showed that anti-M56 r200 kDa protein serum inhibited the binding of *M. catarrhalis* to cultured human epithelial cells.

Having demonstrated that 4223 anti-M56 r200 kDa antibody could block adherence of *M. catarrhalis* strains
35 4223 or Q8 to Chang epithelial cells in a dose-dependent

manner, the studies were extended to other strains. Of particular interest, were those strains that were not killed by anti-M56 r200 kDa antisera in the bactericidal antibody assay. To perform the *in vitro* adherence assay 5 on several strains, a single antibody dilution of 1/16 was used. The data for inhibition of *in vitro* adherence to Hep-2 cells is summarized in Table 9. The procedure for the Hep-2 epithelial cells was identical to the Chang cell procedure described above. The 4223 anti-M56 10 r200 kDa antibody effectively blocked adherence of the homologous strain by 48%. Strain RH408 does not express the 200 kDa gene and in the assay, antibody inhibited adherence of RH408 to 9%. This would be assumed to be a background level. Of 20 strains tested, 16 were 15 inhibited at rates higher than 9%. Among these strains were 19 strains that had not been killed by the 4223 anti-M56 r200 kDa antibody.

To summarize and as shown in Tables 1, 8 and 9, in our collection of 89 strains of *Moraxella catarrhalis*, 20 80 express 200 kDa. Of 57 strains tested with 4223 anti-M56 r200 kDa antibody in the bactericidal antibody assay, 39 were killed (58%). An additional 15 strains were inhibited from binding to epithelial cells by the same antibody for a total of 54 strains (95%), against 25 which a single antibody was effective. These data demonstrate the very high potential of r200 kDa proteins as vaccine antigens.

Example 13

This Example describes the sequence analysis of the 30 200 kDa protein gene from *M. catarrhalis* strain RH408, the non-clumping variant of 4223 described in WO 96/34960.

As described in Example 4 and Table 5, it appeared 35 that the number of G nucleotides in the G tract had a regulatory function on the expression of the 200 kDa gene. *M. catarrhalis* strain 4223 and its non-clumping derivative RH408 appeared to differ only in the

expression of the 200 kDa gene. The 200 kDa gene from strain RH408 was subcloned and sequenced and its sequence compared to the parental gene from strain 4223.

Four partially overlapping fragments of the 200 kDa protein gene were PCR amplified from strain *M. catarrhalis* RH408, using primers illustrated in Figure 16 and Table 10, under the conditions set out in Table 11. The combined sequences of the four PCR products covered approximately 6.5 kb including the entire 200 kDa protein gene and its flanking regions. When the sequence of the 6.5 kb fragment was compared with the sequence of the same region from its parent strain 4223, the only difference was the number of G nucleotides in the G tract. As described in Example 4, the correct number of G nucleotides in the G tract was nine. However, the number G nucleotides in the G tract of RH408 was only eight.

This result, along with the analysis of this region in 24 other strains of *M. catarrhalis* (Table 5) strongly suggests that the number of G nucleotides in the G tract controls the expression of the 200 kDa gene in *M. catarrhalis* strains. Similar mechanisms of transcriptional control are found for other bacterial genes, such as the *N. gonorrhoeae Pilc* gene (ref. 32).

25 Example 14

This Example describes the generation of additional N-terminal truncated r200 kDa proteins and expression studies.

As described in Example 6, the full-length r200 kDa protein appeared to be toxic to *E. coli* and could not be expressed under normal induction conditions. The M56 r200 kDa proteins were readily expressed, as described in Example 7, and were subsequently shown to be highly promising vaccine candidates in *in vitro* assays (Examples 11 and 12). The expression of r200 kDa proteins of intermediate length and their properties was studied.

Three additional N-terminal truncated 200 kDa genes were constructed from the 4223 200 kDa gene using the procedures described in Example 7. The sites of truncation were chosen based upon and are illustrated in Figure 17. The arrows in Figure 17 indicate the sites of truncation, namely ALA¹², VAL¹⁹ and GLY³⁹, each modified to MET. A 5' fragment up to an internal site was PCR amplified using primers illustrated in Table 8. For the ALA¹² truncation, the primers were 5' 6242.ks and 3' 4257.ks, for the VAL¹⁹ truncation, the primers were 5' 6243.ks and 3' 4257.ks and for the GLY³⁹ truncation, the primers were 5' 6244.ks and 3' 4257.ks (Table 10). The amplification conditions were the same as those used for pKS348 (Table 11). The PCR products were restricted with NdeI and ligated into the NdeI sites of pKS348 for expression. While some expression of r200 kDa was obtained with each of the N-terminal truncations, the level did not approach the levels obtained using pKS348.

Example 15

This Example illustrates the construction of plasmids pQWE and pQWF expressing C-terminal fragments of the 200 kDa gene.

As shown in the amino acid comparison of Figure 6, the carboxy half of the 200 kDa protein is quite conserved, the main difference being a large approximately 300 amino acid residue insert in strain LES-1. Since so much cross-reactivity for the anti-M56 r200 kDa antisera had been observed, the conserved carboxy half of the protein was expressed.

Plasmid pKS348 prepared as described in Example 7 was digested with restriction enzymes, Nde I and Nae I, producing four fragments. The approximately 5.8 kb Nde I/Nae I fragment containing the T7 promoter, ampicillin antibiotic resistance marker and the 3' end of the 200 kDa gene was agarose gel purified. The approximately 480 bp Nde I/Nde I fragment containing the 5' end of the 200 kDa gene was also gel purified. This approximately

480 bp fragment was then restriction digested with the enzymes *Nla* IV and *Pst* I and the *Nde* I/*Nla* IV fragment ligated to the previously isolated 5.8 kb *Nde* I/*Nae* I fragment to produce plasmid pQWE, as illustrated in
5 Figure 19. This plasmid construct contained a 200 kDa gene with the *Nla* IV to *Nae* I fragment deleted. This plasmid construct resulted, upon expression as described
in Example 7, in a fusion 200 kDa protein containing a very short piece of the 5' end and the 3' half of the
10 200 kDa protein.

An approximately 500 bp fragment around the *Eco* RI site in the 200 kDa gene from plasmid pKS348 was PCR amplified utilizing a 5' oligonucleotide, 6425.KS and a 3' oligonucleotide 4272.KS (Table 10) using the
15 conditions outlined in Table 11. The 5' oligonucleotide was synthesized with an ATG translational start codon and a *Nde* I restriction site, while the 3' oligonucleotide was synthesized with an *Eco* RI site. The approximately 500 bp PCR fragment was the restriction
20 digested with the enzymes *Nde* I and *Eco* RI. Plasmid pQWE, prepared as described above, was restriction digested with *Nde* I and *Eco* RI as illustrated in Figure 20, and this larger fragment agarose gel purified. The *Nde* I/*Eco* RI PCR fragment was then ligated into the
25 isolated *Nde* I/*Eco* RI fragment from pQWE, to produce plasmid pQWF. This construct expresses a 5' truncated 200 kDa protein, having only the 3' half of this protein from the region about 40 bp upstream of the *Nde* I site to the 3' end.

30 The constructs pQWE and pQWF, prepared as described above and as illustrated in Figures 19 and 20, were expressed in *E. coli* strain BL21(DE3)/pLySS as described in Example 7. The C-terminal half proteins were obtained at levels of expression approximately twice those
35 achieved using pKS348. Corresponding constructs were prepared from strain LES-1 and produced comparable results.

Antiserum was raised against the C-terminal half of 200 kDa protein produced from construct pQWE following the procedure of Example 10 and was employed in the bactericidal assay described in Example 11. As may be 5 seen in Table 1B the antiserum showed more than 30% of killing against 30 out of 31 strains which were killed by the bactericidal assay using antiserum raised against the product from pKS348.

SUMMARY OF THE DISCLOSURE

10 In summary of this disclosure, nucleotide sequences encoding an about 200 kDa outer membrane protein from several strains of *Moraxella catarrhalis* are described along with recombinant production of such protein. Modifications are possible within the scope of this 15 invention.

Table 1A

Examination of 200 kDa protein in *M. catarrhalis* strains

STRAIN	ANATOMICAL ORIGIN	SOURCE	EXPRESSION OF 200 kDa PROTEIN
4223	MID. EAR FLUID	T.F. MURPHY	+++
RH408	MUTANT OF 4223		-
3	SPUTUM	"	-
56	SPUTUM	"	-
135	MID. EAR FLUID	"	+++
585	BACTEREMIA	"	+
5191	MID. EAR FLUID	"	+++
8185	NASOPHARYNX	"	+++
M2	SPUTUM	"	+++
M5	SPUTUM	"	-
ATCC25240		ATCC	-
H-04	OTITIS	G.D. CAMPBELL	+++
H-12	"	"	-
PO-34	"	"	+++
PO-51	"	"	+++
E-07	"	"	+++
E-22	"	"	+++
E-23	"	"	+++
E-24	"	"	+++
M-02	"	"	+++
M-20	"	"	+++
M-29	"	"	+++
M-32	"	"	+++
M-35	"	"	+++
Q-2	EXPECTORATION	M.G. BERGERON	+
Q-6	"	"	-
Q-8	"	"	+++
Q-9	"	"	-
Q-10	"	"	+++
Q-11	"	"	+++
Q-12	"	"	-
R-1	BRONCHIAL SECRETIONS	"	+
R-2	"	"	-
R-4	OTITIS	"	+++
R-5	"	"	+++
R-6	"	"	+++
R-7	"	"	+++
N-209	BLOOD	"	+++
VH-1	OTITIS	V. HOWIE	+++
VH-2	"	"	+++
VH-3	"	"	+++
VH-4	"	"	+++
VH-5	"	"	+++
VH-6	"	"	+++
VH-7	"	"	+++

VH-8	"	"	+++
VH-9	"	"	+++
VH-10	"	"	+++
VH-11	"	"	+++
VH-12	"	"	+++
VH-13	"	"	+++
VH-14	"	"	+++
VH-15	"	"	+++
VH-16	"	"	+++
VH-17	"	"	+++
VH-18	"	"	+++
VH-19	"	"	+++
VH-20	"	"	+++
VH-23	"	"	+++
VH-24	"	"	+++
VH-25	"	"	+++
VH-26	"	"	+++
VH-27	"	"	+++
VH-28	"	"	+++
VH-29	"	"	+++
VH-30	"	"	+++
LES1	OTITIS	L.S. STENFORS	+++
LES2	"	"	+++
LES4	"	"	+++
LES5	"	"	+++
LES6	"	"	+++
LES7	"	"	+++
LES8	"	"	+++
LES9	"	"	+++
LES10	"	"	+++
LES11	"	"	+++
LES12	"	"	+++
LES13	"	"	+++
LES16	"	"	+++
LES17	"	"	+++
LES21	"	"	+++
30607	OTITIS	C.W. FORD	+++
CJ1	"	C. JOHNSON	+++
CJ3	"	"	+++
CJ4	"	"	+++
CJ7	"	"	+++
CJ8	"	"	+++
CJ9	"	"	+++
CJ11	"	"	+++

Bacteria were lysed and proteins were separated on SDS-PAGE gels. The expression of 200 kDa protein was examined by Coomassie Blue staining and by Western blot using anti-200 kDa protein guinea pig serum.

TABLE 1B

Bactericidal assay results against *Moraxella catarrhalis* using antisera raised against recombinant M56 200 kDa protein from strains 4223 and LES1, and recombinant C-terminal half of 200 kDa protein from strain 4223.

STRAIN	Killed by anti-M56 200 kDa from 4223	Killed by anti-C-terminal half of 200 kDa from 4223	Killed by anti-M56 200 kDa from LES1
4223	++	++	-
135	++	++	++
H-04	++	++	?
H-12*	-	NT	-
PO-34	-	NT	++
PO-51	-	NT	-
E-07	-	NT	++
E-22	++	++	-
E-24	-	NT	-
M-02	++	++	++
M-20	++	+	-
M-29	++	++	++
M-32	++	++	++
M-35	++	++	++
R4	-	NT	++
R5	++	++	++
R6	++	+	+
R7	++	NT	?
Q8**	++	+	NT
VH-1	++	NT	++
VH-2	++	NT	++
VH-4	-	NT	++
VH-5	++	++	-
VH-7	++	+	?
VH-8	++	++	++
VH-9	-	NT	++
VH-10	++	++	++
VH-13	-	NT	-
VH-15	++	++	++
VH-17	-	NT	-
VH-19	++	++	++
VH-20	+	+	++
VH-23	+	NT	++
VH-24	++	++	-
VH-25	-	NT	++
VH-26	-	NT	++
VH-27	-	NT	-
VH-28	+	NT	-
VH-29	++	++	++
VH-30	-	NT	++
LES1	-	NT	++
LES2	++	++	+
LES4	+	NT	++
LES5	-	NT	++
LES9	++	++	++
LES11	+	+	+
LES12	-	NT	?
LES13	-	NT	++
LES16	+	++	++
LES17	++	++	-
LES21	++	++	-
30607	+	NT	++

CJ1	++	++	++
CJ3	++	-	++
CJ4	++	++	++
CJ7	++	++	++
CJ8	++	++	?

* This strain does not produce 200 kDa protein.

** This is the only non-otitis media strain (isolated from expectorate) in this Table.

++: Killed more than 60% (>60%), +: killed between 30% and 60%,
-: killed 30% or less, NT: not tested, ?: the results not tested.

TABLE 2

The number of G nucleotides in the G tract of the 200 kDa protein gene determined by sequencing of subcloned genes from a λ EMBL3 clone.

Plasmid*	Number of G's
pKS10	10
pKS59	10
PKS63	10
PKS71	10

* pKS10 and pKS71 carried a DNA insert directly subcloned from a λ EMBL3 clone. pKS59 and pKS63 carried a subcloned DNA fragment, pKS9, which was a subclone from an λ EMBL3 clone. pKS59, pKS63 and pKS71 carried identical DNA inserts.

TABLE 3

The number of G nucleotides in the G tract of the 200 kDa protein gene amplified by PCR from subcloned genes

Primers	Template DNA	Number of G's
4211 and 4213	pKS9	10
4211 and 4213	pKS10	10
4211 and 4213	pKS71	10

* pKS9, pKS10 and pKS71, which contain a 5' fragment of the 200 kDa protein gene, were independently subcloned from the λ EMBL3 clone.

TABLE 4

The number of G nucleotides in the G tract of the 200 kDa protein gene amplified by PCR from chromosomal DNA of strain 4223

Primers	Template	Number of G
4211 and 4166	4223B	9
4211 and 4213	4223B	9
4211 and 4213	4223R	9

* The template chromosomal DNAs, 4223B and 4223R, were independently prepared from *M. catarrhalis* strain 4223.

TABLE 5

The number of G nucleotides in the G tract in different strains of *M. catarrhalis*

Expression	Number of G	Number of strains examined	Possible start codon
+++	3	1	ATG
+++	6	7	ATG
+++	9	7	ATG
+	10	3	GTG
-	7	3	GTG
-	8	2	GTG
-	9	1*	ATG
Total	24		

* The 200 kDa protein gene of this strain was prematurely terminated by a stop codon.

TABLE 6

Anti-M56 r200 kDa antibody titers in guinea pig and rabbit sera

ANTISERA	ANTIBODY TITERS	
	Against M56 r200 kDa (4223)	Against M56 r200 kDa (LES-1)
Gp anti-r200 kDa (4223)	204,800 409,600	102,400 409,600
Gp anti-r200 kDa (LES1)	204,800 102,400	1,638,400 1,638,400
Rb anti-r200 kDa (4223)	102,400 102,400	102,400 102,400
Rb anti-r200 kDa (LES1)	25,600 102,400	204,800 409,600

TABLE 7

Killing of *M. catarrhalis* strain 4223 by the bactericidal antibody activity of guinea pig anti-M56 r200 kDa protein serum

Serum dilution	1/64	1/128	1/256	1/512	1/1024
Killing %	97%	95%	95%	80%	38%

* The guinea pig antiserum was raised against M56 r200 kDa protein from strain 4223, and the bactericidal antibody activity of the serum at various dilutions were examined against the strain 4223.

TABLE 8

Inhibition of the binding of *M. catarrhalis* strains to Chang cells by guinea pig anti-M56 r200 kDa protein serum

Strain	1/4	1/16	1/64
4223	98%	92%	83%
Q8	77%	82%	55%

* The guinea pig antiserum was raised against M56 r200 kDa protein from strain 4223.

TABLE 9

Inhibition of *in vitro* adherence of *Moraxella catarrhalis* to Hep-2 cells by antiserum raised against recombinant 200 kDa protein from strain 4223

STRAIN	Inhibition
4223*	+++
PO-34	+++
PO-51	++
E-07	++
R4	++
VH-4	++
VH-9	-
VH-13	+
VH-17	++
VH-23	++
VH-25	++
VH-26	+++
VH-27	+
VH-28	+++
LES1	++
LES4	-
LES12	-
LES13	-
30607	+

+++: Inhibition was 30% or higher, ++: Inhibition was 20% to 30%, +: Inhibition was 15% to 20%, -: Inhibition was lower than 15%.

*: This strain is the positive control, and the only strain in this Table, which was killed by the bactericidal activity of anti-recombinant 200 kDa protein serum.

TABLE 10

Nucleotide sequences of primers used for PCR amplifications

PRIMER	NUCLEOTIDE SEQUENCE	SEQ ID No:
4211.KS	GATGCCTACGAGTTGATTGGGT	14
4213.KS	GAGCGTTGCACCGATCACCGAGGA	15
4166.KS	CACTAGCCTTACATCACCAACCGATG	16
5295.KS	AAGGTAAACCCATATGAATCACATCTATAAAGTCA	17
4260.KS	GCTTCTAGCTGTGCCACATTGA	18
5471.KS	CGCTCGCTGTCCATATGATCGGTGCAACGCTCA	19
4257.KS	GACCCTGTGCATATGACATGGCT	20
4254.KS	CCTTGGCATCAATCGTGGCACA	21
4278.KS	TTACACTGCATCAATGCCATTGTCT	22
4329.KS	CTGAGGGTGAATACAACCTACA	23
4272.KS	CATCAGAGGTCTTGAGGTGTCAT	24
4118.KS	CATCACCGTGGGTCAAAAGAACGCA	25
4267.KS	GATGTCGGCAATGTTACCTGA	26
4269.KS	CCACATTGACCAGTACTGGCACAGGTGCTA	27
4981.KS	ACCTATGATCAATGGCGATTGGT	28
6425.KS	AAAGATCATATGGTTACCTTGGCATTAAAC	29
6242	GTCATCTTCATATGCCACAGGCACA	30
6243	ACATTTATGCATATGGCAGAGTACGCCA	31
6244	GCTACAGGGCATATGGCAGTGTATGCACT	32

TABLE 11
PCR Cycle Conditions

1. For the construction of pKS294, oligonucleotides 5295 and 4260 and of pKS348, oligonucleotides 5471 and 4257:
95°C for 2 min → 95°C for 1 min, 60°C for 30 sec, 72°C for 1 min (10 cycles) → 95°C for 1 min, 62°C for 30 sec, 72°C for 1 min (20 cycles with extension of 1 sec/cycle) → 72°C for 10 min → 4°C.
2. For the construction of pQWF, oligonucleotides 6425 and 4272:
95°C for 2 min → 95°C for 1 min, 60°C for 30 sec, 72°C for 1 min (10 cycles) → 95°C for 1 min, 60°C for 30 sec, 72°C for 1 min (20 cycles with extension of 1 sec/cycle) → 72°C for 10 min → 4°C.
3. For the amplification of 700 bp fragment for sequencing the G-nucleotide tract from different strains, oligonucleotides 4211 and 4166.
95°C for 2 min → 95°C for 1 min, 60°C for 1 min, 72°C for 2 min (10 cycles) → 95°C for 1 min, 60°C for 1 min, 72°C for 2 min (20 cycles with extension of 5 sec/cycle) → 72°C for 10 min → 4°C.
4. For sequencing 200 kDa protein from *M. catarrhalis* strain RH408,
 - (a) oligonucleotides 4254 and 4278; 4118 and 4267; and 4269 and 4981:
95°C for 2 min → 95°C for 1 min, 62°C for 30 sec, 72°C for 1 min (10 cycles) → 95°C for 1 min, 62°C for 30 sec, 72°C for 1 min (20 cycles with extension of 2 sec/cycle) → 72°C for 10 min → 4°C.
 - (b) oligonucleotides 4329 and 4272
95°C for 2 min → 95°C for 1 min, 58°C for 30 sec, 72°C for 1 min 30 sec (10 cycles) → 95°C for 1 min, 58°C for 30 sec, 72°C for 1 min 30 sec (20 cycles with extension of 1 sec/cycle) → 72°C for 10 min → 4°C.

REFERENCES

1. Van Hare, G.F., P.A. Shurin, C.D. Marchant, N.A. Cartelli, C.E. Johnson, D. Fulton, S. Carlin, and C.H. Kim. Acute otitis media caused by *Branhamella catarrhalis*: biology and therapy. (1987) Rev. Infect. Dis. 9:16-27.
2. Chapman, A.J., D.M. Musher, S. Jonsson, J.E. Clarridge, and R.J. Wallace. 1985. Development of bactericidal antibody during *Branhamella catarrhalis* infection. J. Infect. Dis. 151:878-882.
3. Hager, H., A. Verghese, S. Alvarez, and S.L. Berk. 1987. *Branhamella catarrhalis* respiratory infections. Rev. Infect. Dis. 9:1140-1149.
4. McLeod, D.T., F. Ahmad, M.J. Croughan, and M.A. Calder. 1986. Bronchopulmonary infection due to *M. catarrhalis*. Clinical features and therapeutic response. Drugs 31(Suppl.3):109-112.
5. Nicotra, B., M. Rivera, J.I. Luman, and R.J. Wallace. 1986. *Branhamella catarrhalis* as a lower respiratory tract pathogen in patients with chronic lung disease. Arch. Intern. Med. 146:890-893.
6. Ninane, G., J. Joly, and M. Kraytman. 1978. Bronchopulmonary infection due to *Branhamella catarrhalis* : 11 cases assessed by transtracheal puncture. Br. Med. Jr. 1:276-278.
7. Srinivasan, G., M.J. Raff, W.C. Templeton, S.J. Givens, R.C. Graves, and J.C. Mel. 1981. *Branhamella catarrhalis* pneumonia. Report of two cases and review of the literature. Am. Rev. Respir. Dis. 123:553-555.
8. West, M., S.L. Berk, and J.K. Smith. 1982. *Branhamella catarrhalis* pneumonia. South. Med. J. 75:1021-1023.
9. Brorson, J-E., A. Axelsson, and S.E. Holm. 1976. Studies on *Branhamella catarrhalis* (*Neisseria catarrhalis*) with special reference to maxillary sinusitis. Scan. J. Infect. Dis. 8:151-155.
10. Evans, F.O., Jr., J.B. Sydnor, W.E.C. Moore, G.R. Moore, J.L. Manwaring, A.H. Brill, R.T. Jackson, S. Hanna, J.S. Skaar, L.V. Holdeman, G.S. Fitz-Hugh, M.A. Sande, and J.M. Gwaltney, Jr. 1975. Sinusitis of the maxillary antrum. N. Engl. J. Med. 293:735-739.

11. Tinkelman, D.G., and H.J. Silk. 1989. Clinical and bacteriologic features of chronic sinusitis in children. *Am.J.Dis.Child.* 143:938-942.
12. Wald, E.R., C. Byers, N. Guerra, M. Casselbrant, and D. Beste. 1989. Subacute sinusitis in children. *J.Pediatr.* 115:28-32.
13. Wald, E.R., G.J. Milmoe, A. Bowen, J. Ledesma-Medina, N. Salamon, and C.D. Bluestone. 1981. Acute maxillary sinusitis in children. *N Engl J Med.* 304:749-754.
14. Christensen, J.J., and B. Bruun. 1985. Bacteremia caused by a beta-lactamase producing strain of *Branhamella catarrhalis*. *Acta Pathol. Microbiol. Immunol. Scand. Sect.B* 93:273-275.
15. Craig, D.B., and P.A. Wehrle. 1983. *Branhamella catarrhalis* septic arthritis. *J. Rheumatol.* 10:985-986.
16. Gray, L.D., R.E. Van Scoy, J.P. Anhalt, and P.K.W. Yu. 1989. Wound infection caused by *Branhamella catarrhalis*. *J.Clin.Microbiol.* 27:818-820.
17. Guthrie, R., K. Bakenhaster, R. Nelson, and R. Woskobnick. 1988. *Branhamella catarrhalis* sepsis: a case report and review of the literature. *J.Infect.Dis.* 158:907-908.
18. Hiroshi, S., E.J. Anaissie, N. Khardori, and G.P. Bodey. 1988. *Branhamella catarrhalis* septicemia in patients with leukemia. *Cancer* 61:2315-2317.
19. O'Neill, J.H., and P.W. Mathieson. 1987. Meningitis due to *Branhamella catarrhalis*. *Aust. N.Z. J. Med.* 17:241-242.
20. Murphy, T.F. 1989. The surface of *Branhamella catarrhalis*: a systematic approach to the surface antigens of an emerging pathogen. *Pediatr. Infect. Dis. J.* 8:S75-S77.
21. Klingman, K.L., and T.F. Murphy. 1994. Purification and characterization of a high-molecular-weight outer membrane protein of *Moraxella* (*Branhamella*) *catarrhalis*. *Infect. Immun.* 62:1150-1155.
22. Helminen, M.E., I. Maciver, J.L. Latimer, J. Klesney-Tait, L.D. Cope, M. Paris, G.H. McCracken, Jr., and E.J. Hansen. 1994. A large, antigenically conserved protein on the surface of *Moraxella catarrhalis* is a target for protective antibodies. *J. Infect. Dis.* 170:867-872.

23. Aebi, C., I. Maciver, J.L. Latimer, L.D. Cope, M.K. Stevens, S.E. Thomas, G.H. McCracken, Jr., and E.J. Hansen. 1997. A protective epitope of *Moraxella catarrhalis* is encoded by two different genes. *Infect. Immun.* 65:4367-4377.
24. Nixon-George et al. The adjuvant effect of Stearyl Tyrosine on a recombinant subunit hepatitis B surface antigen. (1990), *J. Immunology* 144:4798-4802.
25. Wiesmuller (1989), Novel low-molecular weight synthetics vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator, *Vaccine* 8:29-33.
26. Deres et al. (1989), *Nature* 342:561.
27. Lockhoff, O. Glycolipids as Immunomodulators: Synthesis and Properties. 1991. *Chem. Int. Ed. Engl.* 30:1611-1620.
28. Taber and Richardson, 1985, *PNAS* 82(4):1074-8.
29. Fitzgerald et al, *FEMS Immunol. & Med. Microbiol.* 18:209-216, 1997.
30. Fitzgerald et al, *FEMS Immunol. & Med Microbiol.* 23:57-66, 1999.
31. Kyd et al, *J. Med. Microbiology*, 47:159-168, 1998.
32. Johnson et al, 1997, *EMBO J.* 10(2):477-488.
33. Benz, I. and Schmidt, M.A., 1992. *Mol Microbiol* 6:1539-1546.

CLAIMS

What we claim is:

1. An isolated and purified nucleic acid molecule having a nucleotide sequence selected from the group consisting of:
 - (a) a nucleotide sequence set forth in Figure 3, 4 or 5 (SEQ ID Nos: 5, 6, 8, 9, 11, 12) for *Moraxella catarrhalis* strains 4223, Q8 and LES-1 respectively or the complementary sequence thereto,
 - (b) a nucleotide sequence encoding an about 200 kDa outer membrane protein of a strain of *Moraxella catarrhalis* and having the derived amino acid sequence shown in Figures 3, 4 or 5 (SEQ ID Nos: 7, 10, 13) for *Moraxella catarrhalis* strains 4223, Q8 and LES-1 respectively, and
 - (c) a nucleotide sequence encoding an about 200 kDa outer membrane protein of another strain of *Moraxella catarrhalis* which is characterized by a tract of consecutive G nucleotides which is 3 or a multiple thereof in length, an ATG start codon about 80 to 90 bp upstream of said tract and said tract being located between about amino acids 25 and 35 encoded by the nucleotide sequence.
2. The nucleic acid molecule of claim 1 wherein said another strain of *Moraxella catarrhalis* in (c) is a strain as identified in Table 1A other than strains 4223, Q8 and LES-1 and expressing an about 200 kDa protein.
3. An isolated and purified nucleic acid molecule having a nucleotide sequence selected from the group consisting of:
 - (a) a nucleotide sequence set forth in Figure 8 (SEQ ID No: 12) for a 5'-truncation of the gene encoding an about 200 kDa outer membrane protein of *Moraxella catarrhalis* strain 4223,

(b) a nucleotide sequence encoding the derived amino acid sequence set forth in Figure 9 (SEQ ID No: 13) for a N-terminal truncation of an about 200 kDa outer membrane protein of *Moraxella catarrhalis* strain 4223, and

(c) a nucleotide sequence encoding a 5'-truncation of a gene encoding an about 200 kDa outer membrane protein of another strain of *Moraxella catarrhalis* and being capable of expressing the corresponding N-terminally truncated about 200 kDa outer membrane protein from *E. coli*.

4. An isolated and purified nucleic acid molecule which is a contiguous *Nde* I - *Pst* I fragment of SEQ ID No: 5.

5. A vector for transforming a host comprising a nucleic acid molecule as claimed in any one of claims 1 to 4.

6. The vector of claim 5 which is a plasmid vector.

7. The vector of claim 5 which has the identifying characteristics of pKS348 (ATCC 203529) shown in Figure 10 or pKS294 (ATCC 203528) shown in Figure 9.

8. The vector of claim 5 which has the identifying characteristic of pQWE shown in Figure 19 or pQWF shown in Figure 20.

9. A host cell transformed by a vector as claimed in claim 5 and expressing an about 200 kDa protein of a strain of *Moraxella catarrhalis* or an approximately C-terminal half thereof.

10. The host cell of claim 9 which is *E. coli*.

11. A recombinant about 200 kDa outer membrane protein of a strain of *Moraxella catarrhalis* or an approximately C-terminal half thereof producible by the transformed host of claim 9.

12. The recombinant protein of claim 11 producible in inclusion bodies.

13. An immunogenic composition comprising the recombinant about 200 kDa outer membrane protein or an approximately C-terminal half thereof of claim 11.

14. The immunogenic composition of claim 13 formulated as a vaccine for *in vivo* administration to protect against disease caused by *Moraxella catarrhalis*.

15. The immunogenic composition of claim 13 in combination with a targeting molecule for delivery to specific cells of the immune system or to mucosal surfaces.

16. The immunogenic composition of claim 13 formulated as a microparticle, capsule or liposome preparation.

17. The immunogenic composition of claim 13 further comprising an adjuvant.

18. A method of inducing protection against disease caused by *Moraxella catarrhalis*, comprising administering to a susceptible host an effective amount of the immunogenic composition of claim 13.

19. The method of claim 18 wherein said susceptible host is a human.

20. A method for the production of an about 200 kDa outer membrane protein of a strain of *Moraxella catarrhalis* or an approximately C-terminal half thereof, which comprises:

transforming a host with a vector as claimed in claim 5,

growing the host cell to express the encoded about 200 kDa protein or an approximately C-terminal half thereof, and

isolating and purifying the expressed about 200 kDa protein or an approximately C-terminal half thereof.

21. The method of claim 20 wherein the host cell is *E. coli*.

22. The method of claim 20 wherein said encoded about 200 kDa protein is expressed in inclusion bodies.

23. The method of claim 22 wherein said isolation and purification of the expressed about 200 kDa protein is effected by:

disrupting the grown transformed cells to produce a supernatant and the inclusion bodies,

solubilizing the inclusion bodies to produce a solution of the recombinant about 200 kDa protein,

chromatographically purifying the solution of recombinant about 200 kDa protein free from contaminating proteins, and

isolating the purified recombinant about 200 kDa protein.

ABSTRACT OF THE DISCLOSURE

An isolated and purified outer membrane protein of a *Moraxella* strain, particularly *M. catarrhalis*, having a molecular mass of about 200 kDa, is provided by 5 recombinant means. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for *in vivo* administration to a host to confer protection against 10 disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.

FIGURE 1

Subclones of portions of the 200 kDa protein gene from λ EMBL3 clone 8II and PCR amplification of 5' region




Figure 2. *M. catarrhalis* strain 4223 λEMBL3 clone 200kDa gene

ccatggatat gggcagggtgt gctgcctgc cgtatgatgg cgatgacacc ccatttgc	60
cataatctgta cgatttgaca tgtgatatga tttaacatgt gacatgattt aacattgttt	120
aataactgttg ccatcattac cataatttag taacgcattt agtaacgcatt ttgtaaaaat	180
cattgcgc	cccc
cattatgtgt atcatatgaa tagaatatta tgattgtatc tgattattgt	240
atcagaatgg ttagtgcata ttagtgcatt tacgagttga tttgggttaa tcactctatg	300
atttgatata ttttgaaaact aatctattga cttaaatcac catatggta taatttagca	360
taatggtagg ctttttgtaa aaatcacatc gcaatattgt tctactgtta ctaccatgct	420
tgaatgacga tcccaatcac cagattcatt caagtgtgt gtttgtatac gcaccattta	480
ccctaattat ttcaatcaaa tgcctatgtc agcatgtatc attttttaa ggttaaaccac	540
catt aatcac atctataaaag tcattttaa caaagccaca ggcacattta tggcagtggc	600
agagtacgcc aaatcccaca gcac <u>gggggggg</u> <u>gggg</u> tagctg tgctacaggg caagttggca	660
gtgtatgcac tctgagctt gcccgatttgcgatcgctgc tgccctc gtg atc ggt	716
Val Ile Gly	
1	
gca acg ctc agt ggc agt gct tat gct caa aaa aaa gat acc aaa cat	764
Ala Thr Leu Ser Gly Ser Ala Tyr Ala Gln Lys Lys Asp Thr Lys His	
5 10 15	
atc gca att ggt gaa caa aac cag cca aga cgc tca ggc act gcc aag	812
Ile Ala Ile Gly Glu Gln Asn Gln Pro Arg Arg Ser Gly Thr Ala Lys	
20 25 30 35	
gcg gac ggt gat cga gcc att gct att ggt gaa aat gct aac gca cag	860
Ala Asp Gly Asp Arg Ala Ile Ala Ile Gly Glu Asn Ala Asn Ala Gln	
40 45 50	
ggc ggt caa gcc atc gcc atc ggt agt agt aat aaa act gtc aat gga	908
Gly Gly Gln Ala Ile Ala Ile Gly Ser Ser Asn Lys Thr Val Asn Gly	
55 60 65	
agc agt ttg gat aag ata ggt acc gat gct acg ggt caa gag tcc atc	956
Ser Ser Leu Asp Lys Ile Gly Thr Asp Ala Thr Gly Gln Glu Ser Ile	
70 75 80	
gcc atc ggt ggt gat gta aag gct agt ggt gat gcc tcg att gcc atc	1004
Ala Ile Gly Gly Asp Val Lys Ala Ser Gly Asp Ala Ser Ile Ala Ile	
85 90 95	
ggt agt gat gac tta cat ttg ctt gat cag cat ggt aat cct aaa cat	1052
Gly Ser Asp Asp Leu His Leu Leu Asp Gln His Gly Asn Pro Lys His	
100 105 110 115	
ccg aaa ggt act ctg att aac gat ctt att aac ggc cat gca gta tta	1100
Pro Lys Gly Thr Leu Ile Asn Asp Leu Ile Asn Gly His Ala Val Leu	
120 125 130	

aaa gaa ata cga agc tca aag gat aat gat gta aaa tat aga cgc aca Lys Glu Ile Arg Ser Ser Lys Asp Asn Asp Val Lys Tyr Arg Arg Thr 135	140	145	1148
acc gca agc gga cac gcc agt act gca gtg gga gcc atg tca tat gca Thr Ala Ser Gly His Ala Ser Thr Ala Val Gly Ala Met Ser Tyr Ala 150	155	160	1196
cag ggt cat ttt tcc aac gcc ttt ggt aca cgg gca aca gct aaa agt Gln Gly His Phe Ser Asn Ala Phe Gly Thr Arg Ala Thr Ala Lys Ser 165	170	175	1244
gcc tat tcc ttg gca gtg ggt ctt gcc gcc aca gag ggc caa tct Ala Tyr Ser Leu Ala Val Gly Leu Ala Ala Thr Ala Glu Gly Gln Ser 180	185	190	1292
aca atc gct att ggt tct gat gca aca tct agc tcg ttg gga gcg ata Thr Ile Ala Ile Gly Ser Asp Ala Thr Ser Ser Leu Gly Ala Ile 200	205	210	1340
gcc ctt ggt gca ggt act cgt gct cag cta cag ggc agt att gcc cta Ala Leu Gly Ala Gly Thr Arg Ala Gln Leu Gln Gly Ser Ile Ala Leu 215	220	225	1388
ggc caa ggt tct gtt gtc act cag agt gat aat aat tct aga ccg gcc Gly Gln Gly Ser Val Val Thr Gln Ser Asp Asn Asn Ser Arg Pro Ala 230	235	240	1436
tat aca cca aat acc cag gca cta gac ccc aag ttt caa gcc acc aat Tyr Thr Pro Asn Thr Gln Ala Leu Asp Pro Lys Phe Gln Ala Thr Asn 245	250	255	1484
aat acg aag gcg ggt cca ctt tcc att ggt agt aac tct atc aaa cgt Asn Thr Lys Ala Gly Pro Leu Ser Ile Gly Ser Asn Ser Ile Lys Arg 260	265	270	1532
aaa atc atc aat gtc ggt gca ggt gtt aat aaa acc gat gcg gtc aat Lys Ile Ile Asn Val Gly Ala Gly Val Asn Lys Thr Asp Ala Val Asn 280	285	290	1580
gtg gca cag cta gaa gcg gtg gtg aag tgg gct aag gag cgt aga att Val Ala Gln Leu Glu Ala Val Val Lys Trp Ala Lys Glu Arg Arg Ile 295	300	305	1628
act ttt cag ggt gat gat aac agt act gac gta aaa ata ggt ttg gat Thr Phe Gln Gly Asp Asp Asn Ser Thr Asp Val Lys Ile Gly Leu Asp 310	315	320	1676
aat act tta act att aaa ggt ggt gca gag acc aac gca tta acc gat Asn Thr Leu Thr Ile Lys Gly Gly Ala Glu Thr Asn Ala Leu Thr Asp 325	330	335	1724
aat aat atc ggt gtg gta aaa gag gct gat aat agt ggt ctg aaa gtt Asn Asn Ile Gly Val Val Lys Glu Ala Asp Asn Ser Gly Leu Lys Val 340	345	350	1772
aaa ctt gct aaa act tta aac aat ctt act gag gtg aat aca act aca Lys Leu Ala Lys Thr Leu Asn Asn Leu Thr Glu Val Asn Thr Thr Thr 355			1820

© 2007 Bio 201

	360	365	370	
tta aat gcc aca acc aca gtt aag gta ggt agt agt agt act aca Leu Asn Ala Thr Thr Val Lys Val Gly Ser Ser Ser Thr Thr	375	380	385	1868
gct gaa tta ttg agt gat agt tta acc ttt acc cag ccc aat aca ggc Ala Glu Leu Leu Ser Asp Ser Leu Thr Phe Thr Gln Pro Asn Thr Gly	390	395	400	1916
agt caa agc aca agc aaa acc gtc tat ggc gtt aat ggg gtg aag ttt Ser Gln Ser Thr Ser Lys Thr Val Tyr Gly Val Asn Gly Val Lys Phe	405	410	415	1964
act aat aat gca gaa aca aca gca atc ggc act act cgt att acc Thr Asn Asn Ala Glu Thr Thr Ala Ala Ile Gly Thr Thr Arg Ile Thr	420	425	430	2012
aga gat aaa att ggc ttt gct cga gat ggt gat gtt gat gaa aaa caa Arg Asp Lys Ile Gly Phe Ala Arg Asp Gly Asp Val Asp Glu Lys Gln	440	445	450	2060
gca cca tat ttg gat aaa aaa caa ctt aaa gtg ggt agt gtt gca att Ala Pro Tyr Leu Asp Lys Lys Gln Leu Lys Val Gly Ser Val Ala Ile	455	460	465	2108
acc ata gac aat ggc att gat gca ggt aat aaa aag atc agt aat ctt Thr Ile Asp Asn Gly Ile Asp Ala Gly Asn Lys Lys Ile Ser Asn Leu	470	475	480	2156
gcc aaa ggt agc agt gct aac gat gcg gtt acc atc gaa cag ctc aaa Ala Lys Gly Ser Ser Ala Asn Asp Ala Val Thr Ile Glu Gln Leu Lys	485	490	495	2204
gcc gcc aag cct act tta aac gca ggc gct ggc atc agt gtc aca cct Ala Ala Lys Pro Thr Leu Asn Ala Gly Ala Gly Ile Ser Val Thr Pro	500	505	510	2252
act gaa ata tca gtt gat gct aag agt ggc aat gtt acc gcc cca act Thr Glu Ile Ser Val Asp Ala Lys Ser Gly Asn Val Thr Ala Pro Thr	520	525	530	2300
tac aac att ggc gtg aaa acc acc gag ctt aac agt gat ggc act agt Tyr Asn Ile Gly Val Lys Thr Thr Glu Leu Asn Ser Asp Gly Thr Ser	535	540	545	2348
gat aaa ttt agt gtt aag ggt agt ggt acg aac aat agc tta gtt acc Asp Lys Phe Ser Val Lys Gly Ser Gly Thr Asn Asn Ser Leu Val Thr	550	555	560	2396
gcc gaa cat ttg gca agc tat cta aat gaa gtc aat cga acg gct gac Ala Glu His Leu Ala Ser Tyr Leu Asn Glu Val Asn Arg Thr Ala Asp	565	570	575	2444
agt gct cta caa agc ttt acc gtt aaa gaa gaa gac gat gat gac gcc Ser Ala Leu Gln Ser Phe Thr Val Lys Glu Glu Asp Asp Asp Asp Ala	580	585	590	2492
aac got atc acc gtg gct aaa gat acg aca aaa aat gcc ggc gca gtc				2540

Asn Ala Ile Thr Val Ala Lys Asp Thr Thr Lys Asn Ala Gly Ala Val			
600	605	610	
agc atc tta aaa ctc aaa ggt aaa aac ggt cta acg gtt gct acc aaa			2588
Ser Ile Leu Lys Leu Lys Gly Lys Asn Gly Leu Thr Val Ala Thr Lys			
615	620	625	
aaa gat ggt acg gtt acc ttt ggg ctt agc caa gat agc ggt ctg acc			2636
Lys Asp Gly Thr Val Thr Phe Gly Leu Ser Gln Asp Ser Gly Leu Thr			
630	635	640	
att ggc aaa agc acc cta aac aac gat ggc ttg act gtt aaa gat acc			2684
Ile Gly Lys Ser Thr Leu Asn Asn Asp Gly Leu Thr Val Lys Asp Thr			
645	650	655	
aac gaa caa atc caa gtc ggt gct aat ggc att aaa ttt act aat gtg			2732
Asn Glu Gln Ile Gln Val Gly Ala Asn Gly Ile Lys Phe Thr Asn Val			
660	665	670	675
aat ggt agt aat cca ggt act ggc att gca aat acc gct cgc att acc			2780
Asn Gly Ser Asn Pro Gly Thr Gly Ile Ala Asn Thr Ala Arg Ile Thr			
680	685	690	
aga gat aaa att ggc ttt gct ggt tct gat ggt gca gtt gat aca aac			2828
Arg Asp Lys Ile Gly Phe Ala Gly Ser Asp Gly Ala Val Asp Thr Asn			
695	700	705	
aaa cct tat ctt gat caa gac aag cta caa gtt ggc aat gtt aag att			2876
Lys Pro Tyr Leu Asp Gln Asp Lys Leu Gln Val Gly Asn Val Lys Ile			
710	715	720	
acc aac act ggc att aac gca ggt ggt aaa gcc atc aca ggg ctg tcc			2924
Thr Asn Thr Gly Ile Asn Ala Gly Gly Lys Ala Ile Thr Gly Leu Ser			
725	730	735	
cca aca ctg cct agc att gcc gat caa agt agc cgc aac ata gaa ctg			2972
Pro Thr Leu Pro Ser Ile Ala Asp Gln Ser Ser Arg Asn Ile Glu Leu			
740	745	750	755
ggc aat aca atc caa gac aaa gac aaa tcc aac gct gcc agc att aat			3020
Gly Asn Thr Ile Gln Asp Lys Asp Lys Ser Asn Ala Ala Ser Ile Asn			
760	765	770	
gat ata tta aat aca ggc ttt aac cta aaa aat aat aac aac ccc att			3068
Asp Ile Leu Asn Thr Gly Phe Asn Leu Lys Asn Asn Asn Pro Ile			
775	780	785	
gac ttt gtc tcc act tat gac att gtt gac ttt gcc aat ggc aat gcc			3116
Asp Phe Val Ser Thr Tyr Asp Ile Val Asp Phe Ala Asn Gly Asn Ala			
790	795	800	
acc acc gcc aca gta acc cat gat acc gct aac aaa acc agt aaa gtg			3164
Thr Thr Ala Thr Val Thr His Asp Thr Ala Asn Lys Thr Ser Lys Val			
805	810	815	
gta tat gat gtg aat gtg gat gat aca acc att cat cta aca ggc act			3212
Val Tyr Asp Val Asn Val Asp Asp Thr Thr Ile His Leu Thr Gly Thr			
820	825	830	835

gat gac aat aaa aaa ctt ggc gtc aaa acc acc aaa ctg aac aaa aca Asp Asp Asn Lys Lys Leu Gly Val Thr Thr Lys Leu Asn Lys Thr 840	845	850	3260
agt gct aat ggt aat aca gca act aac ttt aat gtt aac tct agt gat Ser Ala Asn Gly Asn Thr Ala Thr Asn Phe Asn Val Asn Ser Ser Asp 855	860	865	3308
gaa gat gcc ctt gtt aac gcc aaa gac atc gcc gaa aat cta aac acc Glu Asp Ala Leu Val Asn Ala Lys Asp Ile Ala Glu Asn Leu Asn Thr 870	875	880	3356
cta gcc aag gaa att cac acc acc aaa ggc aca gca gac acc gcc cta Leu Ala Lys Glu Ile His Thr Thr Lys Gly Thr Ala Asp Thr Ala Leu 885	890	895	3404
caa acc ttt acc gtt aaa aag gta gat gaa aat aat aat gct gat gac Gln Thr Phe Thr Val Lys Val Asp Glu Asn Asn Asn Ala Asp Asp 900	905	910	3452
gcc aac gcc atc acc gtg ggt caa aag aac gca aat aat caa gtc aac Ala Asn Ala Ile Thr Val Gly Gln Lys Asn Ala Asn Asn Gln Val Asn 920	925	930	3500
acc cta aca ctc aaa ggt gaa aac ggt ctt aat att aaa acc gac aaa Thr Leu Thr Leu Lys Gly Glu Asn Gly Leu Asn Ile Lys Thr Asp Lys 935	940	945	3548
aat ggt acg gtt acc ttt ggc att aac acc aca agc ggt ctt aaa gcc Asn Gly Thr Val Thr Phe Gly Ile Asn Thr Thr Ser Gly Leu Lys Ala 950	955	960	3596
ggc aaa agc acc cta aac gac ggt ggc ttg tct att aaa aac ccc act Gly Lys Ser Thr Leu Asn Asp Gly Gly Leu Ser Ile Lys Asn Pro Thr 965	970	975	3644
ggt agc gaa caa atc caa gtc ggt gct gat ggc gtg aag ttt gcc aag Gly Ser Glu Gln Ile Gln Val Gly Ala Asp Gly Val Lys Phe Ala Lys 980	985	990	3692
gtt aat aat aat ggt gtt gta ggt gct ggc att gat ggc aca act cgc Val Asn Asn Gly Val Val Gly Ala Gly Ile Asp Gly Thr Thr Arg 1000	1005	1010	3740
att acc aga gat gaa att ggc ttt act ggg act aat ggc tca ctt gat Ile Thr Arg Asp Glu Ile Gly Phe Thr Gly Thr Asn Gly Ser Leu Asp 1015	1020	1025	3788
aaa agc aaa ccc cac cta agc aaa gac ggc att aac gca ggt ggt aaa Lys Ser Lys Pro His Leu Ser Lys Asp Gly Ile Asn Ala Gly Gly Lys 1030	1035	1040	3836
aag att acc aac att caa tca ggt gag att gcc caa aac agc cat gat Lys Ile Thr Asn Ile Gln Ser Gly Glu Ile Ala Gln Asn Ser His Asp 1045	1050	1055	3884
gct gtg aca ggc ggc aag att tat gat tta aaa acc gaa ctt gaa aac Ala Val Thr Gly Gly Lys Ile Tyr Asp Leu Lys Thr Glu Leu Glu Asn 1060	1065	1070	3932
		1075	

aaa atc agc agt act gcc aaa aca gca caa aac tca tta cac gaa ttc Lys Ile Ser Ser Thr Ala Lys Thr Ala Gln Asn Ser Leu His Glu Phe 1080	1085	1090	3980	
tca gta gca gat gaa caa ggt aat aac ttt acg gtt agt aac cct tac Ser Val Ala Asp Glu Gln Gly Asn Asn Phe Thr Val Ser Asn Pro Tyr 1095	1100	1105	4028	
tcc agt tat gac acc tca aag acc tct gat gtc atc acc ttt gca ggt Ser Ser Tyr Asp Thr Ser Lys Thr Ser Asp Val Ile Thr Phe Ala Gly 1110	1115	1120	4076	
gaa aac ggc att acc acc aag gta aat aaa ggt gtg gtg cgt gtg ggc Glu Asn Gly Ile Thr Thr Lys Val Asn Lys Gly Val Val Arg Val Gly 1125	1130	1135	4124	
att gac caa acc aaa ggc tta acc acg cct aag ctg acc gtg ggt aat Ile Asp Gln Thr Lys Gly Leu Thr Thr Pro Lys Leu Thr Val Gly Asn 1140	1145	1150	1155	4172
aat aat ggc aaa ggc att gtc att gac agc caa aat ggt caa aat acc Asn Asn Gly Lys Gly Ile Val Ile Asp Ser Gln Asn Gly Gln Asn Thr 1160	1165	1170	4220	
atc aca gga cta agc aac act cta gct aat gtt acc aat gat aaa ggt Ile Thr Gly Leu Ser Asn Thr Leu Ala Asn Val Thr Asn Asp Lys Gly 1175	1180	1185	4268	
agc gta cgc acc aca gaa cag ggc aat ata atc aaa gac gaa gac aaa Ser Val Arg Thr Thr Glu Gln Gly Asn Ile Ile Lys Asp Glu Asp Lys 1190	1195	1200	4316	
acc cgt gcc gcc agc att gtt gat gtg cta agc gca ggc ttt aac ttg Thr Arg Ala Ala Ser Ile Val Asp Val Leu Ser Ala Gly Phe Asn Leu 1205	1210	1215	4364	
caa ggc aat ggt gaa gcg gtt gac ttt gtc tcc act tat gac acc gtc Gln Gly Asn Gly Glu Ala Val Asp Phe Val Ser Thr Tyr Asp Thr Val 1220	1225	1230	1235	4412
aac ttt gcc gat ggc aat gcc acc acc gct aag gtg acc tat gat gac Asn Phe Ala Asp Gly Asn Ala Thr Thr Ala Lys Val Thr Tyr Asp Asp 1240	1245	1250	4460	
aca agc aaa acc agt aaa gtg gtc tat gat gtc aat gtg gat gat aca Thr Ser Lys Thr Ser Lys Val Val Tyr Asp Val Asn Val Asp Asp Thr 1255	1260	1265	4508	
acc att gaa gtt aaa gat aaa aaa ctt ggc gta aaa acc acc aca ttg Thr Ile Glu Val Lys Asp Lys Lys Leu Gly Val Lys Thr Thr Leu 1270	1275	1280	4556	
acc agt act ggc aca ggt gct aat aaa ttt gcc cta agc aat caa gct Thr Ser Thr Gly Thr Gly Ala Asn Lys Phe Ala Leu Ser Asn Gln Ala 1285	1290	1295	4604	
act ggc gat gcg ctt gtc aag gcc agt gat atc gtt gct cat cta aac Thr Gly Asp Ala Leu Val Lys Ala Ser Asp Ile Val Ala His Leu Asn			4652	

1300	1305	1310	1315	
acc tta tct ggc gac atc caa act gcc aaa ggg gca agc caa gcg aac Thr Leu Ser Gly Asp Ile Gln Thr Ala Lys Gly Ala Ser Gln Ala Asn				4700
1320		1325		1330
aac tca gca ggc tat gtg gat gct gat ggc aat aag gtc atc tat gac Asn Ser Ala Gly Tyr Val Asp Ala Asp Gly Asn Lys Val Ile Tyr Asp				4748
1335		1340		1345
agt acc gat aac aag tac tat caa gcc aaa aat gat ggc aca gtt gat Ser Thr Asp Asn Lys Tyr Tyr Gln Ala Lys Asn Asp Gly Thr Val Asp				4796
1350		1355		1360
aaa acc aaa gaa gtt gcc aaa gac aaa ctg gtc gcc caa gcc caa acc Lys Thr Lys Glu Val Ala Lys Asp Lys Leu Val Ala Gln Ala Gln Thr				4844
1365		1370		1375
cca gat ggc aca ttg gct caa atg aat gtc aaa tca gtc att aac aaa Pro Asp Gly Thr Leu Ala Gln Met Asn Val Lys Ser Val Ile Asn Lys				4892
1380		1385		1390
gaa caa gta aat gat gcc aat aaa aag caa ggc atc aat gaa gac aac Glu Gln Val Asn Asp Ala Asn Lys Gln Gly Ile Asn Glu Asp Asn				4940
1400		1405		1410
gcc ttt gtt aaa gga ctt gaa aaa gcc gct tct gat aac aaa acc aaa Ala Phe Val Lys Gly Leu Glu Lys Ala Ala Ser Asp Asn Lys Thr Lys				4988
1415		1420		1425
aac gcc gca gta act gtg ggt gat tta aat gcc gtt gcc caa aca ccg Asn Ala Ala Val Thr Val Gly Asp Leu Asn Ala Val Ala Gln Thr Pro				5036
1430		1435		1440
ctg acc ttt gca ggg gat aca ggc aca acg gct aaa aaa ctg ggc gag Leu Thr Phe Ala Gly Asp Thr Gly Thr Thr Ala Lys Lys Leu Gly Glu				5084
1445		1450		1455
act ttg acc atc aaa ggt ggg caa aca gac acc aat aag cta acc gat Thr Leu Thr Ile Lys Gly Gly Gln Thr Asp Thr Asn Lys Leu Thr Asp				5132
1460		1465		1470
aat aac atc ggt gtg gta gca ggt act gat ggc ttc act gtc aaa ctt Asn Asn Ile Gly Val Val Ala Gly Thr Asp Gly Phe Thr Val Lys Leu				5180
1480		1485		1490
gcc aaa gac cta acc aat ctt aac agc gtt aat gca ggt ggc acc aaa Ala Lys Asp Leu Thr Asn Leu Asn Ser Val Asn Ala Gly Gly Thr Lys				5228
1495		1500		1505
att gat gac aaa ggc gtg tct ttt gta gac tca agc ggt caa gcc aaa Ile Asp Asp Lys Gly Val Ser Phe Val Asp Ser Ser Gly Gln Ala Lys				5276
1510		1515		1520
gca aac acc cct gtg cta agt gcc aat ggg ctg gac ctg ggt ggc aag Ala Asn Thr Pro Val Leu Ser Ala Asn Gly Leu Asp Leu Gly Gly Lys				5324
1525		1530		1535
gtc atc agt aat gtg ggc aaa ggc aca aaa gat acc gac gct gcc aat				5372

Val Ile Ser Asn Val Gly Lys Gly Thr Lys Asp Thr Asp Ala Ala Asn				
1540	1545	1550	1555	
gta caa cag tta aac gaa gta cgc aac ttg ttg ggt ctt ggt aat gct				5420
Val Gln Gln Leu Asn Glu Val Arg Asn Leu Leu Gly Leu Gly Asn Ala				
1560	1565	1570		
ggt aat gat aac gct gac ggc aat cag gta aac att gcc gac atc aaa				5468
Gly Asn Asp Asn Ala Asp Gly Asn Gln Val Asn Ile Ala Asp Ile Lys				
1575	1580	1585		
aaa gac cca aat tca ggt tca tca tct aac cgc act gtc atc aaa gca				5516
Lys Asp Pro Asn Ser Gly Ser Ser Asn Arg Thr Val Ile Lys Ala				
1590	1595	1600		
ggc acg gta ctt ggc ggt aaa ggt aat aac gat acc gaa aaa ctt gcc				5564
Gly Thr Val Leu Gly Gly Lys Asn Asn Asp Thr Glu Lys Leu Ala				
1605	1610	1615		
act ggt ggt ata caa gtg ggc gtg gat aaa gac ggc aac gct aac ggc				5612
Thr Gly Gly Ile Gln Val Gly Val Asp Lys Asp Gly Asn Ala Asn Gly				
1620	1625	1630	1635	
gat tta agc aat gtt tgg gtc aaa acc caa aaa gat ggc agc aaa aaa				5660
Asp Leu Ser Asn Val Trp Val Lys Thr Gln Lys Asp Gly Ser Lys Lys				
1640	1645	1650		
gcc ctg ctc gcc act tat aac gcc gca ggt cag acc aac tat ttg acc				5708
Ala Leu Leu Ala Thr Tyr Asn Ala Ala Gly Gln Thr Asn Tyr Leu Thr				
1655	1660	1665		
aac aac ccc gca gaa gcc att gac aga ata aat gaa caa ggt atc cgc				5756
Asn Asn Pro Ala Glu Ala Ile Asp Arg Ile Asn Glu Gln Gly Ile Arg				
1670	1675	1680		
ttc ttc cat gtc aac gat ggc aat caa gag cct gtg gta caa ggg cgt				5804
Phe Phe His Val Asn Asp Gly Asn Gln Glu Pro Val Val Gln Gly Arg				
1685	1690	1695		
aac ggc att gac tca agt gcc tca ggc aag cac tca gtg gcg ata ggt				5852
Asn Gly Ile Asp Ser Ser Ala Ser Gly Lys His Ser Val Ala Ile Gly				
1700	1705	1710	1715	
ttc cag gcc aag gca gat ggt gaa gcc gcc gtt gcc ata ggc aga caa				5900
Phe Gln Ala Lys Ala Asp Gly Glu Ala Ala Val Ala Ile Gly Arg Gln				
1720	1725	1730		
acc caa gca ggc aac caa tcc atc gcc atc ggt gat aac gca caa gcc				5948
Thr Gln Ala Gly Asn Gln Ser Ile Ala Ile Gly Asp Asn Ala Gln Ala				
1735	1740	1745		
acg ggc gat caa tcc atc gcc atc ggt aca ggc aat gtg gta gca ggt				5996
Thr Gly Asp Gln Ser Ile Ala Ile Gly Thr Gly Asn Val Val Ala Gly				
1750	1755	1760		
aag cac tct ggt gcc atc ggc gac cca agc act gtt aag gct gat aac				6044
Lys His Ser Gly Ala Ile Gly Asp Pro Ser Thr Val Lys Ala Asp Asn				
1765	1770	1775		

agt tac agt gtg ggt aat aac aac cag ttt acc gat gcc act caa acc Ser Tyr Ser Val Gly Asn Asn Asn Gln Phe Thr Asp Ala Thr Gln Thr	1780	1785	1790	1795	6092
gat gtc ttt ggt gtg ggc aat aac atc acc gtg acc gaa agt aac tcg Asp Val Phe Gly Val Gly Asn Asn Ile Thr Val Thr Glu Ser Asn Ser	1800		1805		6140
gtt gcc tta ggt tca aac tct gcc atc agt gca ggc aca cac gca ggc Val Ala Leu Gly Ser Asn Ser Ala Ile Ser Ala Gly Thr His Ala Gly	1815		1820		6188
aca caa gcc aaa aaa tct gac ggc aca gca ggt aca acc acc aca gca Thr Gln Ala Lys Lys Ser Asp Gly Thr Ala Gly Thr Thr Thr Ala	1830		1835		6236
ggt gca acc ggt acg gtt aaa ggc ttt gct gga caa acg gcg gtt ggt Gly Ala Thr Gly Thr Val Lys Gly Phe Ala Gly Gln Thr Ala Val Gly	1845		1850		6284
gcg gtc tcc gtg ggt gcc tca ggt gct gaa cgc cgt atc caa aat gtg Ala Val Ser Val Gly Ala Ser Gly Ala Glu Arg Arg Ile Gln Asn Val	1860		1865		6332
gca gca ggt gag gtc agt gcc acc agc acc gat gcg gtc aat ggt agc Ala Ala Gly Glu Val Ser Ala Thr Ser Thr Asp Ala Val Asn Gly Ser	1880		1885		6380
cag ttg tac aaa gcc acc caa agc att gcc aac gca acc aat gag ctt Gln Leu Tyr Lys Ala Thr Gln Ser Ile Ala Asn Ala Thr Asn Glu Leu	1895		1900		6428
gac cat cgt atc cac caa aac gaa aat aag gcc aat gca ggg att tca Asp His Arg Ile His Gln Asn Glu Asn Lys Ala Asn Ala Gly Ile Ser	1910		1915		6476
tca gcg atg gcg atg gcg tcc atg cca caa gcc tac att cct ggc aga Ser Ala Met Ala Met Ala Ser Met Pro Gln Ala Tyr Ile Pro Gly Arg	1925		1930		6524
tcc atg gtt acc ggg ggt att gcc acc cac aac ggt caa ggt gcg gtg Ser Met Val Thr Gly Gly Ile Ala Thr His Asn Gly Gln Gly Ala Val	1940		1945		6572
gca gtg gga ctg tcg aag ctg tcg gat aat ggt caa tgg gta ttt aaa Ala Val Gly Leu Ser Lys Leu Ser Asp Asn Gly Gln Trp Val Phe Lys	1960		1965		6620
atc aat ggt tca gcc gat acc caa ggc cat gta ggg gcg gca gtt ggt Ile Asn Gly Ser Ala Asp Thr Gln Gly His Val Gly Ala Ala Val Gly	1975		1980		6668
gca ggt ttt cac ttt taagccataa atcgcaagat tttacttaaa aatcaatctc Ala Gly Phe His Phe	1990				6723
accatagttg tataaaaacag catcagcatc agtcatatta ctgatgctga tgtttttat					6783
cacttaaacc attttaccgc tcaagtgatt ctctttcacc atgaccaaat cgccatttgat					6843

cataggtaaa cttattgagt aaattttatc aatgttagttg ttagatatgg ttaaaattgt 6903
gccattgacc aaaaaatgac cgatttatcc cgaaaatttc tgattatgat ccgttgacct 6963
gcaggtcgac 6973

Figure 3. *M. catarrhalis* strain 4223 genomic 200kDa gene.

```

ccatggatat gggcaggtgt gctcgccctgc cgtatgatgg cgatgacacc ccatttgc 60
catatctgta cgatttgaca tgtgatatga tttaacatgt gacatgattt aacattgttt 120
aatactgttg ccatcattac cataatttag taacgcattt agtaacgcatt ttgtaaaaat 180
cattgcgccc cttagtgtgt atcatatgaa tagaatatta tgattgtatc tgattattgt 240
atcagaatgg ttagtgcata ttagtgcattc tacgagttga tttgggttaa tcactctatg 300
atttgatata ttttggaaact aatctattga cttaaatcac catatggta taatttagca 360
taatggtagg cttttgtaa aaatcacatc gcaatattgt tctactgtta ctaccatgct 420
tgaatgacga tcccaatcac cagattcatt caagtgtatc gtttgcatac gcaccattta 480
ccctaattat ttcaatcaaa tgcctatgtc agcatgtatc attttttaa ggtaaaccac 540

c atg aat cac atc tat aaa gtc atc ttt aac aaa gcc aca gca aca ttt 589
Met Asn His Ile Tyr Lys Val Ile Phe Asn Lys Ala Thr Gly Thr Phe
    1           5           10          15

atg gca gtg gca gag tac gcc aaa tcc cac agc acg ggg ggg ggt agc      637
Met Ala Val Ala Glu Tyr Ala Lys Ser His Ser Thr Gly Gly Ser
    20          25          30

tgt gct aca ggg caa gtt ggc agt gta tgc act ctg agc ttt gcc cgt      685
Cys Ala Thr Gly Gln Val Gly Ser Val Cys Thr Leu Ser Phe Ala Arg
    35          40          45

att gcc gcg ctc gct gtc ctc gtg atc ggt gca acg ctc agt ggc agt      733
Ile Ala Ala Leu Ala Val Leu Val Ile Gly Ala Thr Leu Ser Gly Ser
    50          55          60

gct tat gct caa aaa aaa gat acc aaa cat atc gca att ggt gaa caa      781
Ala Tyr Ala Gln Lys Lys Asp Thr Lys His Ile Ala Ile Gly Glu Gln
    65          70          75          80

aac cag cca aga cgc tca ggc act gcc aag gcg gac ggt gat cga gcc      829
Asn Gln Pro Arg Arg Ser Gly Thr Ala Lys Ala Asp Gly Asp Arg Ala
    85          90          95

att gct att ggt gaa aat gct aac gca cag ggc ggt caa gcc atc gcc      877
Ile Ala Ile Gly Glu Asn Ala Asn Ala Gln Gly Gly Gln Ala Ile Ala
    100         105         110

atc ggt agt agt aat aaa act gtc aat gga agc agt ttg gat aag ata      925
Ile Gly Ser Ser Asn Lys Thr Val Asn Gly Ser Ser Leu Asp Lys Ile
    115         120         125

ggt acc gat gct acg ggt caa gag tcc atc gcc atc ggt ggt gat gta      973
Gly Thr Asp Ala Thr Gly Gln Glu Ser Ile Ala Ile Gly Gly Asp Val
    130         135         140

aag qct agt ggt gat gcc tcg att gcc atc ggt agt gat gac tta cat      1021
Lys Ala Ser Gly Asp Ala Ser Ile Ala Ile Gly Ser Asp Asp Leu His

```

145	150	155	160	
ttg ctt gat cag cat ggt aat cct aaa cat ccg aaa ggt act ctg att Leu Leu Asp Gln His Gly Asn Pro Lys His Pro Lys Gly Thr Ile				1069
165		170	175	
aac gat ctt att aac ggc cat gca gta tta aaa gaa ata cga agc tca Asn Asp Leu Ile Asn Gly His Ala Val Leu Lys Glu Ile Arg Ser Ser				1117
180	185		190	
aag gat aat gat gta aaa tat aga cgc aca acc gca agc gga cac gcc Lys Asp Asn Asp Val Lys Tyr Arg Arg Thr Thr Ala Ser Gly His Ala				1165
195	200		205	
agt act gca gtg gga gcc atg tca tat gca cag ggt cat ttt tcc aac Ser Thr Ala Val Gly Ala Met Ser Tyr Ala Gln Gly His Phe Ser Asn				1213
210	215	220		
gcc ttt ggt aca cgg gca aca gct aaa agt gcc tat tcc ttg gca gtg Ala Phe Gly Thr Arg Ala Thr Ala Lys Ser Ala Tyr Ser Leu Ala Val				1261
225	230	235	240	
ggc ctt gcc gcc aca gag ggc caa tct aca atc gct att ggt tct Gly Leu Ala Ala Thr Ala Glu Gly Gln Ser Thr Ile Ala Ile Gly Ser				1309
245	250		255	
gat gca aca tct agc tcg ttg gga gcg ata gcc ctt ggt gca ggt act Asp Ala Thr Ser Ser Leu Gly Ala Ile Ala Leu Gly Ala Gly Thr				1357
260	265		270	
cgt gct cag cta cag ggc agt att gcc cta ggt caa ggt tct gtt gtc Arg Ala Gln Leu Gln Gly Ser Ile Ala Leu Gly Gln Gly Ser Val Val				1405
275	280	285		
act cag agt gat aat aat tct aga ccg gcc tat aca cca aat acc cag Thr Gln Ser Asp Asn Asn Ser Arg Pro Ala Tyr Thr Pro Asn Thr Gln				1453
290	295	300		
gca cta gac ccc aag ttt caa gcc acc aat aat acg aag gcg ggt cca Ala Leu Asp Pro Lys Phe Gln Ala Thr Asn Asn Thr Lys Ala Gly Pro				1501
305	310	315	320	
ctt tcc att ggt agt aac tct atc aaa cgt aaa atc atc aat gtc ggt Leu Ser Ile Gly Ser Asn Ser Ile Lys Arg Lys Ile Ile Asn Val Gly				1549
325	330	335		
gca ggt gtt aat aaa acc gat gcg gtc aat gtg gca cag cta gaa gcg Ala Gly Val Asn Lys Thr Asp Ala Val Asn Val Ala Gln Leu Glu Ala				1597
340	345	350		
gtg gtg aag tgg gct aag gag cgt aga att act ttt cag ggt gat gat Val Val Lys Trp Ala Lys Glu Arg Arg Ile Thr Phe Gln Gly Asp Asp				1645
355	360	365		
aac agt act gac gta aaa ata ggt ttg gat aat act tta act att aaa Asn Ser Thr Asp Val Lys Ile Gly Leu Asp Asn Thr Leu Thr Ile Lys				1693
370	375	380		
ggt ggt gca gag acc aac gca tta acc gat aat aat atc ggt gtg gta				1741

tat cta aat gaa gtc aat cga acg gct gac agt gct cta caa agc ttt Tyr Leu Asn Glu Val Asn Arg Thr Ala Asp Ser Ala Leu Gln Ser Phe 625	630	635	640	2461
acc gtt aaa gaa gaa gac gat gat gac gcc aac gct atc acc gtg gct Thr Val Lys Glu Glu Asp Asp Asp Ala Asn Ala Ile Thr Val Ala 645	650		655	2509
aaa gat acg aca aaa aat gcc ggc gca gtc agc atc tta aaa ctc aaa Lys Asp Thr Thr Lys Asn Ala Gly Ala Val Ser Ile Leu Lys Leu Lys 660	665		670	2557
ggt aaa aac ggt cta acg gtt gct acc aaa aaa gat ggt acg gtt acc Gly Lys Asn Gly Leu Thr Val Ala Thr Lys Lys Asp Gly Thr Val Thr 675	680		685	2605
ttt ggg ctt agc caa gat agc ggt ctg acc att ggc aaa agc acc cta Phe Gly Leu Ser Gln Asp Ser Gly Leu Thr Ile Gly Lys Ser Thr Leu 690	695		700	2653
aac aac gat ggc ttg act gtt aaa gat acc aac gaa caa atc caa gtc Asn Asn Asp Gly Leu Thr Val Lys Asp Thr Asn Glu Gln Ile Gln Val 705	710	715	720	2701
ggt gct aat ggc att aaa ttt act aat gtg aat ggt agt aat cca ggt Gly Ala Asn Gly Ile Lys Phe Thr Asn Val Asn Gly Ser Asn Pro Gly 725	730		735	2749
act ggc att gca aat acc gct cgc att acc aga gat aaa att ggc ttt Thr Gly Ile Ala Asn Thr Ala Arg Ile Thr Arg Asp Lys Ile Gly Phe 740	745		750	2797
gct ggt tct gat ggt gca gtt gat aca aac aaa cct tat ctt gat caa Ala Gly Ser Asp Gly Ala Val Asp Thr Asn Lys Pro Tyr Leu Asp Gln 755	760		765	2845
gac aag cta caa gtt ggc aat gtt aag att acc aac act ggc att aac Asp Lys Leu Gln Val Gly Asn Val Lys Ile Thr Asn Thr Gly Ile Asn 770	775		780	2893
gca ggt ggt aaa gcc atc aca ggg ctg tcc cca aca ctg cct agc att Ala Gly Gly Lys Ala Ile Thr Gly Leu Ser Pro Thr Leu Pro Ser Ile 785	790	795	800	2941
gcc gat caa agt agc cgc aac ata gaa ctg ggc aat aca atc caa gac Ala Asp Gln Ser Ser Arg Asn Ile Glu Leu Gly Asn Thr Ile Gln Asp 805	810		815	2989
aaa gac aaa tcc aac gct gcc agc att aat gat ata tta aat aca ggc Lys Asp Lys Ser Asn Ala Ala Ser Ile Asn Asp Ile Leu Asn Thr Gly 820	825		830	3037
ttt aac cta aaa aat aat aac aac ccc att gac ttt gtc tcc act tat Phe Asn Leu Lys Asn Asn Asn Pro Ile Asp Phe Val Ser Thr Tyr 835	840		845	3085
gac att gtt gac ttt gcc aat ggc aat gcc acc acc gcc aca gta acc Asp Ile Val Asp Phe Ala Asn Gly Asn Ala Thr Thr Ala Thr Val Thr 850	855		860	3133

cat gat acc gct aac aaa acc agt aaa gtg gta tat gat gtg aat gtg His Asp Thr Ala Asn Lys Thr Ser Lys Val Val Tyr Asp Val Asn Val 865 870 875 880	3181
gat gat aca acc att cat cta aca ggc act gat gac aat aaa aaa ctt Asp Asp Thr Thr Ile His Leu Thr Gly Thr Asp Asp Asn Lys Lys Leu 885 890 895	3229
ggc gtc aaa acc acc aaa ctg aac aaa aca agt gct aat ggt aat aca Gly Val Lys Thr Thr Lys Leu Asn Lys Thr Ser Ala Asn Gly Asn Thr 900 905 910	3277
gca act aac ttt aat gtt aac tct agt gat gaa gat gcc ctt gtt aac Ala Thr Asn Phe Asn Val Asn Ser Ser Asp Glu Asp Ala Leu Val Asn 915 920 925	3325
gcc aaa gac atc gcc gaa aat cta aac acc cta gcc aag gaa att cac Ala Lys Asp Ile Ala Glu Asn Leu Asn Thr Leu Ala Lys Glu Ile His 930 935 940	3373
acc acc aaa ggc aca gca gac acc gcc cta caa acc ttt acc gtt aaa Thr Thr Lys Gly Thr Ala Asp Thr Ala Leu Gln Thr Phe Thr Val Lys 945 950 955 960	3421
aag gta gat gaa aat aat aat gct gat gac gcc aac gcc atc acc gtg Lys Val Asp Glu Asn Asn Ala Asp Asp Ala Asn Ala Ile Thr Val 965 970 975	3469
ggt caa aag aac gca aat aat caa gtc aac acc cta aca ctc aaa ggt Gly Gln Lys Asn Ala Asn Asn Gln Val Asn Thr Leu Thr Leu Lys Gly 980 985 990	3517
gaa aac ggt ctt aat att aaa acc gac aaa aat ggt acg gtt acc ttt Glu Asn Gly Leu Asn Ile Lys Thr Asp Lys Asn Gly Thr Val Thr Phe 995 1000 1005	3565
ggc att aac acc aca agc ggt ctt aaa gcc ggc aaa agc acc cta aac Gly Ile Asn Thr Thr Ser Gly Leu Lys Ala Gly Lys Ser Thr Leu Asn 1010 1015 1020	3613
gac ggt ggc ttg tct att aaa aac ccc act ggt agc gaa caa atc caa Asp Gly Gly Leu Ser Ile Lys Asn Pro Thr Gly Ser Glu Gln Ile Gln 1025 1030 1035 1040	3661
gtc ggt gct gat ggc gtg aag ttt gcc aag gtt aat aat aat ggt gtt Val Gly Ala Asp Gly Val Lys Phe Ala Lys Val Asn Asn Asn Gly Val 1045 1050 1055	3709
gta ggt gct ggc att gat ggc aca act cgc att acc aga gat gaa att Val Gly Ala Gly Ile Asp Gly Thr Thr Arg Ile Thr Arg Asp Glu Ile 1060 1065 1070	3757
ggc ttt act ggg act aat ggc tca ctt gat aaa agc aaa ccc cac cta Gly Phe Thr Gly Thr Asn Gly Ser Leu Asp Lys Ser Lys Pro His Leu 1075 1080 1085	3805
agc aaa gac ggc att aac gca ggt ggt aaa aag att acc aac att caa Ser Lys Asp Gly Ile Asn Ala Gly Lys Lys Ile Thr Asn Ile Gln	3853

1090	1095	1100	
tca ggt gag att gcc caa aac agc cat gat gct gtg aca ggc ggc aag Ser Gly Glu Ile Ala Gln Asn Ser His Asp Ala Val Thr Gly Gly Lys 1105	1110	1115	3901
att tat gat tta aaa acc gaa ctt gaa aac aaa atc agc agt act gcc Ile Tyr Asp Leu Lys Thr Glu Leu Glu Asn Lys Ile Ser Ser Thr Ala 1125	1130	1135	3949
aaa aca gca caa aac tca tta cac gaa ttc tca gta gca gat gaa caa Lys Thr Ala Gln Asn Ser Leu His Glu Phe Ser Val Ala Asp Glu Gln 1140	1145	1150	3997
ggg aat aac ttt acg gtt agt aac cct tac tcc agt tat gac acc tca Gly Asn Asn Phe Thr Val Ser Asn Pro Tyr Ser Ser Tyr Asp Thr Ser 1155	1160	1165	4045
aag acc tct gat gtc atc acc ttt gca ggt gaa aac ggc att acc acc Lys Thr Ser Asp Val Ile Thr Phe Ala Gly Glu Asn Gly Ile Thr Thr 1170	1175	1180	4093
aag gta aat aaa ggt gtg gtg cgt gtg ggc att gac caa acc aaa ggc Lys Val Asn Lys Gly Val Val Arg Val Gly Ile Asp Gln Thr Lys Gly 1185	1190	1195	4141
tta acc acg cct aag ctg acc gtg ggt aat aat aat ggc aaa ggc att Leu Thr Thr Pro Lys Leu Thr Val Gly Asn Asn Asn Gly Lys Gly Ile 1205	1210	1215	4189
gtc att gac agc caa aat ggt caa aat acc atc aca gga cta agc aac Val Ile Asp Ser Gln Asn Gly Gln Asn Thr Ile Thr Gly Leu Ser Asn 1220	1225	1230	4237
act cta gct aat gtt acc aat gat aaa ggt agc gta cgc acc aca gaa Thr Leu Ala Asn Val Thr Asn Asp Lys Gly Ser Val Arg Thr Thr Glu 1235	1240	1245	4285
cag ggc aat ata atc aaa gac gaa gac aaa acc cgt gcc gcc agc att Gln Gly Asn Ile Ile Lys Asp Glu Asp Lys Thr Arg Ala Ala Ser Ile 1250	1255	1260	4333
gtt gat gtg cta agc gca ggc ttt aac ttg caa ggc aat ggt gaa gcg Val Asp Val Leu Ser Ala Gly Phe Asn Leu Gln Gly Asn Gly Glu Ala 1265	1270	1275	4381
gtt gac ttt gtc tcc act tat gac acc gtc aac ttt gcc gat ggc aat Val Asp Phe Val Ser Thr Tyr Asp Thr Val Asn Phe Ala Asp Gly Asn 1285	1290	1295	4429
gcc acc acc gct aag gtg acc tat gat gac aca agc aaa acc agt aaa Ala Thr Thr Ala Lys Val Thr Tyr Asp Asp Thr Ser Lys Thr Ser Lys 1300	1305	1310	4477
gtg gtc tat gat gtc aat gtg gat gat aca acc att gaa gtt aaa gat Val Val Tyr Asp Val Asn Val Asp Asp Thr Thr Ile Glu Val Lys Asp 1315	1320	1325	4525
aaa aaa ctt ggc gta aaa acc acc aca ttg acc agt act ggc aca ggt			4573

Lys	Lys	Leu	Gly	Val	Lys	Thr	Thr	Leu	Thr	Ser	Thr	Gly	Thr	Gly				
1330					1335					1340								
gct aat aaa ttt gcc cta agc aat caa gct act ggc gat gcg ctt gtc															4621			
Ala	Asn	Lys	Phe	Ala	Leu	Ser	Asn	Gln	Ala	Thr	Gly	Asp	Ala	Leu	Val			
1345					1350					1355					1360			
aag gcc agt gat atc gtt gct cat cta aac acc tta tct ggc gac atc															4669			
Lys	Ala	Ser	Asp	Ile	Val	Ala	His	Leu	Asn	Thr	Leu	Ser	Gly	Asp	Ile			
															1365	1370	1375	
caa act gcc aaa ggg gca agc caa gcg aac aac tca gca ggc tat gtg															4717			
Gln	Thr	Ala	Lys	Gly	Ala	Ser	Gln	Ala	Asn	Asn	Ser	Ala	Gly	Tyr	Val			
															1380	1385	1390	
gat gct gat ggc aat aag gtc atc tat gac agt acc gat aac aag tac															4765			
Asp	Ala	Asp	Gly	Asn	Lys	Val	Ile	Tyr	Asp	Ser	Thr	Asp	Asn	Lys	Tyr			
															1395	1400	1405	
tat caa gcc aaa aat gat ggc aca gtt gat aaa acc aaa gaa gtt gcc															4813			
Tyr	Gln	Ala	Lys	Asn	Asp	Gly	Thr	Val	Asp	Lys	Thr	Lys	Glu	Val	Ala			
															1410	1415	1420	
aaa gac aaa ctg gtc gcc caa gcc caa acc cca gat ggc aca ttg gct															4861			
Lys	Asp	Lys	Leu	Val	Ala	Gln	Ala	Gln	Thr	Pro	Asp	Gly	Thr	Leu	Ala			
															1425	1430	1435	1440
caa atg aat gtc aaa tca gtc att aac aaa gaa caa gta aat gat gcc															4909			
Gln	Met	Asn	Val	Lys	Ser	Val	Ile	Asn	Lys	Glu	Gln	Val	Asn	Asp	Ala			
															1445	1450	1455	
aat aaa aag caa ggc atc aat gaa gac aac gcc ttt gtt aaa gga ctt															4957			
Asn	Lys	Lys	Gln	Gly	Ile	Asn	Glu	Asp	Asn	Ala	Phe	Val	Lys	Gly	Leu			
															1460	1465	1470	
gaa aaa gcc gct tct gat aac aaa acc aaa aac gcc gca gta act gtg															5005			
Glu	Lys	Ala	Ala	Ser	Asp	Asn	Lys	Thr	Lys	Asn	Ala	Ala	Val	Thr	Val			
															1475	1480	1485	
ggg gat tta aat gcc gtt gcc caa aca ccg ctg acc ttt gca ggg gat															5053			
Gly	Asp	Leu	Asn	Ala	Val	Ala	Gln	Thr	Pro	Leu	Thr	Phe	Ala	Gly	Asp			
															1490	1495	1500	
aca ggc aca acg gct aaa aaa ctg ggc gag act ttg acc atc aaa ggt															5101			
Thr	Gly	Thr	Ala	Lys	Lys	Leu	Gly	Glu	Thr	Leu	Thr	Ile	Lys	Gly				
															1505	1510	1515	1520
ggg caa aca gac acc aat aag cta acc gat aat aac atc ggt gtg gta															5149			
Gly	Gln	Thr	Asp	Thr	Asn	Lys	Leu	Thr	Asp	Asn	Asn	Ile	Gly	Val	Val			
															1525	1530	1535	
gca ggt act gat ggc ttc act gtc aaa ctt gcc aaa gac cta acc aat															5197			
Ala	Gly	Thr	Asp	Gly	Phe	Thr	Val	Lys	Leu	Ala	Lys	Asp	Leu	Thr	Asn			
															1540	1545	1550	
ctt aac agc gtt aat gca ggt ggc acc aaa att gat gac aaa ggc gtg															5245			
Leu	Asn	Ser	Val	Asn	Ala	Gly	Gly	Thr	Lys	Ile	Asp	Asp	Lys	Gly	Val			
															1555	1560	1565	

tct ttt gta gac tca agc ggt caa gcc aaa gca aac acc acc cct gtg cta Ser Phe Val Asp Ser Ser Gly Gln Ala Lys Ala Asn Thr Pro Val Leu 1570 1575 1580	5293
agt gcc aat ggg ctg gac ctg ggt ggc aag gtc atc agt aat gtg ggc Ser Ala Asn Gly Leu Asp Leu Gly Gly Lys Val Ile Ser Asn Val Gly 1585 1590 1595 1600	5341
aaa ggc aca aaa gat acc gac gct gcc aat gta caa cag tta aac gaa Lys Gly Thr Lys Asp Thr Asp Ala Ala Asn Val Gln Gln Leu Asn Glu 1605 1610 1615	5389
gta cgc aac ttg ttg ggt ctt ggt aat gct ggt aat gat aac gct gac Val Arg Asn Leu Leu Gly Leu Gly Asn Ala Gly Asn Asp Asn Ala Asp 1620 1625 1630	5437
ggc aat cag gta aac att gcc gac atc aaa aaa gac cca aat tca ggt Gly Asn Gln Val Asn Ile Ala Asp Ile Lys Asp Pro Asn Ser Gly 1635 1640 1645	5485
tca tca tct aac cgc act gtc atc aaa gca gcc acg gta ctt ggc ggt Ser Ser Ser Asn Arg Thr Val Ile Lys Ala Gly Thr Val Leu Gly Gly 1650 1655 1660	5533
aaa ggt aat aac gat acc gaa aaa ctt gcc act ggt ggt ata caa gtg Lys Gly Asn Asn Asp Thr Glu Lys Leu Ala Thr Gly Gly Ile Gln Val 1665 1670 1675 1680	5581
ggc gtg gat aaa gac ggc aac gct aac ggc gat tta agc aat gtt tgg Gly Val Asp Lys Asp Gly Asn Ala Asn Gly Asp Leu Ser Asn Val Trp 1685 1690 1695	5629
gtc aaa acc caa aaa gat ggc agc aaa aaa gcc ctg ctc gcc act tat Val Lys Thr Gln Lys Asp Gly Ser Lys Lys Ala Leu Leu Ala Thr Tyr 1700 1705 1710	5677
aac gcc gca ggt cag acc aac tat ttg acc aac aac ccc gca gaa gcc Asn Ala Ala Gly Gln Thr Asn Tyr Leu Thr Asn Asn Pro Ala Glu Ala 1715 1720 1725	5725
att gac aga ata aat gaa caa ggt atc cgc ttc ttc cat gtc aac gat Ile Asp Arg Ile Asn Glu Gln Gly Ile Arg Phe Phe His Val Asn Asp 1730 1735 1740	5773
ggc aat caa gag cct gtg gta caa ggg cgt aac ggc att gac tca agt Gly Asn Gln Glu Pro Val Val Gln Gly Arg Asn Gly Ile Asp Ser Ser 1745 1750 1755 1760	5821
gcc tca ggc aag cac tca gtg gcg ata ggt ttc cag gcc aag gca gat Ala Ser Gly Lys His Ser Val Ala Ile Gly Phe Gln Ala Lys Ala Asp 1765 1770 1775	5869
ggt gaa gcc gcc gtt gcc ata ggc aga caa acc caa gca ggc aac caa Gly Glu Ala Ala Val Ala Ile Gly Arg Gln Thr Gln Ala Gly Asn Gln 1780 1785 1790	5917
tcc atc gcc atc ggt gat aac gca caa gcc acg ggc gat caa tcc atc Ser Ile Ala Ile Gly Asp Asn Ala Gln Ala Thr Gly Asp Gln Ser Ile 1795 1800 1805	5965

gcc atc ggt aca ggc aat gtg gta gca ggt aag cac tct ggt gcc atc Ala Ile Gly Thr Gly Asn Val Val Ala Gly Lys His Ser Gly Ala Ile 1810 1815 1820	6013
ggc gac cca agc act gtt aag gct gat aac agt tac agt gtg ggt aat Gly Asp Pro Ser Thr Val Lys Ala Asp Asn Ser Tyr Ser Val Gly Asn 1825 1830 1835 1840	6061
aac aac cag ttt acc gat gcc act caa acc gat gtc ttt ggt gtg ggc Asn Asn Gln Phe Thr Asp Ala Thr Gln Thr Asp Val Phe Gly Val Gly 1845 1850 1855	6109
aat aac atc acc gtg acc gaa agt aac tcg gtt gcc tta ggt tca aac Asn Asn Ile Thr Val Thr Glu Ser Asn Ser Val Ala Leu Gly Ser Asn 1860 1865 1870	6157
tct gcc atc agt gca ggc aca cac gca ggc aca caa gcc aaa aaa tct Ser Ala Ile Ser Ala Gly Thr His Ala Gly Thr Gln Ala Lys Lys Ser 1875 1880 1885	6205
gac ggc aca gca ggt aca acc acc aca gca ggt gca acc ggt acg gtt Asp Gly Thr Ala Gly Thr Thr Thr Ala Gly Ala Thr Gly Thr Val 1890 1895 1900	6253
aaa ggc ttt gct gga caa acg gcg gtt ggt gcg gtc tcc gtg ggt gcc Lys Gly Phe Ala Gly Gln Thr Ala Val Gly Ala Val Ser Val Gly Ala 1905 1910 1915 1920	6301
tca ggt gct gaa cgc cgt atc caa aat gtg gca gca ggt gag gtc agt Ser Gly Ala Glu Arg Arg Ile Gln Asn Val Ala Ala Gly Glu Val Ser 1925 1930 1935	6349
gcc acc agc acc gat gcg gtc aat ggt agc cag ttg tac aaa gcc acc Ala Thr Ser Thr Asp Ala Val Asn Gly Ser Gln Leu Tyr Lys Ala Thr 1940 1945 1950	6397
caa agc att gcc aac gca acc aat gag ctt gac cat cgt atc cac caa Gln Ser Ile Ala Asn Ala Thr Asn Glu Leu Asp His Arg Ile His Gln 1955 1960 1965	6445
aac gaa aat aag gcc aat gca ggg att tca tca gcg atg gcg atg gcg Asn Glu Asn Lys Ala Asn Ala Gly Ile Ser Ser Ala Met Ala Met Ala 1970 1975 1980	6493
tcc atg cca caa gcc tac att cct ggc aga tcc atg gtt acc ggg ggt Ser Met Pro Gln Ala Tyr Ile Pro Gly Arg Ser Met Val Thr Gly Gly 1985 1990 1995 2000	6541
att gcc acc cac aac ggt caa ggt gcg gtg gca gtg gga ctg tcg aag Ile Ala Thr His Asn Gly Gln Gly Ala Val Ala Val Gly Leu Ser Lys 2005 2010 2015	6589
ctg tcg gat aat ggt caa tgg gta ttt aaa atc aat ggt tca gcc gat Leu Ser Asp Asn Gly Gln Trp Val Phe Lys Ile Asn Gly Ser Ala Asp 2020 2025 2030	6637
acc caa ggc cat gta ggg gcg gca gtt ggt gca ggt ttt cac ttt Thr Gln Gly His Val Gly Ala Ala Val Gly Ala Gly Phe His Phe	6682

2035

2040

2045

taagccataa atcgcaagat tttacttaaa aatcaatctc accatagttg tataaaaacag 6742
catcagcattc agtcatatta ctgatgctga tgtttttat cactaaacc attttaccgc 6802
tcaagtgatt ctcttcacc atgaccaaat cgccattgat cataggtaaa cttattgagt 6862
aaattttatc aatgttagttg ttagatatgg taaaaattgt gccattgacc aaaaaatgac 6922
cgatttatcc cgaaaatttc tgattatgat ccgttgacct gcaggtcgac 6972

Figure 4. *M. catarrhalis* strain Q8 200kDa gene

ATG aat cac atc tat aaa gtc atc ttt aac aaa gcc aca ggc aca ttt Met Asn His Ile Tyr Lys Val Ile Phe Asn Lys Ala Thr Gly Thr Phe	1 5 10 15	48
atg gcc gtg gcg gaa tat gcc aaa tcc cac agt acg <u>qqq</u> <u>qqq</u> <u>qqt</u> agc Met Ala Val Ala Glu Tyr Ala Lys Ser His Ser Thr Gly Gly Ser	20 25 30	96
tgt gct aca ggg caa gtt ggc agt gta cgc act cta agc ttt gcc cgt Cys Ala Thr Gly Gln Val Gly Ser Val Arg Thr Leu Ser Phe Ala Arg	35 40 45	144
att gcc gcg ctc gct gtc ctc gtg atc ggt gcg acg ctc aat ggc agt Ile Ala Ala Leu Ala Val Leu Val Ile Gly Ala Thr Leu Asn Gly Ser	50 55 60	192
gct tat gct caa caa att act acc aag atc gaa att ggt caa aca aac Ala Tyr Ala Gln Gln Ile Thr Thr Lys Ile Glu Ile Gly Gln Thr Asn	65 70 75 80	240
aag ata aac aac acg ctg aaa ggc gat gcc cta gcg aca ggt gaa gca Lys Ile Asn Asn Thr Leu Lys Gly Asp Ala Leu Ala Thr Gly Glu Ala	85 90 95	288
tcc att gct ttt ggt agt ctt tct aag gca caa ggc tct caa gct att Ser Ile Ala Phe Gly Ser Leu Ser Lys Ala Gln Gly Ser Gln Ala Ile	100 105 110	336
gct atc ggt agt gtc aaa cca gat cct aat aat ggt agt aat ggt aat Ala Ile Gly Ser Val Lys Pro Asp Pro Asn Asn Gly Ser Asn Gly Asn	115 120 125	384
gta ggt tcc cac gcc aaa ggt aac gag tcc atc gcc atc ggt ggt gat Val Gly Ser His Ala Lys Gly Asn Glu Ser Ile Ala Ile Gly Gly Asp	130 135 140	432
gta ttg gct gag ggt gat gcc tcg att gcc atc ggt agt gat gac tta Val Leu Ala Glu Gly Asp Ala Ser Ile Ala Ile Gly Ser Asp Asp Leu	145 150 155 160	480
tat ttg cct aag aat ctt gat ctg aag aat gaa ttt cac aaa ctt att Tyr Leu Pro Lys Asn Leu Asp Leu Lys Asn Glu Phe His Lys Leu Ile	165 170 175	528
cat ggc cat gaa ata tta aaa aaa ata caa acc tca acc gat ggt aaa His Gly His Glu Ile Leu Lys Lys Ile Gln Thr Ser Thr Asp Gly Lys	180 185 190	576
atc aaa tat cga cgc aca aga gca caa ggg cac gcc agt act gca gtg Ile Lys Tyr Arg Arg Ala Gln Gly His Ala Ser Thr Ala Val	195 200 205	624
gga gcc atg tca tat gca cag ggt cat ttt tcc aac gcc ttt ggt aca Gly Ala Met Ser Tyr Ala Gln Gly His Phe Ser Asn Ala Phe Gly Thr	210 215 220	672

tac gca aca gct gaa gct gcc tat tcc ttg gca gta ggt ctt gcc gcc Tyr Ala Thr Ala Glu Ala Ala Tyr Ser Leu Ala Val Gly Leu Ala Ala 225	230	235	240	720
caa gcc aca aaa caa tct tca atc gct gtt ggt tcc aat gca aaa gct Gln Ala Thr Lys Gln Ser Ser Ile Ala Val Gly Ser Asn Ala Lys Ala 245		250	255	768
aac gcg ttt gca gcg aca gcc att ggt gga aat act gta gtt aat ttg Asn Ala Phe Ala Ala Thr Ala Ile Gly Gly Asn Thr Val Val Asn Leu 260	265		270	816
ggc cga ggc gtt gcc cta ggt ttt ggt tct cag atc ctt gat agg gat Gly Arg Gly Val Ala Leu Gly Phe Gly Ser Gln Ile Leu Asp Arg Asp 275	280		285	864
aat aat aca gat gcc agt gcc tat gta cca cta ggt aaa acg tta gca Asn Asn Thr Asp Ala Ser Ala Tyr Val Pro Leu Gly Lys Thr Leu Ala 290	295		300	912
gac cag tat aaa gcc acc cgc cag ggt gat tct acg gat ata ttt tcc Asp Gln Tyr Lys Ala Thr Arg Gln Gly Asp Ser Thr Asp Ile Phe Ser 305	310	315	320	960
att ggt aat agt aat aat aat agc agt atc agg cgt aaa atc atc Ile Gly Asn Ser Asn Asn Asn Ser Ser Ile Arg Arg Lys Ile Ile 325		330	335	1008
aat gtc ggt gcg ggt tct cgg gat acc gat gcg gtc aat gtg gca cag Asn Val Gly Ala Gly Ser Arg Asp Thr Asp Ala Val Asn Val Ala Gln 340	345		350	1056
ctt aaa ttg gtg gag gaa ctg gct aat cgt aaa att act ttt aag ggt Leu Lys Leu Val Glu Leu Ala Asn Arg Lys Ile Thr Phe Lys Gly 355	360		365	1104
gat ggt gac aat aat agc aat agc gta gaa aga ggt ttg ggc aat act Asp Gly Asp Asn Asn Ser Asn Ser Val Glu Arg Gly Leu Gly Asn Thr 370	375		380	1152
tta act att aaa ggt gat gca cag acc aac gca tta acc gaa gct aac Leu Thr Ile Lys Gly Asp Ala Gln Thr Asn Ala Leu Thr Glu Ala Asn 385	390	395	400	1200
atc ggt gtg gta aca gat ggc aat ggt ctg aaa gtt aaa ctt gct aaa Ile Gly Val Val Thr Asp Gly Asn Gly Leu Lys Val Lys Leu Ala Lys 405	410		415	1248
gag ctg act gga ttg acc agt gtc tcc gct acc aac aaa atc acc gtt Glu Leu Thr Gly Leu Thr Ser Val Ser Ala Thr Asn Lys Ile Thr Val 420	425		430	1296
agt aat acc aac aac aac aac gcc gag cta caa agc ggt ggt ttg acc Ser Asn Thr Asn Asn Asn Ala Glu Leu Gln Ser Gly Gly Leu Thr 435	440		445	1344
ttt agc cca ata aca ggt aca aaa aca gat aaa acc gtc tac agc att Phe Ser Pro Ile Thr Gly Thr Lys Thr Asp Lys Thr Val Tyr Ser Ile 450	455		460	1392

gat gga ttg aag ttt act aat gat agt aat gtc act aaa ggt Asp Gly Leu Lys Phe Thr Asn Asp Ser Ser Ile Ala Thr Lys Gly 465 470 475 480	1440
act act cgt att acc aaa aag aaa att ggt ttt gct ggt act aat gat Thr Thr Arg Ile Thr Lys Lys Ile Gly Phe Ala Gly Thr Asn Asp 485 490 495	1488
gga gtt gat gaa agc aaa cct tat ctt gac aac gaa aag cta aaa gtt Gly Val Asp Glu Ser Lys Pro Tyr Leu Asp Asn Glu Lys Leu Lys Val 500 505 510	1536
ggc aac agc acc cta aac agt ggt agc ttg act gtt aat aac acc act Gly Asn Ser Thr Leu Asn Ser Gly Ser Leu Thr Val Asn Asn Thr Thr 515 520 525	1584
ggt aat aaa caa atc caa gtc ggt gct aat ggc att aaa ttt gcc aca Gly Asn Lys Gln Ile Gln Val Gly Ala Asn Gly Ile Lys Phe Ala Thr 530 535 540	1632
gtc gct aat aat gtt gca aat acc tca gca aca gtc ggc act gct cgt Val Ala Asn Asn Val Ala Asn Thr Ser Ala Thr Val Gly Thr Ala Arg 545 550 555 560	1680
att acc gaa gag aaa att ggt ttt gct ggt act aat gat gga gtt gat Ile Thr Glu Glu Lys Ile Gly Phe Ala Gly Thr Asn Asp Gly Val Asp 565 570 575	1728
gaa caa gca cca tat ttg gat aaa gaa cga ctt aaa gtg ggt cgt gtt Glu Gln Ala Pro Tyr Leu Asp Lys Glu Arg Leu Lys Val Gly Arg Val 580 585 590	1776
gaa att acc aca gat agt ggt att aat gct ggt aat cac aag att acc Glu Ile Thr Thr Asp Ser Gly Ile Asn Ala Gly Asn His Lys Ile Thr 595 600 605	1824
gga ctt act aat ggt ata gca aat acc gat gcg gtt acc atc aaa cag Gly Leu Thr Asn Gly Ile Ala Asn Thr Asp Ala Val Thr Ile Lys Gln 610 615 620	1872
ctc aaa gac gcc aag cct act tta aac gca ggc gat ggc atc agt att Leu Lys Asp Ala Lys Pro Thr Leu Asn Ala Gly Asp Gly Ile Ser Ile 625 630 635 640	1920
aat agt aat aac ggg gat cta gtt gat agt agt ggc aat att acc acc Asn Ser Asn Asn Gly Asp Leu Val Asp Ser Ser Gly Asn Ile Thr Thr 645 650 655	1968
cca act tat aac att agc gtg aaa acc act aag ctt aac agt aat ggc Pro Thr Tyr Asn Ile Ser Val Lys Thr Thr Lys Leu Asn Ser Asn Gly 660 665 670	2016
acc agt ggt aat aat aaa ttt agt gtt agt aat gct cat gat aac aat Thr Ser Gly Asn Asn Lys Phe Ser Val Ser Asn Ala His Asp Asn Asn 675 680 685	2064
agc tta gtt acc gcc aaa gat ttg gca gac tat cta aat aaa gtc aat Ser Leu Val Thr Ala Lys Asp Leu Ala Asp Tyr Leu Asn Lys Val Asn	2112

690	695	700	
gaa acg gct gac agt gct cta cca agc ttt aaa gtc caa aac ggt gat Glu Thr Ala Asp Ser Ala Leu Pro Ser Phe Lys Val Gln Asn Gly Asp 705	710	715	2160
aat agc aac aac gcc atc acc gtg ggt aaa gat aca aac ggc aag acc Asn Ser Asn Asn Ala Ile Thr Val Gly Lys Asp Thr Asn Gly Lys Thr 725		730	2208
		735	
ttc aac acc tta aaa ctc aaa ggt gaa aac ggt gtt aat att acg acc Phe Asn Thr Leu Lys Leu Lys Gly Glu Asn Gly Val Asn Ile Thr Thr 740	745	750	2256
aat aga gcc aca ggt aca gtt acc ttt ggc att gac caa agt aat ggt Asn Arg Ala Thr Gly Thr Val Thr Phe Gly Ile Asp Gln Ser Asn Gly 755	760	765	2304
ctc acc acg cct aag ctg acc gtg ggt agc gat aca aat ggt aat cga Leu Thr Thr Pro Lys Leu Thr Val Gly Ser Asp Thr Asn Gly Asn Arg 770	775	780	2352
ttg gtt att gag caa gtc cct agc gct gac ggt aac agc acc aaa aac Leu Val Ile Glu Gln Val Pro Ser Ala Asp Gly Asn Ser Thr Lys Asn 785	790	795	2400
		800	
atc att aaa gga ttg tcc cca aca ctg cct agc att gcc agt cca agt Ile Ile Lys Gly Leu Ser Pro Thr Leu Pro Ser Ile Ala Ser Pro Ser 805	810	815	2448
ggc cgc aac ata gca ctg ggc aat aca atc gaa gaa aaa gac aaa tcc Gly Arg Asn Ile Ala Leu Gly Asn Thr Ile Glu Glu Lys Asp Lys Ser 820	825	830	2496
aac gct gcc agc att gat gat gtg cta aat gca ggc ttt aac cta aaa Asn Ala Ala Ser Ile Asp Asp Val Leu Asn Ala Gly Phe Asn Leu Lys 835	840	845	2544
aat aat ggc aaa gac aaa gac ttt gtc tcc act tat gac act gtt gac Asn Asn Gly Lys Asp Lys Asp Phe Val Ser Thr Tyr Asp Thr Val Asp 850	855	860	2592
ttt atc gat ggc aat gcc acc acc gcc aca gta act tat gat gaa gcc Phe Ile Asp Gly Asn Ala Thr Thr Ala Thr Val Thr Tyr Asp Glu Ala 865	870	875	2640
		880	
aat caa acc agt aaa gtg gcg tat gat gtg aat gtg gat gag aaa acc Asn Gln Thr Ser Lys Val Ala Tyr Asp Val Asn Val Asp Glu Lys Thr 885	890	895	2688
att gaa ctg aca ggc gat aat ggc aag aaa caa ctt ggc gtc aaa acc Ile Glu Leu Thr Gly Asp Asn Gly Lys Lys Gln Leu Gly Val Lys Thr 900	905	910	2736
atc aaa ctg acc gaa aca agt act aat ggt aat gca act aca ttt agt Ile Lys Leu Thr Glu Thr Ser Thr Asn Gly Asn Ala Thr Thr Phe Ser 915	920	925	2784
acc gac gat gac cat gcc ctt gtt aaa gcc agt gat atc gcc ggc aat 2832			

Thr Asp Asp Asp His Ala Leu Val Lys Ala Ser Asp Ile Ala Gly Asn			
930	935	940	
ctt aac acc cta gcc gag gaa att cac acc acc aaa ggc aca gca aac			2880
Leu Asn Thr Leu Ala Glu Glu Ile His Thr Thr Lys Gly Thr Ala Asn			
945	950	955	960
acc gcc cta caa acc ttt acc gtt aaa aag gta gat gaa aat gat aag			2928
Thr Ala Leu Gln Thr Phe Thr Val Lys Lys Val Asp Glu Asn Asp Lys			
965	970	975	
gct gat gac acc aac gcc atc acc gtg ggt aaa gat ggc aca agt ggt			2976
Ala Asp Asp Thr Asn Ala Ile Thr Val Gly Lys Asp Gly Thr Ser Gly			
980	985	990	
aaa gtc aac acc tta aaa ctc aaa ggt aaa aac ggt ctt gat att aaa			3024
Lys Val Asn Thr Leu Lys Leu Lys Gly Lys Asn Gly Leu Asp Ile Lys			
995	1000	1005	
acc gac aaa gat ggt acg gtt acc ttt ggc att aac acc caa agc ggt			3072
Thr Asp Lys Asp Gly Thr Val Thr Phe Gly Ile Asn Thr Gln Ser Gly			
1010	1015	1020	
ctt aaa gcc ggc gac agc acc act cta aac aac aat ggc ttg tct att			3120
Leu Lys Ala Gly Asp Ser Thr Thr Leu Asn Asn Asn Gly Leu Ser Ile			
1025	1030	1035	1040
aaa aac acc gct agt aac gaa caa atc caa gtc ggt gct gat ggc gtg			3168
Lys Asn Thr Ala Ser Asn Glu Gln Ile Gln Val Gly Ala Asp Gly Val			
1045	1050	1055	
aag ttt gcc atg gtt aat aat ggt gtt gta ggt gct gat ggc att gat ggc			3216
Lys Phe Ala Met Val Asn Asn Gly Val Val Gly Ala Gly Ile Asp Gly			
1060	1065	1070	
aca act cgc att acc aga gat gaa att ggc ttt act ggg act aat ggc			3264
Thr Thr Arg Ile Thr Arg Asp Glu Ile Gly Phe Thr Gly Thr Asn Gly			
1075	1080	1085	
tca ctt gat aaa agc aaa ccc cac cta agc aaa gac ggc att aac gca			3312
Ser Leu Asp Lys Ser Lys Pro His Leu Ser Lys Asp Gly Ile Asn Ala			
1090	1095	1100	
ggt ggt aaa aag att acc aac att caa tca ggt gag att gcc aaa aac			3360
Gly Gly Lys Lys Ile Thr Asn Ile Gln Ser Gly Glu Ile Ala Lys Asn			
1105	1110	1115	1120
agc cat gat gct gtg aca ggc ggc aag att tat gat tta aaa acc gaa			3408
Ser His Asp Ala Val Thr Gly Gly Lys Ile Tyr Asp Leu Lys Thr Glu			
1125	1130	1135	
ctt gaa aat aaa atc agc agt act gcc aaa aca gca caa aac tca tta			3456
Leu Glu Asn Lys Ile Ser Ser Thr Ala Lys Thr Ala Gln Asn Ser Leu			
1140	1145	1150	
cac gaa ttc tca gta gca gat gaa caa ggt aat aac ttt acg gtt agt			3504
His Glu Phe Ser Val Ala Asp Glu Gln Gly Asn Asn Phe Thr Val Ser			
1155	1160	1165	

aac cct tac tcc agt tat gac acc tca aag acc tct gat gtc atc acc Asn Pro Tyr Ser Ser Tyr Asp Thr Ser Lys Thr Ser Asp Val Ile Thr 1170 1175 1180	3552
ttt gca ggt gaa aac ggc att acc acc aag gta aat aaa ggt gtg gtg Phe Ala Gly Glu Asn Gly Ile Thr Thr Lys Val Asn Lys Gly Val Val 1185 1190 1195 1200	3600
cgt gtg ggc att gac caa acc aaa ggc tta acc acg cct aag ctg acc Arg Val Gly Ile Asp Gln Thr Lys Gly Leu Thr Thr Pro Lys Leu Thr 1205 1210 1215	3648
gtg ggt aat aat aat ggc aaa ggc att gtc att aac agc caa aat ggt Val Gly Asn Asn Gly Lys Gly Ile Val Ile Asn Ser Gln Asn Gly 1220 1225 1230	3696
caa aat acc atc aca gga cta agc aac act cta gct aat gtt acc aat Gln Asn Thr Ile Thr Gly Leu Ser Asn Thr Leu Ala Asn Val Thr Asn 1235 1240 1245	3744
gat aaa ggt agc gta cgc acc aca gaa cag ggc aat ata atc aaa gac Asp Lys Gly Ser Val Arg Thr Thr Glu Gln Gly Asn Ile Ile Lys Asp 1250 1255 1260	3792
gaa gac aaa acc cgt gcc gcc agc att gtt gat gtg cta agc gca ggc Glu Asp Lys Thr Arg Ala Ala Ser Ile Val Asp Val Leu Ser Ala Gly 1265 1270 1275 1280	3840
ttt aac ttg caa ggc aat ggt gaa gcg gtt gac ttt gtc tcc act tat Phe Asn Leu Gln Gly Asn Gly Glu Ala Val Asp Phe Val Ser Thr Tyr 1285 1290 1295	3888
gac acc gtc aac ttt gcc aat ggc aat acc acc acc gct aag gtg acc Asp Thr Val Asn Phe Ala Asn Gly Asn Thr Thr Ala Lys Val Thr 1300 1305 1310	3936
tat gat gac aca agc aaa acc agt aaa gtg gtc tat gat gtc aat gtg Tyr Asp Asp Thr Ser Lys Thr Ser Lys Val Val Tyr Asp Val Asn Val 1315 1320 1325	3984
gat gat aca acc att gaa gtt aaa gat aaa aaa ctt ggc gta aaa acc Asp Asp Thr Thr Ile Glu Val Lys Asp Lys Lys Leu Gly Val Lys Thr 1330 1335 1340	4032
acc aca ttg acc agt act ggc aca ggt gct aat aaa ttt gcc cta agc Thr Thr Leu Thr Ser Thr Gly Thr Gly Ala Asn Lys Phe Ala Leu Ser 1345 1350 1355 1360	4080
aat caa gct act ggc gat gcg ctt gtc aag gcc agt gat atc gtt gct Asn Gln Ala Thr Gly Asp Ala Leu Val Lys Ala Ser Asp Ile Val Ala 1365 1370 1375	4128
cat cta aac acc tta tct ggc gac atc caa act gcc aaa ggg gca agc His Leu Asn Thr Leu Ser Gly Asp Ile Gln Thr Ala Lys Gly Ala Ser 1380 1385 1390	4176
caa gcg aac aac tca gca ggc tat gtg gat gct gat ggc aat aag gtc Gln Ala Asn Asn Ser Ala Gly Tyr Val Asp Ala Asp Gly Asn Lys Val 1395 1400 1405	4224

atc tat gac agt acc gat aac aag tac tat caa gcc aaa aat gat ggc Ile Tyr Asp Ser Thr Asp Asn Lys Tyr Tyr Gln Ala Lys Asn Asp Gly 1410 1415 1420	4272
aca gtt gat aaa acc aaa gaa gtt gcc aaa gac aaa ctg gtc gcc caa Thr Val Asp Lys Thr Lys Glu Val Ala Lys Asp Lys Leu Val Ala Gln 1425 1430 1435 1440	4320
gcc caa acc cca gat ggc aca ttg gct caa atg aat gtc aaa tca gtc Ala Gln Thr Pro Asp Gly Thr Leu Ala Gln Met Asn Val Lys Ser Val 1445 1450 1455	4368
att aac aaa gaa caa gta aat gat gcc aat aaa aag caa ggc atc aat Ile Asn Lys Glu Gln Val Asn Asp Ala Asn Lys Lys Gln Gly Ile Asn 1460 1465 1470	4416
gaa gac aac gcc ttt gtt aaa gga ctt gaa aaa gcc gct tct gat aac Glu Asp Asn Ala Phe Val Lys Gly Leu Glu Lys Ala Ala Ser Asp Asn 1475 1480 1485	4464
aaa acc aaa aac gcc gca gta act gtg ggt gat tta aat gcc gtt gcc Lys Thr Lys Asn Ala Ala Val Thr Val Gly Asp Leu Asn Ala Val Ala 1490 1495 1500	4512
caa aca ccg ctg acc ttt gca ggg gat aca ggc aca acg gct aaa aaa Gln Thr Pro Leu Thr Phe Ala Gly Asp Thr Gly Thr Thr Ala Lys Lys 1505 1510 1515 1520	4560
ctg ggc gag act ttg acc atc aaa ggt ggg caa aca gac acc aat aag Leu Gly Glu Thr Leu Thr Ile Lys Gly Gln Thr Asp Thr Asn Lys 1525 1530 1535	4608
cta acc gat aat aac atc ggt gtg gta gca ggt act gat ggc ttc act Leu Thr Asp Asn Asn Ile Gly Val Val Ala Gly Thr Asp Gly Phe Thr 1540 1545 1550	4656
gtc aaa ctt gcc aaa gac cta acc aat ctt aac agc gtt aat gca ggt Val Lys Leu Ala Lys Asp Leu Thr Asn Leu Asn Ser Val Asn Ala Gly 1555 1560 1565	4704
ggc acc aaa att gat gaa aaa ggc atc tct ttt gta gac gca aac ggt Gly Thr Lys Ile Asp Glu Lys Gly Ile Ser Phe Val Asp Ala Asn Gly 1570 1575 1580	4752
caa gcc aaa gca aac acc cct gtg cta agt gcc aat ggg ctg gac ctg Gln Ala Lys Ala Asn Thr Pro Val Leu Ser Ala Asn Gly Leu Asp Leu 1585 1590 1595 1600	4800
ggt ggc aag gtc atc agt aat gtg ggc aaa ggc aca aaa gat acc gac Gly Gly Lys Val Ile Ser Asn Val Gly Lys Gly Thr Lys Asp Thr Asp 1605 1610 1615	4848
gct gcc aat gta caa cag tta aac gaa gta cgc aac ttg ttg ggt ctt Ala Ala Asn Val Gln Gln Leu Asn Glu Val Arg Asn Leu Leu Gly Leu 1620 1625 1630	4896
ggt aat gat aac gct gac ggc aat cag gta aac att gcc gac atc aaa Gly Asn Asp Asn Ala Asp Gly Asn Gln Val Asn Ile Ala Asp Ile Lys	4944

1635	1640	1645	
aaa gac cca aat tca ggt tca tca tct aac cgc act gtc atc aaa gca Lys Asp Pro Asn Ser Gly Ser Ser Ser Asn Arg Thr Val Ile Lys Ala			4992
1650	1655	1660	
ggc acg gta ctt ggc ggt aaa ggt aat aac gat acc gaa aaa ctt gcc Gly Thr Val Leu Gly Gly Lys Asn Asn Asp Thr Glu Lys Leu Ala			5040
1665	1670	1675	1680
act ggt ggt gta caa gtg ggc gtg gat aaa gac ggc aac gct aac ggc Thr Gly Gly Val Gln Val Gly Val Asp Lys Asp Gly Asn Ala Asn Gly			5088
1685	1690	1695	
gat tta agc aat gtt tgg gtc aaa acc caa aaa gat ggc agc aaa aaa Asp Leu Ser Asn Val Trp Val Lys Thr Gln Lys Asp Gly Ser Lys Lys			5136
1700	1705	1710	
gcc ctg ctc gcc act tat aac gcc gca ggt cag acc aac tat gtg acc Ala Leu Leu Ala Thr Tyr Asn Ala Ala Gly Gln Thr Asn Tyr Val Thr			5184
1715	1720	1725	
aac aac ccc gca gaa gcc att gac aga ata aat gaa caa ggt atc cgc Asn Asn Pro Ala Glu Ala Ile Asp Arg Ile Asn Glu Gln Gly Ile Arg			5232
1730	1735	1740	
tcc ttc cat gtc aac gat ggc aat caa gag cct gtg gta caa ggg cgt Phe Phe His Val Asn Asp Gly Asn Gln Glu Pro Val Val Gln Gly Arg			5280
1745	1750	1755	1760
aac ggc att gac tca agt gcc tca ggc aag cac tca gtg gcg ata ggt Asn Gly Ile Asp Ser Ser Ala Ser Gly Lys His Ser Val Ala Ile Gly			5328
1765	1770	1775	
tcc cag gcc aag gca gat ggt gaa gcc gcc gtt gcc ata ggc aga caa Phe Gln Ala Lys Ala Asp Gly Glu Ala Ala Val Ala Ile Gly Arg Gln			5376
1780	1785	1790	
acc caa gca ggc aac caa tcc atc gcc atc ggt gat aac gca caa gcc Thr Gln Ala Gly Asn Gln Ser Ile Ala Ile Gly Asp Asn Ala Gln Ala			5424
1795	1800	1805	
acg ggc gat caa tcc atc gcc atc ggt aca ggc aat gtg gta gca ggt Thr Gly Asp Gln Ser Ile Ala Ile Gly Thr Gly Asn Val Val Ala Gly			5472
1810	1815	1820	
aag cac tct ggt gcc atc ggc gac cca agc act gtt aag gct gat aac Lys His Ser Gly Ala Ile Gly Asp Pro Ser Thr Val Lys Ala Asp Asn			5520
1825	1830	1835	1840
agt tac agt gtg ggt aat aac aac cag ttt acc gat gcc act caa acc Ser Tyr Ser Val Gly Asn Asn Gln Phe Thr Asp Ala Thr Gln Thr			5568
1845	1850	1855	
gat gtc ttt ggt gtg ggc aat aac atc acc gtg acc gaa agt aac tcg Asp Val Phe Gly Val Gly Asn Asn Ile Thr Val Thr Glu Ser Asn Ser			5616
1860	1865	1870	
gtt gcc tta ggt tca aac tct gcc atc agt gca ggc aca cac gca ggc			5664

Val Ala Leu Gly Ser Asn Ser Ala Ile Ser Ala Gly Thr His Ala Gly			
1875	1880	1885	
aca caa gcc aaa aaa tct gac ggc aca gca ggt aca acc acc aca gca			5712
Thr Gln Ala Lys Lys Ser Asp Gly Thr Ala Gly Thr Thr Thr Ala			
1890	1895	1900	
ggt gcc aca ggt acg gtt aaa ggc ttt gct gga caa acg gcg gtt ggt			5760
Gly Ala Thr Gly Thr Val Lys Gly Phe Ala Gly Gln Thr Ala Val Gly			
1905	1910	1915	1920
gcg gtc tcc gtg ggt gcc tca ggt gct gaa cgc cgt atc caa aat gtg			5808
Ala Val Ser Val Gly Ala Ser Gly Ala Glu Arg Arg Ile Gln Asn Val			
1925	1930	1935	
gca gca ggt gag gtc agt gcc acc agc acc gat gcg gtc aat ggt agc			5856
Ala Ala Gly Glu Val Ser Ala Thr Ser Thr Asp Ala Val Asn Gly Ser			
1940	1945	1950	
cag ttg tac aaa gcc acc caa agc att gcc aac gca acc aat gag ctt			5904
Gln Leu Tyr Lys Ala Thr Gln Ser Ile Ala Asn Ala Thr Asn Glu Leu			
1955	1960	1965	
gac cat cgt atc cac caa aac gaa aat aaa gcc aat gca ggg att tca			5952
Asp His Arg Ile His Gln Asn Glu Asn Lys Ala Asn Ala Gly Ile Ser			
1970	1975	1980	
tca gcg atg gcg atg gcg tcc atg cca caa gcc tac att cct ggc aga			6000
Ser Ala Met Ala Met Ala Ser Met Pro Gln Ala Tyr Ile Pro Gly Arg			
1985	1990	1995	2000
tcc atg gtt acc ggg ggt att gcc acc cac aac ggt caa ggt gcg gtg			6048
Ser Met Val Thr Gly Gly Ile Ala Thr His Asn Gly Gln Gly Ala Val			
2005	2010	2015	
gca gtg gga ctg tcg aag ctg tcg gat aat ggt caa tgg gta ttt aaa			6096
Ala Val Gly Leu Ser Lys Leu Ser Asp Asn Gly Gln Trp Val Phe Lys			
2020	2025	2030	
atc aat ggt tca gcc gat acc caa ggc cat gta ggg gcg gca gtt ggt			6144
Ile Asn Gly Ser Ala Asp Thr Gln Gly His Val Gly Ala Ala Val Gly			
2035	2040	2045	
gca ggt ttt cac ttt			6159
Ala Gly Phe His Phe			
2050			

Figure 5. *Moraxella catarrhalis* les1 200kDa

ATG aat cac atc tat aaa gtc atc ttt aac aaa gcc aca ggc aca ttt Met Asn His Ile Tyr Lys Val Ile Phe Asn Lys Ala Thr Gly Thr Phe	48
1 5 10 15	
atg gcc gtg gca gag tgc gcc aaa tcc cac agc gga <u>ggg</u> agt agc agt Met Ala Val Ala Glu Cys Ala Lys Ser His Ser Gly Gly Ser Ser Ser	96
20 25 30	
agt acc gca gga cag gtg ggc agc tct cct gtc atc cgc ctg act cgt Ser Thr Ala Gly Gln Val Gly Ser Ser Pro Val Ile Arg Leu Thr Arg	144
35 40 45	
gtt gcc acg ctc gct atc cta gtg atc ggt gcg acg ctc aat ggc agt Val Ala Thr Leu Ala Ile Leu Val Ile Gly Ala Thr Leu Asn Gly Ser	192
50 55 60	
gct tat gct caa aat aat agc aag atc gca ttt ggt acc aca ggc aac Ala Tyr Ala Gln Asn Asn Ser Lys Ile Ala Phe Gly Thr Thr Gly Asn	240
65 70 75 80	
aat gac aat gcc tcg gct agc aat gaa gca tcc att gct att ggt agt Asn Asp Asn Ala Ser Ala Ser Asn Glu Ala Ser Ile Ala Ile Gly Ser	288
85 90 95	
ctt gct aag gca cat gcc aat caa gct att gct atc ggt ggt agc aaa Leu Ala Lys Ala His Ala Asn Gln Ala Ile Ala Ile Gly Gly Ser Lys	336
100 105 110	
cca gat cct cgt aat caa gcg gct aat cag aag gca ggt tcc cac gcc Pro Asp Pro Arg Asn Gln Ala Ala Asn Gln Lys Ala Gly Ser His Ala	384
115 120 125	
aaa ggt aaa gag tcc atc gcc atc ggt ggt gat gta ctg gct gag ggt Lys Gly Lys Glu Ser Ile Ala Ile Gly Gly Asp Val Leu Ala Glu Gly	432
130 135 140	
gat gcc tcg att gcc att ggt agt gat gac tta tat ttg gat agg aat Asp Ala Ser Ile Ala Ile Gly Ser Asp Asp Leu Tyr Leu Asp Arg Asn	480
145 150 155 160	
agc act aac tct aaa tat cca aat ggt ctt ctt agc act ctt att caa Ser Thr Asn Ser Lys Tyr Pro Asn Gly Leu Leu Ser Thr Leu Ile Gln	528
165 170 175	
aac cat aca gta tta cgc caa ata cga gac tca aat ggt tct cag aaa Asn His Thr Val Leu Arg Gln Ile Arg Asp Ser Asn Gly Ser Gln Lys	576
180 185 190	
tat aga cgc aca gca gca gaa gga cac gcc agt act gca gtg gga gcc Tyr Arg Arg Thr Ala Ala Glu Gly His Ala Ser Thr Ala Val Gly Ala	624
195 200 205	
atg gca tat gca aag ggt cat ttt gcc aac gcc ttt ggt aca cggt tca Met Ala Tyr Ala Lys Gly His Phe Ala Asn Ala Phe Gly Thr Arg Ser	672

210	215	220	
aca gct gaa ggc aac tat tcc ttg gca gta ggt ctt acc gcc aaa gcc Thr Ala Glu Gly Asn Tyr Ser Leu Ala Val Gly Leu Thr Ala Lys Ala 225 230 235 240			720
gaa aaa gga tat aca atc gct att ggt tct aat gca caa gct atc aat Glu Lys Gly Tyr Thr Ile Ala Ile Gly Ser Asn Ala Gln Ala Ile Asn 245 250 255			768
tat gga gca cta gcc ctt ggt gca gat act cga gtt gat ttg gat tac Tyr Gly Ala Leu Ala Leu Gly Ala Asp Thr Arg Val Asp Leu Asp Tyr 260 265 270			816
ggt att gcc cta ggt tat ggt tct cag atc ctt aat aat aat aat aat Gly Ile Ala Leu Gly Tyr Gly Ser Gln Ile Leu Asn Asn Asn Asn Asn 275 280 285			864
aat aat aat aaa gcc tat gta cca gaa ggt aat ggg tca aac ata aaa Asn Asn Asn Lys Ala Tyr Val Pro Glu Gly Asn Gly Ser Asn Ile Lys 290 295 300			912
tcg tct aaa gcc acc ggc aat ggt tta ttt tcc att ggt agt agc act Ser Ser Lys Ala Thr Gly Asn Gly Leu Phe Ser Ile Gly Ser Ser Thr 305 310 315 320			960
atc aag cgt aaa atc atc aat gtc ggt gca ggt tat gag gat acc gat Ile Lys Arg Lys Ile Ile Asn Val Gly Ala Gly Tyr Glu Asp Thr Asp 325 330 335			1008
gcg gtc aat gtg gca cag cta aaa gcg gtg gag aat ctg gct aag cgt Ala Val Asn Val Ala Gln Leu Lys Ala Val Glu Asn Leu Ala Lys Arg 340 345 350			1056
caa att act ttt aag ggt gat gat aac ggt act ggc gtt aag aaa aaa Gln Ile Thr Phe Lys Gly Asp Asp Asn Gly Thr Gly Val Lys Lys Lys 355 360 365			1104
ctg ggc gag act tta acc att aaa ggt ggt gag acc caa gcg gac aag Leu Gly Glu Thr Leu Thr Ile Lys Gly Glu Thr Gln Ala Asp Lys 370 375 380			1152
cta acc gat aat aat aac att ggt gtg gta aca gat aat aat act ggt Leu Thr Asp Asn Asn Ile Gly Val Val Thr Asp Asn Asn Thr Gly 385 390 395 400			1200
ctg aaa gtt aaa ctt gct aaa aac cta agc ggt ctt gaa aca gtt agc Leu Lys Val Lys Leu Ala Lys Asn Leu Ser Gly Leu Glu Thr Val Ser 405 410 415			1248
acc aaa aac cta acc gcc agc gag aaa gtt acg gta ggt agt ggt aat Thr Lys Asn Leu Thr Ala Ser Glu Lys Val Thr Val Gly Ser Gly Asn 420 425 430			1296
aac acc gct gag cta caa agc ggt ggt tta acc ttt acc cca aca aca Asn Thr Ala Glu Leu Gln Ser Gly Gly Leu Thr Phe Thr Pro Thr Thr 435 440 445			1344

aat gca agc aca gac aaa acc gtc tat ggc act gat ggg ctt aag ttt Asn Ala Ser Thr Asp Lys Thr Val Tyr Gly Thr Asp Gly Leu Lys Phe 450 455 460	1392
act gat aat tct aat acg gca ctt gaa gat act act cgt atc acc aaa Thr Asp Asn Ser Asn Thr Ala Leu Glu Asp Thr Thr Arg Ile Thr Lys 465 470 475 480	1440
gat aaa att ggt ttt agc aat aaa gct ggt aca gtt gat gaa aac aaa Asp Lys Ile Gly Ser Asn Lys Ala Gly Thr Val Asp Glu Asn Lys 485 490 495	1488
cct tat ctt gat aaa gac aag cta aaa gtt ggc aac agc acc cta aac Pro Tyr Leu Asp Lys Asp Lys Leu Lys Val Gly Asn Ser Thr Leu Asn 500 505 510	1536
aac ggt ggc ttg act gtt aat aac acc att ggt ggt agc aat aaa caa Asn Gly Gly Leu Thr Val Asn Asn Thr Ile Gly Gly Ser Asn Lys Gln 515 520 525	1584
atc caa gtc ggt gct gat ggc att aaa ttt gcc gat gtg aat gtt aat Ile Gln Val Gly Ala Asp Gly Ile Lys Phe Ala Asp Val Asn Val Asn 530 535 540	1632
gta tca aat gcc gca aaa ttc ggc act act cgt att acc gaa gag gaa Val Ser Asn Ala Ala Lys Phe Gly Thr Thr Arg Ile Thr Glu Glu Glu 545 550 555 560	1680
att ggc ttt gct gat gct gat ggt aaa gtt gat aaa aag tca cca tat Ile Gly Phe Ala Asp Ala Asp Gly Lys Val Asp Lys Lys Ser Pro Tyr 565 570 575	1728
ttg gat aaa aaa caa ctt caa gtg ggt ggt gtt aaa att acc aaa gac Leu Asp Lys Lys Gln Leu Gln Val Gly Gly Val Lys Ile Thr Lys Asp 580 585 590	1776
agt ggc att aat gca ggt gat caa aag atc agt aat gtt aaa gat gca Ser Gly Ile Asn Ala Gly Asp Gln Lys Ile Ser Asn Val Lys Asp Ala 595 600 605	1824
acg gac gat acc gat gca gtc act tat aaa cag ctt aaa caa gtc caa Thr Asp Asp Thr Asp Ala Val Thr Tyr Lys Gln Leu Lys Gln Val Gln 610 615 620	1872
caa gac gcc gac ggt gcc cta caa agc ttc tct att cgt gat gaa aaa Gln Asp Ala Asp Gly Ala Leu Gln Ser Phe Ser Ile Arg Asp Glu Lys 625 630 635 640	1920
ggt cag gaa ttt acg att agt aac ttg tat tct aat ggt aat acc cca Gly Gln Glu Phe Thr Ile Ser Asn Leu Tyr Ser Asn Gly Asn Thr Pro 645 650 655	1968
aat acc ttt gag acc atc acc ttt gca ggt gaa aac ggc atc agt atc Asn Thr Phe Glu Thr Ile Thr Phe Ala Gly Glu Asn Gly Ile Ser Ile 660 665 670	2016

agc aat gac ata gcc aaa ggt aaa gtc aaa gtt ggt att gac cca atc Ser Asn Asp Ile Ala Lys Gly Lys Val Lys Val Gly Ile Asp Pro Ile	675 680 685	2064
aat ggt ctc acc acg cct aag ctg acc gtg ggt agc gat aaa gat ggt Asn Gly Leu Thr Thr Pro Lys Leu Thr Val Gly Ser Asp Lys Asp Gly	690 695 700	2112
aaa actcaa ttg gtt att gag caa gtg gct agc ggt aac gac acc aaa Lys Thr Gln Leu Val Ile Glu Gln Val Ala Ser Gly Asn Asp Thr Lys	705 710 715 720	2160
aac atc att aga gga ttg tcc cca aca ctg cct agc att acc aat gca Asn Ile Ile Arg Gly Leu Ser Pro Thr Leu Pro Ser Ile Thr Asn Ala	725 730 735	2208
ggt ggc gta cgc acc aca gaa cag ggc aat aca atc acc agc gac gaa Gly Gly Val Arg Thr Thr Glu Gln Gly Asn Thr Ile Thr Ser Asp Glu	740 745 750	2256
gac aaa tcc aaa gcc gcc agt atc ggt gat ata tta aat aca ggc ttt Asp Lys Ser Lys Ala Ala Ser Ile Gly Asp Ile Leu Asn Thr Gly Phe	755 760 765	2304
aac cta aaa aat aat agc aac tcc gtt ggc ttt gtc tcc act tat aac Asn Leu Lys Asn Asn Ser Val Gly Phe Val Ser Thr Tyr Asn	770 775 780	2352
act gtt gac ttt atc gat ggc aat gcc acc acc gct aag gta act tac Thr Val Asp Phe Ile Asp Gly Asn Ala Thr Thr Ala Lys Val Thr Tyr	785 790 795 800	2400
gat gaa acc aat caa acc agt aaa gta act tat gat gtc aat gtg gat Asp Glu Thr Asn Gln Thr Ser Lys Val Thr Tyr Asp Val Asn Val Asp	805 810 815	2448
gag aaa acc att gaa ctc aca ggc gat aat ggc aag aca aac aaa att Glu Lys Thr Ile Glu Leu Thr Gly Asp Asn Gly Lys Thr Asn Lys Ile	820 825 830	2496
ggc gtc aaa acc acc aca ctg acc aca aca aat gct aat ggt aaa gca Gly Val Lys Thr Thr Leu Thr Thr Asn Ala Asn Gly Lys Ala	835 840 845	2544
acc aac ttt agt acc acc gat aac gat gcc ctt gtt aac gcc aaa gac Thr Asn Phe Ser Thr Thr Asp Asn Asp Ala Leu Val Asn Ala Lys Asp	850 855 860	2592
atc gcc gaa aat cta aac acc cta gcc aag gaa att cac acc acc aaa Ile Ala Glu Asn Leu Asn Thr Leu Ala Lys Glu Ile His Thr Thr Lys	865 870 875 880	2640
ggc aca gca gac acc gcc cta caa acc ttt aaa gtc aaa aaa gac ggt Gly Thr Ala Asp Thr Ala Leu Gln Thr Phe Lys Val Lys Lys Asp Gly	885 890 895	2688
gca act gat gac gaa acc atc acc gtg ggt aaa gat ggt aca caa aac		2736

Ala Thr Asp Asp Glu Thr Ile Thr Val Gly Lys Asp Gly Thr Gln Asn			
900	905	910	
ggc aag acc gtc aac act cta aaa ctc aaa ggt gaa aac ggt cta acg			2784
Gly Lys Thr Val Asn Thr Leu Lys Leu Lys Gly Glu Asn Gly Leu Thr			
915	920	925	
gtt gct acc aat aaa gat ggt acg gtt acc ttt ggc att aac acc caa			2832
Val Ala Thr Asn Lys Asp Gly Thr Val Thr Phe Gly Ile Asn Thr Gln			
930	935	940	
agc ggt ctt aaa gcc ggc gac agc acc act cta aac aaa gat ggc ttg			2880
Ser Gly Leu Lys Ala Gly Asp Ser Thr Thr Leu Asn Lys Asp Gly Leu			
945	950	955	960
tct att aaa aac ccc gct agt aac gaa caa atc caa gtc ggt gct gat			2928
Ser Ile Lys Asn Pro Ala Ser Asn Glu Gln Ile Gln Val Gly Ala Asp			
965	970	975	
ggc gtg aag ttt gcc aag gtt gat aag ggt aat tca agc act ggc att			2976
Gly Val Lys Phe Ala Lys Val Asp Lys Gly Asn Ser Ser Thr Gly Ile			
980	985	990	
gat ggc aca agc cgt atc acc aaa gat caa att ggc ttt act ggg gct			3024
Asp Gly Thr Ser Arg Ile Thr Lys Asp Gln Ile Gly Phe Thr Gly Ala			
995	1000	1005	
aat ggc tca ctt gat acc acc aaa ccc cac cta acc aaa gac aag ctt			3072
Asn Gly Ser Leu Asp Thr Thr Lys Pro His Leu Thr Lys Asp Lys Leu			
1010	1015	1020	
aaa gtg ggt gaa gtt gaa att acc aac act ggc att aac gca ggt ggt			3120
Lys Val Gly Val Glu Ile Thr Asn Thr Gly Ile Asn Ala Gly Gly			
1025	1030	1035	1040
aaa aag att acc aac att caa tca ggt gat att acc caa aac agc aat			3168
Lys Lys Ile Thr Asn Ile Gln Ser Gly Asp Ile Thr Gln Asn Ser Asn			
1045	1050	1055	
gat gct gtg aca ggc ggt cggttat gat tta aaa acc gaa ctt gaa			3216
Asp Ala Val Thr Gly Arg Val Tyr Asp Leu Lys Thr Glu Leu Glu			
1060	1065	1070	
agc aaa atc aac agt gct gct aaa aca gca caa aac tca tta cac gaa			3264
Ser Lys Ile Asn Ser Ala Ala Lys Thr Ala Gln Asn Ser Leu His Glu			
1075	1080	1085	
ttc tca gta gca gat gaa caa ggt aat cac ttt acg gtt agt aac cct			3312
Phe Ser Val Ala Asp Glu Gln Gly Asn His Phe Thr Val Ser Asn Pro			
1090	1095	1100	
tac tcc agt tat gac acc tca aag acc tct gat gtc atc acc ttt gca			3360
Tyr Ser Ser Tyr Asp Thr Ser Lys Thr Ser Asp Val Ile Thr Phe Ala			
1105	1110	1115	1120
ggt gaa aac ggc att acc acc aag gta aat aaa ggt gtg gtg cgt gtg			3408
Gly Glu Asn Gly Ile Thr Thr Lys Val Asn Lys Gly Val Val Arg Val			

1125	1130	1135	
ggc att gac caa acc aaa ggc tta acc acg cct aag ctg acc gtg ggt Gly Ile Asp Gln Thr Lys Gly Leu Thr Thr Pro Lys Leu Thr Val Gly 1140	1145	1150	3456
aat aat aat ggc aaa ggc att gtc att gac agt aaa gat ggt caa aat Asn Asn Asn Gly Lys Gly Ile Val Ile Asp Ser Lys Asp Gly Gln Asn 1155	1160	1165	3504
acc atc aca gga cta agc aac act cta gct aat gtt acc aat gat ggt Thr Ile Thr Gly Leu Ser Asn Thr Leu Ala Asn Val Thr Asn Asp Gly 1170	1175	1180	3552
gca gga cac gca cta agc caa ggg ctt gcc aat gac acc gac aaa acc Ala Gly His Ala Leu Ser Gln Gly Leu Ala Asn Asp Thr Asp Lys Thr 1185	1190	1195	3600
cgt gcc gcc agc att ggt gat gtg cta aac gca ggc ttt aac ttg caa Arg Ala Ala Ser Ile Gly Asp Val Leu Asn Ala Gly Phe Asn Leu Gln 1205	1210	1215	3648
ggc aat ggt gaa gcg gtt gac ttt gtc tcc act tat gac act gtt gac Gly Asn Gly Glu Ala Val Asp Phe Val Ser Thr Tyr Asp Thr Val Asp 1220	1225	1230	3696
ttt atc gat ggc aat gcc acc acc gct aag gtg acc tat gat gac aca Phe Ile Asp Gly Asn Ala Thr Thr Ala Lys Val Thr Tyr Asp Asp Thr 1235	1240	1245	3744
agc aaa acc agt aaa gtg gtc tat gat gtc aat gtg gat aat aaa acc Ser Lys Thr Ser Lys Val Val Tyr Asp Val Asn Val Asp Asn Lys Thr 1250	1255	1260	3792
att gaa gtg aca agt gat aaa aaa ctt ggc gtc aaa acc acc aca ctg Ile Glu Val Thr Ser Asp Lys Lys Leu Gly Val Lys Thr Thr Leu 1265	1270	1275	3840
acc aaa aca agt gct aat ggt aat gca acc aaa ttt agt gcc gac gat Thr Lys Thr Ser Ala Asn Gly Asn Ala Thr Lys Phe Ser Ala Ala Asp 1285	1290	1295	3888
ggc gat gcc ctt gtt aaa gcc agt gat atc gcc acc cat cta aat acc Gly Asp Ala Leu Val Lys Ala Ser Asp Ile Ala Thr His Leu Asn Thr 1300	1305	1310	3936
ttg gct ggc gac atc caa acc gcc aaa ggg gca agc caa gca agc agc Leu Ala Gly Asp Ile Gln Thr Ala Lys Gly Ala Ser Gln Ala Ser Ser 1315	1320	1325	3984
tca gca agc tat gtg gat gct gat ggc aac aag gtc atc tat gac agt Ser Ala Ser Tyr Val Asp Ala Asp Gly Asn Lys Val Ile Tyr Asp Ser 1330	1335	1340	4032
acc gat aag aag tac tat caa gtc aat gac aag ggt caa gtg gac aaa Thr Asp Lys Lys Tyr Tyr Gln Val Asn Asp Lys Gly Gln Val Asp Lys 1345	1350	1355	4080
		1360	

aac aaa gaa gtt gcc aaa gac aaa ctg gtc gcc caa gcc caa acc cca Asn Lys Glu Val Ala Lys Asp Lys Leu Val Ala Gln Ala Gln Thr Pro	1365	1370	1375	4128	
gat ggc aca ttg gct caa atg aat gtc aaa tca gtc att aac aaa gag Asp Gly Thr Leu Ala Gln Met Asn Val Lys Ser Val Ile Asn Lys Glu	1380	1385	1390	4176	
caa gta aat gat gcc aat aaa aag caa ggc atc aat gaa gac aac gcc Gln Val Asn Asp Ala Asn Lys Lys Gln Gly Ile Asn Glu Asp Asn Ala	1395	1400	1405	4224	
ttt atc aaa ggg ctt gaa aac gcc gcc aaa gac acc aaa acc aaa aac Phe Ile Lys Gly Leu Glu Asn Ala Ala Lys Asp Thr Lys Thr Lys Asn	1410	1415	1420	4272	
gcc gca gta act gtg ggt gat tta aat gcc gtt gcc caa aca ccg ctg Ala Ala Val Thr Val Gly Asp Leu Asn Ala Val Ala Gln Thr Pro Leu	1425	1430	1435	1440	4320
acc ttt gca ggg gat aca ggc aca acg gct aaa aaa ctg ggc gag act Thr Phe Ala Gly Asp Thr Gly Thr Ala Lys Lys Leu Gly Glu Thr	1445	1450	1455	4368	
ttg acc atc aaa ggt ggg caa aca gac acc aat aag cta acc gat aat Leu Thr Ile Lys Gly Gln Thr Asp Thr Asn Lys Leu Thr Asp Asn	1460	1465	1470	4416	
aac atc ggt gtg gta gca ggt act gat ggc ttc act gtc aaa ctt gcc Asn Ile Gly Val Val Ala Gly Thr Asp Gly Phe Thr Val Lys Leu Ala	1475	1480	1485	4464	
aaa gac cta acc aat ctt aac agc gtt aat gca ggt ggc acc aga att Lys Asp Leu Thr Asn Leu Asn Ser Val Asn Ala Gly Gly Thr Arg Ile	1490	1495	1500	4512	
gat gaa aaa ggc atc tct ttt gta gac gca aac ggt caa gcc aaa gca Asp Glu Lys Gly Ile Ser Phe Val Asp Ala Asn Gly Gln Ala Lys Ala	1505	1510	1515	1520	4560
aac acc cct gtg cta agt gcc aat ggg ctg gac ctg ggt ggc aaa cgc Asn Thr Pro Val Leu Ser Ala Asn Gly Leu Asp Leu Gly Gly Lys Arg	1525	1530	1535	4608	
atc agt aac atc ggt gca gct gtt gat gat aac gat gcg gtg aac ttt Ile Ser Asn Ile Gly Ala Ala Val Asp Asp Asn Asp Ala Val Asn Phe	1540	1545	1550	4656	
aag cag ttt aat gaa gtt gcc aaa acg gtc aac aac cta aac aac caa Lys Gln Phe Asn Glu Val Ala Lys Thr Val Asn Asn Leu Asn Asn Gln	1555	1560	1565	4704	
agt aac tca ggt gcg tca tta ccc ttt gtg gta acc gat gcc aat ggc Ser Asn Ser Gly Ala Ser Leu Pro Phe Val Val Thr Asp Ala Asn Gly	1570	1575	1580	4752	

aag ccc atc aat ggc acc gat ggc aag ccc caa aaa gcc atc aag ggc Lys Pro Ile Asn Gly Thr Asp Gly Lys Pro Gln Lys Ala Ile Lys Gly 1585 1590 1595 1600	4800
gcc gat ggt aaa tac tat cac gcc aac gcc aac ggc gta cct gtg gac Ala Asp Gly Lys Tyr Tyr His Ala Asn Ala Asn Gly Val Pro Val Asp 1605 1610 1615	4848
aaa gat ggc aag ccc atc acc gat gcg gac aaa ctt gcc aat ctg gca Lys Asp Gly Lys Pro Ile Thr Asp Ala Asp Lys Leu Ala Asn Leu Ala 1620 1625 1630	4896
gct cat ggc aaa ccc ctt gat gca ggt cat caa gtg gtg gca agc cta Ala His Gly Lys Pro Leu Asp Ala Gly His Gln Val Val Ala Ser Leu 1635 1640 1645	4944
ggc ggc aac tca gat gcc atc acc cta acc aac atc aag tcc act ttg Gly Gly Asn Ser Asp Ala Ile Thr Leu Thr Asn Ile Lys Ser Thr Leu 1650 1655 1660	4992
cca caa att gac aca cca aac aca ggt aat gcc aat gca ggg caa gcc Pro Gln Ile Asp Thr Pro Asn Thr Gly Asn Ala Asn Ala Gly Gln Ala 1665 1670 1675 1680	5040
caa agt ctg ccc agc cta tca gca gca cag caa agt aat gct gcc agt Gln Ser Leu Pro Ser Leu Ser Ala Ala Gln Gln Ser Asn Ala Ala Ser 1685 1690 1695	5088
gtc aaa gat gtg cta aat gta ggc ttt aac ttg cag acc aat cac aat Val Lys Asp Val Leu Asn Val Gly Phe Asn Leu Gln Thr Asn His Asn 1700 1705 1710	5136
caa gtg gac ttt gtc aaa gcc tat gat acc gtc aac ttt gtc aat ggt Gln Val Asp Phe Val Lys Ala Tyr Asp Thr Val Asn Phe Val Asn Gly 1715 1720 1725	5184
aca ggt gcc gac atc aca agc gtg cgt agt gct gat ggc acg atg agt Thr Gly Ala Asp Ile Thr Ser Val Arg Ser Ala Asp Gly Thr Met Ser 1730 1735 1740	5232
aac atc acc gtc aac acc gcc tta gca gcg acc gat gat gat ggc aat Asn Ile Thr Val Asn Thr Ala Leu Ala Ala Thr Asp Asp Asp Gly Asn 1745 1750 1755 1760	5280
gtg ctt atc aaa gcc aaa gat ggt aag ttc tac aaa gca gac gac ctc Val Leu Ile Lys Ala Lys Asp Gly Lys Phe Tyr Lys Ala Asp Asp Leu 1765 1770 1775	5328
atg cca aac ggc tca cta aaa gca ggc aaa tca gcc agt gat gcc aaa Met Pro Asn Gly Ser Leu Lys Ala Gly Lys Ser Ala Ser Asp Ala Lys 1780 1785 1790	5376
act cca act ggt cta agc ctt gtt aac ccc aat gct ggt aaa ggc agt Thr Pro Thr Gly Leu Ser Leu Val Asn Pro Asn Ala Gly Lys Gly Ser 1795 1800 1805	5424
aca ggc gat gca gtg gct ctt aat aac tta tca aaa gcg gta ttt aaa	5472

Thr Gly Asp Ala Val Ala Leu Asn Asn Leu Ser Lys Ala Val Phe Lys			
1810	1815	1820	
tcc aaa gat ggt aca act act acc aca gta agc tct gat ggc atc agt			5520
Ser Lys Asp Gly Thr Thr Thr Thr Val Ser Ser Asp Gly Ile Ser			
1825	1830	1835	1840
atc caa ggc aaa gat aac agc agc atc acc cta agc aaa gat ggg ctg			5568
Ile Gln Gly Lys Asp Asn Ser Ser Ile Thr Leu Ser Lys Asp Gly Leu			
1845	1850	1855	
aat gta ggc ggt aag gtc atc agc aat gtg ggt aaa ggc aca aaa gac			5616
Asn Val Gly Gly Lys Val Ile Ser Asn Val Gly Lys Gly Thr Lys Asp			
1860	1865	1870	
acc gac gct gcc aat gta caa cag tta aac gaa gta cgc aac ttg ttg			5664
Thr Asp Ala Ala Asn Val Gln Gln Leu Asn Glu Val Arg Asn Leu Leu			
1875	1880	1885	
ggt ctt ggt aat gct ggt aat gat aac gct gac ggc aat cag gta aac			5712
Gly Leu Gly Asn Ala Gly Asn Asp Asn Ala Asp Gly Asn Gln Val Asn			
1890	1895	1900	
att gcc gac atc aaa aaa gac cca aat tca ggt tca tca tct aac cgc			5760
Ile Ala Asp Ile Lys Lys Asp Pro Asn Ser Gly Ser Ser Ser Asn Arg			
1905	1910	1915	1920
act gtc atc aaa gca ggc acg gta ctt ggc ggt aaa ggt aat aac gat			5808
Thr Val Ile Lys Ala Gly Thr Val Leu Gly Gly Lys Gly Asn Asn Asp			
1925	1930	1935	
acc gaa aaa ctt gcc act ggt gta caa gtg ggc gtg gat aaa gac			5856
Thr Glu Lys Leu Ala Thr Gly Gly Val Gln Val Gly Val Asp Lys Asp			
1940	1945	1950	
ggc aac gct aac ggc gat tta agc aat gtt tgg gtc aaa acc caa aaa			5904
Gly Asn Ala Asn Gly Asp Leu Ser Asn Val Trp Val Lys Thr Gln Lys			
1955	1960	1965	
gat ggc agc aaa aaa gcc ctg ctc gcc act tat aac gcc gca ggt cag			5952
Asp Gly Ser Lys Lys Ala Leu Leu Ala Thr Tyr Asn Ala Ala Gly Gln			
1970	1975	1980	
acc aac tat ttg acc aac aac ccc gca gaa gcc att gac aga ata aat			6000
Thr Asn Tyr Leu Thr Asn Asn Pro Ala Glu Ala Ile Asp Arg Ile Asn			
1985	1990	1995	2000
gaa caa ggt atc cgc ttc ttc cat gtc aac gat ggc aat caa gag cct			6048
Glu Gln Gly Ile Arg Phe Phe His Val Asn Asp Gly Asn Gln Glu Pro			
2005	2010	2015	
gtg gta caa ggg cgt aac ggc att gac tca agt gcc tca ggc aag cac			6096
Val Val Gln Gly Arg Asn Gly Ile Asp Ser Ser Ala Ser Gly Lys His			
2020	2025	2030	
tca gtg gcg ata ggt ttc cag gcc aag gca gat ggt gaa gcc gcc gtt			6144
Ser Val Ala Ile Gly Phe Gln Ala Lys Ala Asp Gly Glu Ala Ala Val			

2035	2040	2045	
gcc ata ggc aga caa acc caa gca ggc aac caa tcc atc gcc atc ggt Ala Ile Gly Arg Gln Thr Gln Ala Gly Asn Gln Ser Ile Ala Ile Gly			6192
2050	2055	2060	
gat aac gca caa gcc acg ggc gat caa tcc atc gcc atc ggt aca ggc Asp Asn Ala Gln Ala Thr Gly Asp Gln Ser Ile Ala Ile Gly Thr Gly			6240
2065	2070	2075	2080
aat gtg gta aca ggt aag cac tct ggt gcc atc ggc gac cca agc act Asn Val Val Thr Gly Lys His Ser Gly Ala Ile Gly Asp Pro Ser Thr			6288
2085	2090	2095	
gtt aag gct gat aac agt tac agt gtg ggt aat aac aac cag ttt atc Val Lys Ala Asp Asn Ser Tyr Ser Val Gly Asn Asn Asn Gln Phe Ile			6336
2100	2105	2110	
gat gcc act cag acc gat gtc ttt ggt gtg ggc aat aac atc acc gtg Asp Ala Thr Gln Thr Asp Val Phe Gly Val Gly Asn Asn Ile Thr Val			6384
2115	2120	2125	
acc gaa agt aac tcg gtt gcc tta ggt tca aac tct gcc atc agt gca Thr Glu Ser Asn Ser Val Ala Leu Gly Ser Asn Ser Ala Ile Ser Ala			6432
2130	2135	2140	
ggc aca cac gca ggc aca caa gcc aaa aaa tct gac ggc aca gca ggt Gly Thr His Ala Gly Thr Gln Ala Lys Lys Ser Asp Gly Thr Ala Gly			6480
2145	2150	2155	2160
aca acc acc aca gca ggt gca aca ggt acg gtt aaa ggc ttt gct gga Thr Thr Thr Ala Gly Ala Thr Gly Thr Val Lys Gly Phe Ala Gly			6528
2165	2170	2175	
caa acg gcg gtt ggt gcg gtc tcc gtg ggt gcc tca ggt gct gaa cgc Gln Thr Ala Val Gly Ala Val Ser Val Gly Ala Ser Gly Ala Glu Arg			6576
2180	2185	2190	
cgt atc caa aat gtg gca gca ggt gag gtc agt gcc acc agc acc gat Arg Ile Gln Asn Val Ala Ala Gly Glu Val Ser Ala Thr Ser Thr Asp			6624
2195	2200	2205	
gcg gtc aat ggt agc cag ttg tac aaa gcc acc caa ggc att gcc aac Ala Val Asn Gly Ser Gln Leu Tyr Lys Ala Thr Gln Gly Ile Ala Asn			6672
2210	2215	2220	
gca acc aat gag ctt gac cat cgt atc cac caa aac gaa aat aaa gcc Ala Thr Asn Glu Leu Asp His Arg Ile His Gln Asn Glu Asn Lys Ala			6720
2225	2230	2235	2240
aat gca ggg att tca tca gcg atg gcg atg gcg tcc atg cca caa gcc Asn Ala Gly Ile Ser Ser Ala Met Ala Met Ala Ser Met Pro Gln Ala			6768
2245	2250	2255	
tac att cct ggc aga tcc atg gtt acc ggg ggt att gcc acc cac aac Tyr Ile Pro Gly Arg Ser Met Val Thr Gly Gly Ile Ala Thr His Asn			6816
2260	2265	2270	

ggt caa ggt gcg gtg gca gtg gga ctg tcg aag ctg tcg gat aat ggt		6864
Gly Gln Gly Ala Val Ala Val Gly Leu Ser Lys Leu Ser Asp Asn Gly		
2275	2280	2285
caa tgg gta ttt aaa atc aat ggt tca gcc gat acc caa ggc cat gta		6912
Gln Trp Val Phe Lys Ile Asn Gly Ser Ala Asp Thr Gln Gly His Val		
2290	2295	2300
ggg gcg gca gtt ggt gca ggt ttt cac ttt		6942
Gly Ala Ala Val Gly Ala Gly Phe His Phe		
2305	2310	

Figure 6. Alignment of amino acid sequence of 200kDa proteins of *M. catarrhalis* strains

10 20 30 40 50 60 70 80 90 100
 MNHIYKVIFNKATGTFMVAEYAKSHSTGGGSCATGQVGSVTLSFARIAALAVLVIAGATLGSAYAQOKKDTKHIAIGEQNQPRRS--GTAKADGDEIAIG
R.....N.....QIT...-E..OT.KINNTLK.D.L.T.EAS..F.
C....G.SS.STA.....SPVIRLT.V.T..I.....N.....NNSK-..F.TTGNDNA----S.SNEAS....
 4223 Q8 LES-1
 110 120 130 140 150 160 170 180 190 200
 ENANAOGGQAIAIGSSNKTUNGSSL-D-KIGTDATGQESIAIGGDVKASGGDASIAIGSSDLHLLDQHGNPKHPKGTLINDLINGHAVLKEIRSSSKDNTDVYKR
 SLSK...S.....VKPDP.NG.NG-NV.SH.K.N.....L.E.....Y.PKNL DL-.NEFHK----.H..EI..K.QT.T.GKI...
 SL.K.HAN.....G.KPDPRNQAAQ.N.A.SH.K.K.....L.E.....Y.DRNST.S.Y.N.L.ST-..QN.T.RQ..D.NGSQ....
 4223 Q8 LES-1
 210 220 230 240 250 260 270 280 290 300
 RTTASGHASTAVGAMSYYAQGHFSNAFGTRATAKSAYSЛАVGLAATAEGOSTIAIGSDATSSSLGAIАLGAГTRAQLQGSIALGQGSVVTQSDNN----SRPAYT
 ..R.O.....Y..EA.....Q.TK..S..V..N.KANAFAT.I.GN.VVN.GRGV..F..QILDR.....TDAS..V
 ..A.E.....A..K..A.....S..EGN..T.K..KGY.....N.QAINY..L..D..VD.DYG..Y.QILNNN...-NNNK..V
 4223 Q8 LES-1
 310 320 330 340 350 360 370 380 390 400
 PNTQALDDKFQ--ATNNTRAGPL-SIG-SN---SIRKRKLINVAGVNKTDAVNVAQLEAVVKWAERRITFOGD-DN-STDVKGILDNTLTIKGGAETNA--LTDNNN-IGVV
 .LGKT.ADQYK--.RQGSTDIF..N.NNNIS..R.....SRD.....KL.EEL.-N.K..K..G..N.NS.ER..G.....D.Q..--..EA.-
 .EGNGSNIKSS..K.--.GNG..F.--.SST.....YED.....K..ENL..-Q..K..-..G..G..KK..GE..-..Q..DK..-..N...
 4223 Q8 LES-1
 410 420 430 440 450 460 470 480 490 500
 KHEADNSCLKVKLAKTLNNTLEVNTTINATTIVKGSSSSSTAELLSDSLTTFTQPNTGSQSTSCKTVGNGVKFTNNAETTAIGTTRITRDKIGFARDG
 TDCGN--...E.TG..S.--.S..NKIT.SNTNNNN..Q.GG..S..I..TK..D...SID.L...DSNSI.TK...KK...GTN
 TNNN-T.....N.SG.ET.S.KN.T.SEK.T..GNN..Q.GG..T.NA..D...TD.L..D.SN.ALED...K...SNKA
 4223 Q8 LES-1
 D--
 .GVDESKPYLDNEKLVKGNSTLNNSGSLTVNNT-TGNNKOIOWGANGTIKEFATVANNVANTSATVGTARITEEKIGFAGTNIDG--
 GTVDEKPYLDKDKLVKGNSTLNNGGLTVNNNTIGGSNKOIOWGADGKTFADVNVSNAAKFGTTRITEEEIGFADAGK..-KS...-Q..G.K..K..S..N.
 510 520 530
 VDEKQAPYLDKKOLKVGSVAITIDNGIDA
 .MLAKGSSANDAVTIEQLKAAKPTLNAGAGISVTPTEILSVDAKSGNVVTAPTPYNTIGVKTTELNSDG
 ..H..T.....G.TN.IANT.....K...D.....D...INSNNGDLVDS..I.T.....S...K...N.
 ..DQ...-..VKDATDDT..YK...-..
 4223 Q8 LES-1
 540 550 560 570 580 590 600
 GNKKIS-----NLAKGSSANDAVTIEQLKAAKPTLNAGAGISVTPTEILSVDAKSGNVVTAPTPYNTIGVKTTELNSDG
 ..H..T.....G.TN.IANT.....K...D.....D...INSNNGDLVDS..I.T.....S...K...N.
 ..DQ...-..VKDATDDT..YK...-..
 4223 Q8 LES-1
 610 620 630 640 650 660 670 680 690 700
 TSTD--KFSVKGSGTNNSLVNEVRADS-AJOSFTVKEEDDDANAITVAKDTTKNAGAVSILKKGKONGLTVTATKKD-GTIVTIVFLGLSQSGSLTIG
 4223 Q8 LES-1

THE BOSTONIAN SOCIETY 101

GNN . . . SNAHD . . . KD . . . D . . . K . . . E . . . P . . . K . . QNG . . . NSN . . . G . . . GKTFTNT . . . E . . VNTT . . NRAT . . . ID . . SN . . . TP
Q . . QOD . . . G . . . SIRD . . . KGQEET . . . SNLYSNGNTNTFETITFA . . E . . ISISNDIAK . . K . . KV . . IDPIN . . TP
LES-1 Q8

ST-----	-LNNDGLTVKDITNEQIV-	-GANGIKFTNNGNSNPGBTGIANTARITRDKIGFAGSDGAVIDTINKPVLQVGNVKITNTGINAGGGKAITTGLSPLTPSI	710	720	730	740	750	760	770	780	790	800
I. VGSDTN	.NR-IV-I.	.VP-SADG-ST.NI.IK										
L. VGSDKD	.K. QLV-I.	.VASG--DT.NIIR-										

4223
Q8
LES-1

KLNKTSANGNTATNFVNSSDED-ALVNAKDIENLNLTKEIHTTKGTDAPTQFTVKVDENNADANAITVGORNANNO--VNLTTLKGENGNLNIKT
TE..T...T...T...T.D.H...K.S...G...E...N...
T.TT.N...K...-STT.N...-DK...T...K...D...
K...-DG.T.DET...KDTSGK...-K...K...D...
KDTQ.GKT...K...K...TVA...
4223
Q8
LES-1

KNGTVTFFINTTSGLKAGKST-LNDGGLSIKNPTGSEQIQVGADGVKFIAKVNNT-	-GVVGAGIDGTTRITRDEIGFTGTINGSLDKSKPFLSKDGINAGGKKI	4223
D.....Q.....D.....T.....NN.....TASN.....M.....	Q8
D.....Q.....D.....T.....KD.....ASN.....DK.....NSST.....S.....K.O.....A.....TT.....T.....KLKV.EVE.TNTGINAGGKKI	LES-1

1210 1220 1230 1240 1250 1260 1270 1280 1290 1300
 PPPKLTIVGNNNGKGIVIDSQNGQNTITGLSNTLAVNTNDKGGSVRTEQQNIIKDEDKTRAASIVDVLSAGFNQLQNGEAVDFVSTYDVTNFADGNATTA
 N.....N.....N.....T.....N.....T.....N.....T.....
 AGHALS..LAN-T.....G...N.....D.I.....
 KD.....
 IES-1

THE BOSTONIAN SOCIETY 13

1310 1320 1330 1340 1350 1360 1370 1380 1390 1400
 KVTYDDTSKTSKVYDVNVDDTTIEVK-DKKLGVKTTTLLSTGTGANKFALSQNATGDAVLKASDIVAHLNTLSGDIQTAGASQANNASAGYVDA
 GGNKVI
 NK...TS... K.SANG.ATKF.A.-D..AT...A...SS...S...
 Q8.....LES-1

4223
Q8
LES-1

SNIGAAVDDNDAVNFQFNEAKTVNNLNNSNSGASLPPFVVTDANGKPINGTDGKPQKA1KGADGKYHANANGVPVDKGKPITDADKLANLAAGKP

4223
Q8
LES-1

LDAGHQWASLGGNNSDAITLNIKSTLPQIDTPNTGNANAGAQASLPSLSAAQSNSAASVKDVLNVGFNLQTNHQVDFVKAYDTVNFGNGTGADITSVR

Q8
LES-1

SADGTMNSNTVNTALAAATDDDGNVLIKAKDGFYKADDLMPNGSLIKAGKSASDAKTPGTGLSLVNPNAGKGSTGDAVALNNLSKAVFKSKDGTTTTVSSD

卷之三

4223
Q8
LRS-1

1600 - GGGVISNVG

G1SLOCKKONSSLTLSKDGHTNV

1710 1720 1730 1740 1750 1760 1770 1780 1790 1800
DGSKKALLATYNAAGGTONYLINNPAEALDRINEQGIRFFFHVNNDGNQEPPVQGRNGIDSSASGHSAIGFQAKADGEAAVAIGRQTQAGNQSIAIGDNA
.....V.....
4.223
Q8

ATGDQSIAIGTGNVVGKHSGAI GDPSTVKADNSYSVGNNNQFTIDATQTDVFGNNNITVTTESSNSVALGSNSAISAGTHAGTOAKKS DGTAGTTTGA
1810 1820 1830 1840 1850 1860 1870 1880 1890 1900
Q8 LFS-1

4223
Q8
LES-1

FIGURE 7

Construction of Plasmids Expressing Portions of the 200 kDa Protein Gene from Strain 4223




Figure 8. *M. catarrhalis* M56 200kDa gene in pKS348.

ATG atc ggt gca acg ctc agt ggc agt gct tat gct caa aaa aaa gat Met Ile Gly Ala Thr Leu Ser Gly Ser Ala Tyr Ala Gln Lys Lys Asp	48
1 5 10 15	
acc aaa cat atc gca att ggt gaa caa aac cag cca aga cgc tca ggc Thr Lys His Ile Ala Ile Gly Glu Gln Asn Gln Pro Arg Arg Ser Gly	96
20 25 30	
act gcc aag gcg gac ggt gat cga gcc att gct att ggt gaa aat gct Thr Ala Lys Ala Asp Gly Asp Arg Ala Ile Ala Ile Gly Glu Asn Ala	144
35 40 45	
aac gca cag ggc ggt caa gcc atc gcc atc ggt agt agt aat aaa act Asn Ala Gln Gly Gly Gln Ala Ile Ala Ile Gly Ser Ser Asn Lys Thr	192
50 55 60	
gtc aat gga agc agt ttg gat aag ata ggt acc gat gct acg ggt caa Val Asn Gly Ser Ser Leu Asp Lys Ile Gly Thr Asp Ala Thr Gly Gln	240
65 70 75 80	
gag tcc atc gcc atc ggt ggt gat gta aag gct agt ggt gat gcc tcg Glu Ser Ile Ala Ile Gly Gly Asp Val Lys Ala Ser Gly Asp Ala Ser	288
85 90 95	
att gcc atc ggt agt gat gac tta cat ttg ctt gat cag cat ggt aat Ile Ala Ile Gly Ser Asp Asp Leu His Leu Leu Asp Gln His Gly Asn	336
100 105 110	
cct aaa cat ccg aaa ggt act ctg att aac gat ctt att aac ggc cat Pro Lys His Pro Lys Gly Thr Leu Ile Asn Asp Leu Ile Asn Gly His	384
115 120 125	
gca gta tta aaa gaa ata cga agc tca aag gat aat gat gta aaa tat Ala Val Leu Lys Glu Ile Arg Ser Ser Lys Asp Asn Asp Val Lys Tyr	432
130 135 140	
aga cgccacaaccgcaagcggcacgactgtactgcagttatgatgttgcgcatgatg Arg Arg Thr Thr Ala Ser Gly His Ala Ser Thr Ala Val Gly Ala Met	480
145 150 160	
tca tat gca cag ggt cat ttt tcc aac gcc ttt ggt aca cgg gca aca Ser Tyr Ala Gln Gly His Phe Ser Asn Ala Phe Gly Thr Arg Ala Thr	528
165 170 175	
gct aaa agt gcc tat tcc ttg gca gtg ggt ctt gcc gcc aca gcc gag Ala Lys Ser Ala Tyr Ser Leu Ala Val Gly Leu Ala Ala Thr Ala Glu	576
180 185 190	
ggc caa tct aca atc gct att ggt tct gat gca aca tct agc tcg ttg Gly Gln Ser Thr Ile Ala Ile Gly Ser Asp Ala Thr Ser Ser Ser Leu	624
195 200 205	
gga gcg ata gcc ctt ggt gca ggt act cgt gct cag cta cag ggc agt Gly Ala Ile Ala Leu Gly Ala Gly Thr Arg Ala Gln Leu Gln Gly Ser	672

210	215	220	
att gcc cta ggt caa ggt tct gtt gtc act cag agt gat aat aat tct Ile Ala Leu Gly Gln Gly Ser Val Val Thr Gln Ser Asp Asn Asn Ser	225	230	720
225	235	240	
aga ccg gcc tat aca cca aat acc cag gca cta gac ccc aag ttt caa Arg Pro Ala Tyr Thr Pro Asn Thr Gln Ala Leu Asp Pro Lys Phe Gln	245	250	768
245	255		
gcc acc aat aat acg aag gcg ggt cca ctt tcc att ggt agt aac tct Ala Thr Asn Asn Thr Lys Ala Gly Pro Leu Ser Ile Gly Ser Asn Ser	260	265	816
260	270		
atc aaa cgt aaa atc atc aat gtc ggt gca ggt gtt aat aaa acc gat Ile Lys Arg Lys Ile Ile Asn Val Gly Ala Gly Val Asn Lys Thr Asp	275	280	864
275	285		
gcg gtc aat gtg gca cag cta gaa gcg gtg gtg aag tgg gct aag gag Ala Val Asn Val Ala Gln Leu Glu Ala Val Val Lys Trp Ala Lys Glu	290	295	912
290	300		
cgt aga att act ttt cag ggt gat gat aac agt act gac gta aaa ata Arg Arg Ile Thr Phe Gln Gly Asp Asp Asn Ser Thr Asp Val Lys Ile	305	310	960
305	315	320	
ggt ttg gat aat act tta act att aaa ggt ggt gca gag acc aac gca Gly Leu Asp Asn Thr Leu Thr Ile Lys Gly Gly Ala Glu Thr Asn Ala	325	330	1008
325	335		
tta acc gat aat aat atc ggt gtg gta aaa gag gct gat aat agt ggt Leu Thr Asp Asn Asn Ile Gly Val Val Lys Glu Ala Asp Asn Ser Gly	340	345	1056
340	350		
ctg aaa gtt aaa ctt gct aaa act tta aac aat ctt act gag gtg aat Leu Lys Val Lys Leu Ala Lys Thr Leu Asn Asn Leu Thr Glu Val Asn	355	360	1104
355	365		
aca act aca tta aat gcc aca acc aca gtt aag gta ggt agt agt agt Thr Thr Leu Asn Ala Thr Thr Val Lys Val Gly Ser Ser Ser	370	375	1152
370	380		
agt act aca gct gaa tta ttg agt gat agt tta acc ttt acc cag ccc Ser Thr Thr Ala Glu Leu Leu Ser Asp Ser Leu Thr Phe Thr Gln Pro	385	390	1200
385	395	400	
aat aca ggc agt caa agc aca agc aaa acc gtc tat ggc gtt aat ggg Asn Thr Gly Ser Gln Ser Thr Ser Lys Thr Val Tyr Gly Val Asn Gly	405	410	1248
405	415		
gtg aag ttt act aat aat gca gaa aca aca gca atc ggc act act Val Lys Phe Thr Asn Asn Ala Glu Thr Thr Ala Ala Ile Gly Thr Thr	420	425	1296
420	430		
cgt att acc aga gat aaa att ggc ttt gct cga gat ggt gat gtt gat Arg Ile Thr Arg Asp Lys Ile Gly Phe Ala Arg Asp Gly Asp Val Asp	435	440	1344
435	445		

gaa aaa caa gca cca tat ttg gat aaa aaa caa ctt aaa gtg ggt agt Glu Lys Gln Ala Pro Tyr Leu Asp Lys Lys Gln Leu Lys Val Gly Ser	1392
450 455 460	
gtt gca att acc ata gac aat ggc att gat gca ggt aat aaa aag atc Val Ala Ile Thr Ile Asp Asn Gly Ile Asp Ala Gly Asn Lys Lys Ile	1440
465 470 475 480	
agt aat ctt gcc aaa ggt agc agt gct aac gat gcg gtt acc atc gaa Ser Asn Leu Ala Lys Gly Ser Ser Ala Asn Asp Ala Val Thr Ile Glu	1488
485 490 495	
cag ctc aaa gcc gcc aag cct act tta aac gca ggc gct ggc atc agt Gln Leu Lys Ala Ala Lys Pro Thr Leu Asn Ala Gly Ala Gly Ile Ser	1536
500 505 510	
gtc aca cct act gaa ata tca gtt gat gct aag agt ggc aat gtt acc Val Thr Pro Thr Glu Ile Ser Val Asp Ala Lys Ser Gly Asn Val Thr	1584
515 520 525	
gcc cca act tac aac att ggc gtg aaa acc acc gag ctt aac agt gat Ala Pro Thr Tyr Asn Ile Gly Val Lys Thr Thr Glu Leu Asn Ser Asp	1632
530 535 540	
ggc act agt gat aaa ttt agt gtt aag ggt agt ggt acg aac aat agc Gly Thr Ser Asp Lys Phe Ser Val Lys Gly Ser Gly Thr Asn Asn Ser	1680
545 550 555 560	
tta gtt acc gcc gaa cat ttg gca agc tat cta aat gaa gtc aat cga Leu Val Thr Ala Glu His Leu Ala Ser Tyr Leu Asn Glu Val Asn Arg	1728
565 570 575	
acg gct gac agt gct cta caa agc ttt acc gtt aaa gaa gaa gac gat Thr Ala Asp Ser Ala Leu Gln Ser Phe Thr Val Lys Glu Glu Asp Asp	1776
580 585 590	
gat gac gcc aac gct atc acc gtg gct aaa gat acg aca aaa aat gcc Asp Asp Ala Asn Ala Ile Thr Val Ala Lys Asp Thr Thr Lys Asn Ala	1824
595 600 605	
ggc gca gtc agc atc tta aaa ctc aaa ggt aaa aac ggt cta acg gtt Gly Ala Val Ser Ile Leu Lys Leu Lys Gly Lys Asn Gly Leu Thr Val	1872
610 615 620	
gct acc aaa aaa gat ggt acg gtt acc ttt ggg ctt agc caa gat agc Ala Thr Lys Lys Asp Gly Thr Val Thr Phe Gly Leu Ser Gln Asp Ser	1920
625 630 635 640	
ggt ctg acc att ggc aaa agc acc cta aac aac gat ggc ttg act gtt Gly Leu Thr Ile Gly Lys Ser Thr Leu Asn Asn Asp Gly Leu Thr Val	1968
645 650 655	
aaa gat acc aac gaa caa atc caa gtc ggt gct aat ggc att aaa ttt Lys Asp Thr Asn Glu Gln Ile Gln Val Gly Ala Asn Gly Ile Lys Phe	2016
660 665 670	

act aat gtg aat ggt aat cca ggt act ggc att gca aat acc gct		2064	
Thr Asn Val Asn Gly Ser Asn Pro Gly Thr Gly Ile Ala Asn Thr Ala			
675	680	685	
cgc att acc aga gat aaa att ggc ttt gct ggt tct gat ggt gca gtt		2112	
Arg Ile Thr Arg Asp Lys Ile Gly Phe Ala Gly Ser Asp Gly Ala Val			
690	695	700	
gat aca aac aaa cct tat ctt gat caa gac aag cta caa gtt ggc aat		2160	
Asp Thr Asn Lys Pro Tyr Leu Asp Gln Asp Lys Leu Gln Val Gly Asn			
705	710	715	720
gtt aag att acc aac act ggc att aac gca ggt ggt aaa gcc atc aca		2208	
Val Lys Ile Thr Asn Thr Gly Ile Asn Ala Gly Gly Lys Ala Ile Thr			
725	730	735	
ggg ctg tcc cca aca ctg cct agc att gcc gat caa agt agc cgc aac		2256	
Gly Leu Ser Pro Thr Leu Pro Ser Ile Ala Asp Gln Ser Ser Arg Asn			
740	745	750	
ata gaa ctg ggc aat aca atc caa gac aaa gac aaa tcc aac gct gcc		2304	
Ile Glu Leu Gly Asn Thr Ile Gln Asp Lys Asp Lys Ser Asn Ala Ala			
755	760	765	
agc att aat gat ata tta aat aca ggc ttt aac cta aaa aat aat aac		2352	
Ser Ile Asn Asp Ile Leu Asn Thr Gly Phe Asn Leu Lys Asn Asn Asn			
770	775	780	
aac ccc att gac ttt gtc tcc act tat gac att gtt gac ttt gcc aat		2400	
Asn Pro Ile Asp Phe Val Ser Thr Tyr Asp Ile Val Asp Phe Ala Asn			
785	790	795	800
ggc aat gcc acc acc gcc aca gta acc cat gat acc gct aac aaa acc		2448	
Gly Asn Ala Thr Thr Ala Thr Val Thr His Asp Thr Ala Asn Lys Thr			
805	810	815	
agt aaa gtg gta tat gat gtg aat gtg gat gat aca acc att cat cta		2496	
Ser Lys Val Val Tyr Asp Val Asn Val Asp Asp Thr Thr Ile His Leu			
820	825	830	
aca ggc act gat gac aat aaa aaa ctt ggc gtc aaa acc acc aaa ctg		2544	
Thr Gly Thr Asp Asp Asn Lys Lys Leu Gly Val Lys Thr Thr Lys Leu			
835	840	845	
aac aaa aca agt gct aat ggt aat aca gca act aac ttt aat gtt aac		2592	
Asn Lys Thr Ser Ala Asn Gly Asn Thr Ala Thr Asn Phe Asn Val Asn			
850	855	860	
tct agt gat gaa gat gcc ctt gtt aac gcc aaa gac atc gcc gaa aat		2640	
Ser Ser Asp Glu Asp Ala Leu Val Asn Ala Lys Asp Ile Ala Glu Asn			
865	870	875	880
cta aac acc cta gcc aag gaa att cac acc acc aaa ggc aca gca gac		2688	
Leu Asn Thr Leu Ala Lys Glu Ile His Thr Thr Lys Gly Thr Ala Asp			
885	890	895	
acc gcc cta caa acc ttt acc gtt aaa aag gta gat gaa aat aat aat		2736	

Thr Ala Leu Gln Thr Phe Thr Val Lys Lys Val Asp Glu Asn Asn Asn			
900	905	910	
gct gat gac gcc aac gcc atc acc gtc ggt caa aag aac gca aat aat		2784	
Ala Asp Asp Ala Asn Ala Ile Thr Val Gly Gln Lys Asn Ala Asn Asn			
915	920	925	
caa gtc aac acc cta aca ctc aaa ggt gaa aac ggt ctt aat att aaa		2832	
Gln Val Asn Thr Leu Thr Leu Lys Gly Glu Asn Gly Leu Asn Ile Lys			
930	935	940	
acc gac aaa aat ggt acg gtt acc ttt ggc att aac acc aca agc ggt		2880	
Thr Asp Lys Asn Gly Thr Val Thr Phe Gly Ile Asn Thr Thr Ser Gly			
945	950	955	960
ctt aaa gcc ggc aaa agc acc cta aac gac ggt ggc ttg tct att aaa		2928	
Leu Lys Ala Gly Lys Ser Thr Leu Asn Asp Gly Gly Leu Ser Ile Lys			
965	970	975	
aac ccc act ggt agc gaa caa atc caa gtc ggt gct gat ggc gtg aag		2976	
Asn Pro Thr Gly Ser Glu Gln Ile Gln Val Gly Ala Asp Gly Val Lys			
980	985	990	
ttt gcc aag gtt aat aat aat ggt gtt gta ggt gct ggc att gat ggc		3024	
Phe Ala Lys Val Asn Asn Asn Gly Val Val Gly Ala Gly Ile Asp Gly			
995	1000	1005	
aca act cgc att acc aga gat gaa att ggc ttt act ggg act aat ggc		3072	
Thr Thr Arg Ile Thr Arg Asp Glu Ile Gly Phe Thr Gly Thr Asn Gly			
1010	1015	1020	
tca ctt gat aaa agc aaa ccc cac cta agc aaa gac ggc att aac gca		3120	
Ser Leu Asp Lys Ser Lys Pro His Leu Ser Lys Asp Gly Ile Asn Ala			
1025	1030	1035	1040
ggt ggt aaa aag att acc aac att caa tca ggt gag att gcc caa aac		3168	
Gly Gly Lys Lys Ile Thr Asn Ile Gln Ser Gly Glu Ile Ala Gln Asn			
1045	1050	1055	
agc cat gat gct gtg aca ggc ggc aag att tat gat tta aaa acc gaa		3216	
Ser His Asp Ala Val Thr Gly Gly Lys Ile Tyr Asp Leu Lys Thr Glu			
1060	1065	1070	
ctt gaa aac aaa atc agc agt act gcc aaa aca gca caa aac tca tta		3264	
Leu Glu Asn Lys Ile Ser Ser Thr Ala Lys Thr Ala Gln Asn Ser Leu			
1075	1080	1085	
cac gaa ttc tca gta gca gat gaa caa ggt aat aac ttt acg gtt agt		3312	
His Glu Phe Ser Val Ala Asp Glu Gln Gly Asn Asn Phe Thr Val Ser			
1090	1095	1100	
aac cct tac tcc agt tat gac acc tca aag acc tct gat gtc atc acc		3360	
Asn Pro Tyr Ser Ser Tyr Asp Thr Ser Lys Thr Ser Asp Val Ile Thr			
1105	1110	1115	1120
ttt gca ggt gaa aac ggc att acc acc aag gta aat aaa ggt gtg gtg		3408	
Phe Ala Gly Glu Asn Gly Ile Thr Thr Lys Val Asn Lys Gly Val Val			

1125	1130	1135	
cgt gtg ggc att gac caa acc aaa ggc tta acc acg cct aag ctg acc Arg Val Gly Ile Asp Gln Thr Lys Gly Leu Thr Thr Pro Lys Leu Thr 1140	1145	1150	3456
gtg ggt aat aat aat ggc aaa ggc att gtc att gac agc caa aat ggt Val Gly Asn Asn Asn Gly Lys Gly Ile Val Ile Asp Ser Gln Asn Gly 1155	1160	1165	3504
caa aat acc atc aca gga cta agc aac act cta gct aat gtt acc aat Gln Asn Thr Ile Thr Gly Leu Ser Asn Thr Leu Ala Asn Val Thr Asn 1170	1175	1180	3552
gat aaa ggt agc gta cgc acc aca gaa cag ggc aat ata atc aaa gac Asp Lys Gly Ser Val Arg Thr Thr Glu Gln Gly Asn Ile Ile Lys Asp 1185	1190	1195	3600
gaa gac aaa acc cgt gcc gcc agc att gtt gat gtg cta agc gca ggc Glu Asp Lys Thr Arg Ala Ala Ser Ile Val Asp Val Leu Ser Ala Gly 1205	1210	1215	3648
ttt aac ttg caa ggc aat ggt gaa gcg gtt gac ttt gtc tcc act tat Phe Asn Leu Gln Gly Asn Gly Glu Ala Val Asp Phe Val Ser Thr Tyr 1220	1225	1230	3696
gac acc gtc aac ttt gcc gat ggc aat gcc acc acc gct aag gtg acc Asp Thr Val Asn Phe Ala Asp Gly Asn Ala Thr Thr Ala Lys Val Thr 1235	1240	1245	3744
tat gat gac aca agc aaa acc agt aaa gtg gtc tat gat gtc aat gtg Tyr Asp Asp Thr Ser Lys Thr Ser Lys Val Val Tyr Asp Val Asn Val 1250	1255	1260	3792
gat gat aca acc att gaa gtt aaa gat aaa aaa ctt ggc gta aaa acc Asp Asp Thr Thr Ile Glu Val Lys Asp Lys Leu Gly Val Lys Thr 1265	1270	1275	3840
acc aca ttg acc agt act ggc aca ggt gct aat aaa ttt gcc cta agc Thr Thr Leu Thr Ser Thr Gly Thr Gly Ala Asn Lys Phe Ala Leu Ser 1285	1290	1295	3888
aat caa gct act ggc gat gcg ctt gtc aag gcc agt gat atc gtt gct Asn Gln Ala Thr Gly Asp Ala Leu Val Lys Ala Ser Asp Ile Val Ala 1300	1305	1310	3936
cat cta aac acc tta tct ggc gac atc caa act gcc aaa ggg gca agc His Leu Asn Thr Leu Ser Gly Asp Ile Gln Thr Ala Lys Gly Ala Ser 1315	1320	1325	3984
caa gcg aac aac tca gca ggc tat gtg gat gct gat ggc aat aag gtc Gln Ala Asn Asn Ser Ala Gly Tyr Val Asp Ala Asp Gly Asn Lys Val 1330	1335	1340	4032
atc tat gac agt acc gat aac aag tac tat caa gcc aaa aat gat ggc Ile Tyr Asp Ser Thr Asp Asn Lys Tyr Tyr Gln Ala Lys Asn Asp Gly 1345	1350	1355	4080

aca gtt gat aaa acc aaa gaa gtt gcc aaa gac aaa ctg gtc gcc caa Thr Val Asp Lys Thr Lys Glu Val Ala Lys Asp Lys Leu Val Ala Gln	1365	1370	1375	4128	
gcc caa acc cca gat ggc aca ttg gct caa atg aat gtc aaa tca gtc Ala Gln Thr Pro Asp Gly Thr Leu Ala Gln Met Asn Val Lys Ser Val	1380	1385	1390	4176	
att aac aaa gaa caa gta aat gat gcc aat aaa aag caa ggc atc aat Ile Asn Lys Glu Gln Val Asn Asp Ala Asn Lys Gln Gly Ile Asn	1395	1400	1405	4224	
gaa gac aac gcc ttt gtt aaa gga ctt gaa aaa gcc gct tct gat aac Glu Asp Asn Ala Phe Val Lys Gly Leu Glu Lys Ala Ala Ser Asp Asn	1410	1415	1420	4272	
aaa acc aaa aac gcc gca gta act gtg ggt gat tta aat gcc gtt gcc Lys Thr Lys Asn Ala Ala Val Thr Val Gly Asp Leu Asn Ala Val Ala	1425	1430	1435	1440	4320
caa aca ccg ctg acc ttt gca ggg gat aca ggc aca acg gct aaa aaa Gln Thr Pro Leu Thr Phe Ala Gly Asp Thr Gly Thr Ala Lys Lys	1445	1450	1455	4368	
ctg ggc gag act ttg acc atc aaa ggt ggg caa aca gac acc aat aag Leu Gly Glu Thr Leu Thr Ile Lys Gly Gly Gln Thr Asp Thr Asn Lys	1460	1465	1470	4416	
cta acc gat aat aac atc ggt gtg gta gca ggt act gat ggc ttc act Leu Thr Asp Asn Asn Ile Gly Val Val Ala Gly Thr Asp Gly Phe Thr	1475	1480	1485	4464	
gtc aaa ctt gcc aaa gac cta acc aat ctt aac agc gtt aat gca ggt Val Lys Leu Ala Lys Asp Leu Thr Asn Leu Asn Ser Val Asn Ala Gly	1490	1495	1500	4512	
ggc acc aaa att gat gac aaa ggc gtg tct ttt gta gac tca agc ggt Gly Thr Lys Ile Asp Asp Lys Gly Val Ser Phe Val Asp Ser Ser Gly	1505	1510	1515	1520	4560
caa gcc aaa gca aac acc cct gtg cta agt gcc aat ggg ctg gac ctg Gln Ala Lys Ala Asn Thr Pro Val Leu Ser Ala Asn Gly Leu Asp Leu	1525	1530	1535	4608	
ggt ggc aag gtc atc agt aat gtg ggc aaa ggc aca aaa gat acc gac Gly Gly Lys Val Ile Ser Asn Val Gly Lys Gly Thr Lys Asp Thr Asp	1540	1545	1550	4656	
gct gcc aat gta caa cag tta aac gaa gta cgc aac ttg ttg ggt ctt Ala Ala Asn Val Gln Gln Leu Asn Glu Val Arg Asn Leu Leu Gly Leu	1555	1560	1565	4704	
ggt aat gct ggt aat gat aac gct gac ggc aat cag gta aac att gcc Gly Asn Ala Gly Asn Asp Asn Ala Asp Gly Asn Gln Val Asn Ile Ala	1570	1575	1580	4752	

gac atc aaa aaa gac cca aat tca ggt tca tca tct aac cgc act gtc Asp Ile Lys Lys Asp Pro Asn Ser Gly Ser Ser Asn Arg Thr Val 1585 1590 1595 1600	4800
atc aaa gca ggc acg gta ctt ggc ggt aaa ggt aat aac gat acc gaa Ile Lys Ala Gly Thr Val Leu Gly Gly Lys Asn Asn Asp Thr Glu 1605 1610 1615	4848
aaa ctt gcc act ggt ggt ata caa gtg ggc gtg gat aaa gac ggc aac Lys Leu Ala Thr Gly Gly Ile Gln Val Gly Val Asp Lys Asp Gly Asn 1620 1625 1630	4896
gct aac ggc gat tta agc aat gtt tgg gtc aaa acc caa aaa gat ggc Ala Asn Gly Asp Leu Ser Asn Val Trp Val Lys Thr Gln Lys Asp Gly 1635 1640 1645	4944
agc aaa aaa gcc ctg ctc gcc act tat aac gcc gca ggt cag acc aac Ser Lys Lys Ala Leu Leu Ala Thr Tyr Asn Ala Ala Gly Gln Thr Asn 1650 1655 1660	4992
tat ttg acc aac aac ccc gca gaa gcc att gac aga ata aat gaa caa Tyr Leu Thr Asn Asn Pro Ala Glu Ala Ile Asp Arg Ile Asn Glu Gln 1665 1670 1675 1680	5040
ggt atc cgc ttc ttc cat gtc aac gat ggc aat caa gag cct gtg gta Gly Ile Arg Phe Phe His Val Asn Asp Gly Asn Gln Glu Pro Val Val 1685 1690 1695	5088
caa ggg cgt aac ggc att gac tca agt gcc tca ggc aag cac tca gtg Gln Gly Arg Asn Gly Ile Asp Ser Ser Ala Ser Gly Lys His Ser Val 1700 1705 1710	5136
gcg ata ggt ttc cag gcc aag gca gat ggt gaa gcc gcc gtt gcc ata Ala Ile Gly Phe Gln Ala Lys Ala Asp Gly Glu Ala Ala Val Ala Ile 1715 1720 1725	5184
ggc aga caa acc caa gca ggc aac caa tcc atc gcc atc ggt gat aac Gly Arg Gln Thr Gln Ala Gly Asn Gln Ser Ile Ala Ile Gly Asp Asn 1730 1735 1740	5232
gca caa gcc acg ggc gat caa tcc atc gcc atc ggt aca ggc aat gtg Ala Gln Ala Thr Gly Asp Gln Ser Ile Ala Ile Gly Thr Gly Asn Val 1745 1750 1755 1760	5280
gta gca ggt aag cac tct ggt gcc atc ggc gac cca agc act gtt aag Val Ala Gly Lys His Ser Gly Ala Ile Gly Asp Pro Ser Thr Val Lys 1765 1770 1775	5328
gct gat aac agt tac agt gtg ggt aat aac aac cag ttt acc gat gcc Ala Asp Asn Ser Tyr Ser Val Gly Asn Asn Gln Phe Thr Asp Ala 1780 1785 1790	5376
act caa acc gat gtc ttt ggt gtg ggc aat aac atc acc gtg acc gaa Thr Gln Thr Asp Val Phe Gly Val Gly Asn Asn Ile Thr Val Thr Glu 1795 1800 1805	5424
agt aac tcg gtt gcc tta ggt tca aac tct gcc atc agt gca ggc aca	5472

Ser Asn Ser Val Ala Leu Gly Ser Asn Ser Ala Ile Ser Ala Gly Thr			
1810	1815	1820	
cac gca ggc aca caa gcc aaa aaa tct gac ggc aca gca ggt aca acc			5520
His Ala Gly Thr Gln Ala Lys Lys Ser Asp Gly Thr Ala Gly Thr Thr			
1825	1830	1835	1840
acc aca gca ggt gca acc ggt acg gtt aaa ggc ttt gct gga caa acg			5568
Thr Thr Ala Gly Ala Thr Gly Thr Val Lys Gly Phe Ala Gly Gln Thr			
1845	1850	1855	
gcg gtt ggt gcg gtc tcc gtg ggt gcc tca ggt gct gaa cgc cgt atc			5616
Ala Val Gly Ala Val Ser Val Gly Ala Ser Gly Ala Glu Arg Arg Ile			
1860	1865	1870	
caa aat gtg gca gca ggt gag gtc agt gcc acc agc acc gat gcg gtc			5664
Gln Asn Val Ala Ala Gly Glu Val Ser Ala Thr Ser Thr Asp Ala Val			
1875	1880	1885	
aat ggt agc cag ttg tac aaa gcc acc caa agc att gcc aac gca acc			5712
Asn Gly Ser Gln Leu Tyr Lys Ala Thr Gln Ser Ile Ala Asn Ala Thr			
1890	1895	1900	
aat gag ctt gac cat cgt atc cac caa aac gaa aat aag gcc aat gca			5760
Asn Glu Leu Asp His Arg Ile His Gln Asn Glu Asn Lys Ala Asn Ala			
1905	1910	1915	1920
ggg att tca tca gcg atg gcg atg gtc atg cca caa gcc tac att			5808
Gly Ile Ser Ser Ala Met Ala Met Ala Ser Met Pro Gln Ala Tyr Ile			
1925	1930	1935	
cct ggc aga tcc atg gtt acc ggg ggt att gcc acc cac aac ggt caa			5856
Pro Gly Arg Ser Met Val Thr Gly Ile Ala Thr His Asn Gly Gln			
1940	1945	1950	
ggt gcg gtg gca gtg gga ctg tcg aag ctg tcg gat aat ggt caa tgg			5904
Gly Ala Val Ala Val Gly Leu Ser Lys Leu Ser Asp Asn Gly Gln Trp			
1955	1960	1965	
gta ttt aaa atc aat ggt tca gcc gat acc caa ggc cat gta ggg gcg			5952
Val Phe Lys Ile Asn Gly Ser Ala Asp Thr Gln Gly His Val Gly Ala			
1970	1975	1980	
gca gtt ggt gca ggt ttt cac ttt taagccataa atcgcaagat tttacttaaa			6006
Ala Val Gly Ala Gly Phe His Phe			
1985	1990		
aatcaatctc accatagttg tataaaacag catcagcatc agtcatatta ctgatgctga			6066
tgttttttat cactaaacc attttaccgc tcaagtgatt ctctttcacc atgaccaaatt			6126
cgccattgat cataggtaaa ctatttgagt aaattttatc aatgttagttg tttagatatgg			6186
ttaaaaattgt gccattgacc aaaaaatgac cgatttatcc cgaaaatttc tgattatgat			6246
ccgttgacct gca			6259

Figure 9A Construction of pKS294




Figure 9B Construction of pKS294




Figure 10. Construction of pKS348




FIGURE 11

Purification of r200 kDa Protein from *E. coli*

***E. coli* Whole Cell**





FIGURE 12

Expression of M56 r200 kDa Protein Gene in *E. coli*




A: KS358 induced when O.D.^{at} 600 nm was 0.26

B: KS358 induced when O.D. at 600 nm was 0.44

a: strain 4223 lysate

b: KS358 cultured overnight

FIGURE 13
Purification of M56 r200 kDa Protein (4223)



1. ***E. coli* Whole cells**
2. **Soluble proteins after 50 mM Tris/ NaCl, pH 8, extraction**
3. **Soluble proteins after Tris/ Triton X-100/ EDTA extraction**
4. **Soluble proteins after Tris/ OG extraction**
5. **Pellet after Tris/ OG extraction**
- 6-7. **Purified 200 kDa protein**

FIGURE 14

Anti-M56 r200 kDa Antibody Titers in Mice




FIGURE 15

Anti-M56 r200 kDa Antibody Titers in Guinea Pigs




FIGURE 16

PCR amplification of DNA fragments carrying a portion of the
200 kDa protein gene from chromosomal DNA of RH408




Figure 17

M. catarrhalis strain 4223 200 kDa

```

CCATGGATATGGGCAGGTGTGCTCGCCTGCCGTATGATGGCGATGACACCCCATTTGCC
10          20          30          40          50          60

CATATCTGTACGATTGACATGTGATATGATTAAACATGTGACATGATTAAACATTGTT
70          80          90          100         110         120

AATACTGTTGCCATCATTACCAATAATTAGTAACGCATTTAGTAACGCATTGTAAAAAT
130         140         150         160         170         180

CATTGCGCCCCTTATGTGTATCATATGAATAGAATATTGATTGTATCTGATTATTGT
190         200         210         220         230         240

ATCAGAACATGGTGTATGCTATATGATGATGCCCTACGAGTTGATTGGTTAACACTCTATG
250         260         270         280         290         300

ATTTGATATATTTGAAACTAATCTATTGACTTAAATCACCATATGGTTATAATTAGCA
310         320         330         340         350         360

TAATGGTAGGCTTTTGAAAAATCACATCGCAATATTGTTCTACTGTTACTACCATGCT
370         380         390         400         410         420

TGAATGACGATCCCAATCACCAAGATTCAAGTGATGTTGTATACGCACCATTTA
430         440         450         460         470         480

CCCTAAATTATTCAAATGCCTATGTCAGCATGATCATTTTTAAAGGTAAACCAAC
490         500         510         520         530         540

↓           ↓
MET ASN HIS ILE TYR LYS VAL ILE PHE ASN LYS ALA12 THR GLY THR PHE MET AIA VAL19 AIA
CATGAATCACATCTATAAAGTCATCTTAAACAAAGCCACAGGCACATTATGGCAGTGGC
550         560         570         580         590         600

↓
GLU TYR AIA LYS SER HIS SER THR GLY GLY SER CYS AIA THR GLY GLN VAL GLY39 SER
AGAGTACGCCAAATCCCACAGCACGGGGGGGGTAGCTGTGCTACAGGGCAAGTTGGCAG
610         620         630         640         650         660

↓
VAL CYS THR ILE SER PHE AIA ARG ILE AIA AIA LEU AIA VAL LEU VAL56 ILE GLY AIA THR
TGTATGCACCTCTGAGCTTGCCTCGTATTGCCGCGCTCGCTGTCCTCGTGATCGGTGCAAC
670         680         690         700         710         720

```

FIGURE 18
3' Half Constructs of 200 kD Protein Gene




Figure 19 Construction of pQWE





Figure 20 Construction of pQWF



Docket No.
1038-921 MIS:jb

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

RECOMBINANT HIGH MOLECULAR WEIGHT MAJOR OUTER MEMBRANE PROTEIN OF MORAXELLA

the specification of which

(check one)

is attached hereto.

was filed on _____ as United States Application No. or PCT International

Application Number _____

and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (*list name and registration number*)

Michael I. Stewart (24,973)

Send Correspondence to: **Sim & McBurney**
6th Floor, 330 University Avenue
Toronto, Ontario
M5G 1R7, Canada.

Direct Telephone Calls to: (*name and telephone number*)
Michael I. Stewart (416) 595-1155

Full name of sole or first inventor Sheena M. Loosmore	
Sole or first inventor's signature	Date
Residence Aurora, Ontario, Canada.	
Citizenship Canadian	
Post Office Address 70 Crawford Rose Drive, Aurora, Ontario, Canada, L4G 4R4.	

Full name of second inventor, if any Ken Sasaki	
Second inventor's signature	Date
Residence Willowdale, Ontario, Canada.	
Citizenship Japanese	
Post Office Address Apt. 512, 1131 Steeles Avenue West, Willowdale, Ontario, Canada, M2R 3W8.	

Full name of third inventor, if any Yan Ping Yang	
Third inventor's signature	Date
Residence Willowdale, Ontario, Canada.	
Citizenship Canadian	
Post Office Address Apt. 709, 120 Torresdale Avenue, Willowdale, Ontario, Canada, M2R 3N7.	

Full name of fourth inventor, if any Michel H. Klein	
Fourth inventor's signature	Date
Residence Willowdale, Ontario, Canada.	
Citizenship Canadian	
Post Office Address 16 Munro Boulevard, Willowdale, Ontario, Canada, M2P 1B9.	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	